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The human lung immune responses to nasopharyngeal pneumococcal 
colonisation in healthy adults.     
 
Pneumococcal pneumonia burden remains high globally, affecting the youngest, the 
oldest and immunocompromised individuals worldwide. Colonisation of the human 
nasopharynx with S. pneumoniae is a pre-requisite for the development of 
pneumococcal disease and the primary reservoir for transmission. Paradoxically, it is also 
the main source of naturally acquired immunity. Currently, there is limited knowledge 
on how nasopharyngeal pneumococcal colonisation impacts on the lung immune 
responses in humans. Experimental human pneumococcal colonisation offers a safe way 
to study the dynamics between a known start-point colonisation episode and the lung 
immune responses.  
The data presented in this thesis show that colonisation of the nasopharynx with S. 
pneumoniae is an immunising event for the human lung, affecting both the innate and 
adaptive arm of immunity. Alveolar macrophage activation and function were altered 
post colonisation, leading to increased opsonophagocytic capacity that persisted for up 
to three months post the challenge. The overall skewed CD4+ Th-1 responses observed 
in the lung indicate that CD4+ T cells may prime alveolar macrophage through IFN-γ 
secretion. In vitro stimulation of lung lymphocytes with pneumococcus suggest that TCR-
γδ T cells can stand as an additional source of IFN-γ in vivo. As described before, 
pneumococcal colonisation seeded the human lung with cognate, IL-17 secreting, CD4+ 
T cells- the only observed memory population amongst lung T cells. Antibody levels 
against the capsule of the challenge strain were also elevated post colonisation. 
Pneumococcal cells found in the lung days to weeks after clearance of nasal colonisation 
suggest that they may be the stimulus for the observed enhanced lung immunity. 
Collectively, the data presented here support the use of respiratory tract as route for 
effective pneumococcal vaccination. On the other hand, they emphasize that heavily 
colonised individuals with defective alveolar macrophage function or elderly due to lack 
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1.1 Streptococcus pneumoniae 
Streptococcus pneumoniae (also known as pneumococcus) is a lancet-shaped, 
gram-positive, opportunistic bacterial pathogen, commonly found in the human 
nasopharynx (Figure 1.1A). It has a thick, multi-layered cell wall made mainly of 
peptidoglycan and teichoic acids and is surrounded by a polysaccharide capsule (CPS), 
which is composed of repeating units of simple sugars (monosaccharides) (Figure 1.1B) 
(Brown, Hammerschmidt and Orihuela 2015). CPS is the major virulence factor and 
immunodominant surface structure of S. pneumoniae. Pneumococcal strains sharing a 
unique capsular structure are grouped into serotypes and currently there are more than 95 
recognised pneumococcal serotypes, with the majority of them described as 
immunologically and structurally distinct from each other  (Weiser, Ferreira and Paton 2018). 
Some serotypes are antigenically similar, forming serogroups, which are denoted by a 
number, and each serotype within the group denoted by a letter (Geno et al. 2015, Rodrigo 
and Lim 2014). 
Figure 1.1. Structure of Streptococcus pneumoniae. A) Image illustrates S. pneumoniae chain 
formation (source: Centres of Disease Control and Prevention Public Health Image Library). 
B) Simple presentation of the main compartments of S. pneumoniae diplococcus (Image 





Pneumococcus is a highly adapted commensal with a relatively simple life cycle. 
Colonisation, transmission and occasionally invasion to sterile human sites are the three 
distinct stages observed during his life cycle within its human host (Figure 1.2). 
 
 
Figure 1.2. The life cycle of S. pneumoniae and the pathogenesis of pneumococcal disease. 
S. pneumoniae colonises the mucosal surfaces of the upper respiratory tract (URT), a state 
known as pneumococcal carriage. Pneumococcal carriers can shed bacteria in nasal 
secretions and thereby transmit the bacterium. Dissemination beyond its niche along the 
naso/oro-pharyngeal epithelium, either by aspiration, translocation through the epithelium 
or local spread, can lead to invasive diseases, such as pneumonia, meningitis and otitis 




1.2 Nasopharyngeal pneumococcal colonisation 
Pneumococcus has evolved to colonise the mucosal surfaces of the human upper 
respiratory tract (Kadioglu et al. 2008). This state is known as pneumococcal colonisation 
or carriage. As the majority of colonised adults will not develop clinical symptoms, 
pneumococcal colonisation is considered an asymptomatic state of pneumococcal 
infection (Bogaert, De Groot and Hermans 2004). In children, although, high densities of 
colonisation, especially in the presence of viral infection, have been associated with 
rhinitis symptoms (Rodrigues et al. 2013). Prevalence of colonisation varies considerably 
between countries, while within a country it appears to persist at approximately a 
constant level (Numminen et al. 2015). Nasopharyngeal pneumococcal colonisation is 
also the main source of pneumococcal transmission between individuals. Commonly 
colonisation precedes invasion and, therefore, it is also considered a pre-requisite for 
the development of pneumococcal disease (Simell et al. 2012). 
Data from longitudinal studies have demonstrated that carriage is a dynamic 
process (Murad et al. 2019). The timing of acquisition and clearance is normally 
influenced by factors including serotype, age, and previous pneumococcal exposure 
(Turner et al. 2012) (Hill et al. 2008). 
 
1.2.1. Epidemiology of pneumococcal colonisation 
Rates of nasopharyngeal pneumococcal colonisation are age-dependent. In 
young children, colonisation rates are particularly high, ranging from 20-50% in 
developed countries, (McCullers 2006), whereas its prevalence is significantly higher in 
low-middle countries. In Gambia, over 90% of healthy children under 5 years of age carry 
pneumococcus (Adegbola et al. 2014). Colonisation rates decline with increasing age 
(Waroux et al., 2014) and stabilise at 1-10% in adults. However, adults with small children 
at home may have a higher colonisation rate (Hussain et al. 2005).  Unlike in children, 
carriage in the elderly is considered a rare event. Controversially, a study conducted in a 
Dutch elderly cohort with influenza-like-illness detected an ample reservoir of 
pneumococci, including serotypes 6B and 3, in the saliva of the seniors (Krone et al. 
2015), implying change in the niche of colonisation with advanced age. However, this 
finding has not yet been replicated elsewhere. Appropriate qPCR assays are crucial when 




pneumococcus-like viridans which otherwise can be misidentified as S. pneumoniae 
(Carvalho Mda et al. 2007).  
In infancy, the peak of pneumococcal colonisation, over 80% of children acquire 
pneumococcus within the first month of their life (Hill et al. 2008).  Also, young children 
experience multiple carriage episodes in the length of a year. A study in Thailand 
reported a median of seven pneumococcal acquisitions during the first 24 months of life 
(Turner et al. 2012). In addition, simultaneous colonisation with up to four pneumococcal 
serotypes has been observed in young children, which is described as a common 
phenomenon  in low- and middle-income countries (Satzke et al. 2015). 
Not only carriage rates decrease with age, but so also does the density and 
duration of the colonisation episode. This is most likely due to the progressive acquisition 
of immunity as a result of prior pneumococcal colonisation episodes. However, large 
variations in the duration of carriage have been observed in different cohorts. 
Longitudinal studies conducted in rural Gambia villages have demonstrated that 
increased age was associated with shorter colonisation episodes (Hill et al. 2010), as well 
as decrease in density (Roca et al. 2012). In a study done in Sweden, the mean carriage 
duration of penicillin-resistant pneumococci in children under five was 43 days as 
compared to 25 days in those over the age of five (Hogberg et al. 2007). The increased 
frequency of influenza A and B infection in younger than older children and adults is an 
additional driver of the inverse correlation between age and pneumococcal density 
(Peltola, Ziegler and Ruuskanen 2003).  
Pneumococcal serogroup is also an important parameter of the carriage duration 
and density. Serotypes with thicker capsules tend to have longer durations of 
nasopharyngeal carriage in young children compared to those with thinner capsules 
(Cobey and Lipsitch 2012). In terms of density, a study conducted in healthy pre-school 
children in day-care in Portugal used molecular methods of serotyping and found 
differences in pneumococcal density amongst different serotypes, such as 3 and 35, 
describing an hierarchy of distinct pneumococcal serotype carriage densities (Rodrigues 
et al. 2016).  
Overall, the fall of carriage rates with age in a serotype-independent manner, as 




frequent exposure to circulating strains during childhood builds up naturally-acquired 
immunity to pneumococcus. Epidemiological and modelling data have demonstrated 
that the immunising effect of carriage is likely mediated by a combination of serotype-
dependent and serotype-independent mechanisms (Weinberger et al. 2008, Granat et 
al. 2009, Cobey and Lipsitch 2012). On the other hand, population-based studies have 
shown that natural anti-pneumococcal capsule IgG and IgM levels fall in the elderly 
populations and antibody function may also decline (Simell et al. 2008, Goldblatt et al. 
2009). These observations do not explain the low colonisation-high disease rates 
paradox commonly seen in this age group (Figure 1.3) but add value to the role of these 
antibody types to protection against pneumococcal disease.   
 
 
Figure 1.3. Schematic of pneumococcal colonisation, disease rates and antibody levels in 
different age groups. Pneumococcal colonisation and disease rates are high in young 
children, fall dramatically during adulthood, whereas in elderly colonisation is infrequent, 
and rates of pneumococcal disease increase. Naturally acquired pneumococcal anti-CPS 
antibody levels rise with recurrent exposure. Young adults have high levels of naturally 
acquired antibodies, occasional episodes of colonisation, and low rates of disease. In the 








1.2.2 Mechanisms of pneumococcal colonisation  
Pneumococcal colonisation is a constant interplay between various pathogen- and 
host-specific factors. Many of these factors have dual functions in disease pathogenesis, 
as well as in pneumococcal carriage and transmission into new hosts.  
1.2.2.1 The role of capsule on colonisation 
The polysaccharide capsule attached to the bacterial surface is the main 
pneumococcal virulence factor, but its presence is also important during the colonisation 
phase of the bacterium. In murine models, unencapsulated mutants are capable to 
colonise the nasopharynx but at reduced density and duration compared to the 
encapsulated parent strains (Cohen et al. 2012, Hyams et al. 2010, Nelson et al. 2007). 
In humans, pneumococcal isolates lacking capsule (unencapsulated pneumococcal 
strains) are occasionally found as nasopharyngeal coloniser, but they do not cause 
invasive pneumococcal disease as septicaemia. However, one study demonstrated that 
strains of a distinct cluster of unencapsulated S. pneumoniae are capable to cause 
conjunctivitis in humans (Valentino et al. 2014).  
The majority of CPSs serotypes (all but four) are negatively charged. In early 
colonisation, the pneumococcal capsule is suggested to have a physiochemical effector 
mechanism by limiting  mucus-mediated clearance of pneumococci (Nelson et al. 2007).  
Later on, to neutralise the inhibitory effect of negatively charged capsule on adhesive 
interaction with epithelial host cells, the bacteria are able to bind positively charged host 
molecules  (Fab antibody fragments) on their surface and thereby enhance 
pneumococcal adherence (Weiser et al. 2003).  
While pneumococcus requires the capsule in order to evade clearance by the host 
immune mechanisms, excessive capsule expression has been shown to inhibit adherence 
to the epithelium (Talbot, Paton and Paton 1996). To achieve balance, the 
pneumococcus spontaneously switches capsule expression between two phenotypes. 
This high-frequency phenotypic variation (also known as phase variation) results in 
different display of various bacterial features and be recognised by colony morphology 
between two phenotypes: opaque and transparent (Simell et al. 2012, Weiser et al. 
1994). Opaque colonies have a greater amount of capsule than the transparent form. 
Using animal models, it has been shown that transparent pneumococcal colonies 




whereas the opaque variants with thicker capsule and resistance to opsonophagocytic 
killing survive better in the bloodstream (Kim and Weiser 1998). 
During disease pathogenesis, the capsule confers resistance to complement 
mediated opsonophagocytosis (ingestion of bacteria by the host phagocytic cells) (Bruyn, 
Zegers and van Furth 1992, Watson, Musher and Verhoef 1995). It forms a physical 
barrier that limits access of antibodies and complement to the pneumococcal surface 
(Brown et al. 1982). By reducing binding of C-reactive protein, the capsule further inhibits 
complement activation of the classical complement pathway. 
 
1.2.2.2 Adherence of S. pneumoniae to the upper respiratory tract epithelium 
The glycocalyx overlying the upper respiratory tract epithelium is composed of gel-
like mucin glycoproteins and contains antimicrobial peptides and immunoglobulins (Rose 
and Voynow 2006). Although, this mucoid layer forms the first host defence against 
acquisition of colonisation, it also provides an environment rich of nutrients for S. 
pneumoniae.  
After S. pneumoniae has achieved transit from the lumenal mucus to the epithelial 
surface (Nelson et al. 2007), it seeks access and adherence to the epithelium (Figure 1.4). 
Until very recently, our understanding of S. pneumoniae–host cell interactions came 
primarily from models that use cultured human epithelial cells. The latest findings on 
pneumococcus-epithelium interaction come from an in vivo model of experimental 
human pneumococcal colonisation (EHPC) (Gritzfeld et al. 2013), whereby human 
mucosal samples were obtained by minimally-invasive curette microbiopsy (Jochems et 
al. 2017). This human study revealed that S. pneumoniae colonisation is associated with 
epithelial surface adherence, micro-colony formation and migration across the epithelial 
barrier (micro-invasion), without overt disease. The micro-invasion phase triggered 
inflammatory and innate immune responses, which were associated with clearance 






Figure 1.4: Phases of early colonisation. Pneumococcal cells A) entrapped in mucus and B) 
adhered to the nasal epithelium. Pneumococci stained with red dye and epithelial cells with 




Figure 1.5: Model of pneumococcal colonisation at the human mucosal epithelium. 
Pneumococcal adhesion and micro-colony formation on the epithelial surface may lead to 
micro-invasion; internalisation of the bacteria and/or transmigration across the epithelial 






1.2.2.3 Pneumococcal surface proteins and enzymes with involvement to cell 
adherence  
Once pneumococcus has accessed the epithelial surface it secretes enzymes and 
utilises surface proteins to bind to host cell-surface carbohydrates and initiate 
colonisation.  
Phosphorylcholine (ChoP) moieties, component of the cell wall teichoic acid, bind 
to the platelet-activating factor receptor (PAFR) on epithelial cells and serve as an anchor 
for a number of choline-binding proteins (Cundell et al. 1995). One of these adhesins, 
the choline-binding protein A (CbpA; also known as PspC) binds the secretory component 
of the polymeric immunoglobulin receptor (pIgR), mediating adherence to the mucosal 
epithelium (Zhang et al. 2000).  CbpA also binds the host proteins factor H, regulator of 
the alternative complement pathway, enabling the pneumococci to evade the host 
immune response and aiding adherence to epithelial cells (Hammerschmidt et al. 2007). 
Another choline-binding protein, the pneumococcal choline-binding protein A (PcpA), is 
also able to facilitate pneumococcal adherence to nasopharyngeal and lung epithelial 
cells (Khan et al. 2012). Also, if it is present, pilus- a multimeric filamentous surface 
structures attached to the cell wall- promotes pneumococcal adherence to the 
epithelium (Bagnoli et al. 2008). 
Zinc metalloprotease ZmpA (also known as IgA1 protease) expressed by S. 
pneumoniae is a protease that cleaves the hinge region of human IgA1. The remaining 
bound Fab fragments on the surface of pneumococcus have been associated with 
increased adherence-promoting properties, as they may neutralise the inhibitory effect 
of negatively charged capsules on adhesive interaction with host cells. This coating of 
pneumococcus with anticapsular polysaccharide antibody has been shown to unmask 
the bacterial ChoP ligand, allowing for increased adherence mediated by binding to the 
PAFr on epithelial cells (Weiser et al. 2003). 
S. pneumoniae also encodes extracellular glycosidases, some of which have been 
reported to enhance adherence by modifying host glyco-conjugates to reveal glycan 
receptors (King 2010). One of them, the pneumococcal neuraminidase (NanA) cleaves N-
acetylneuraminic acid from mucin, decreasing the viscosity of the mucus and exposing 
host epithelial cell surface receptors for pneumococcus. This action facilitates 




Manco et al. 2006). Neuraminidase enzymatic action has been related with the synergy 
between pneumococcus and influenza viruses in causing illness. In animal models, 
neuraminidase was found to contribute both to epithelial adherence and biofilm viability 
and its effect on the latter was independent of its sialidase activity (Wren et al. 2017).  
The role of these pneumococcal factors in enabling and promoting colonisation is 
summarised in table 1.1.  
 
Table 1.1. Pneumococcal factors with described role on colonisation.  
Pneumococcal factor  Function 
Polysaccharide capsule  Negatively charge capsule limit clearance of 
pneumococci mediated by mucus during early 
colonisation (Nelson et al. 2007) 
Protection against opsonophagocytic killing (Melin et 
al. 2010) 
 
Phosphorylcholine (ChoP) Binds to PAFr on epithelial cells, increasing adhesion 
(Cundell et al. 1995) 
 
Pneumococcal choline-
binding protein A (PcpA), 
Contributes to pneumococcal adherence to 




protein C (PspC) 
Binds pIgR and mediates adherence to the mucosal 
epithelium (Zhang et al. 2000) 
 
IgA1 protease  Cleaves human IgA1; encapsulated pneumococci 
coated with the Fab fragments have been associated 
with increased ability to adhere to the epithelium 
(Weiser et al. 2003).  
 
Neuraminidase A Cleaves terminal sialic acids from host glycopeptides 
and reveals adhesion receptors on the epithelium 
(Tong et al. 2000, Manco et al. 2006) 
 






1.2.2.4 S. pneumoniae interactions with the nasopharyngeal flora  
The nasopharyngeal microbiome is a dynamic ecosystem, complex and 
extensive. It is established in the first year after birth and varies throughout a person's 
lifetime (Shak, Vidal and Klugman 2013). Recent studies have shown that early in life 
certain URT microbiome profiles (Biesbroek et al. 2014) are associated with an increased 
risk and frequency of subsequent respiratory infections and disease severity (de 
Steenhuijsen Piters et al. 2016). Early interactions between infectious agents such as 
viruses and the respiratory microbiome have shown to modulate host immune 
responses potentially affecting the course of the disease and future respiratory health 
(Unger and Bogaert 2017). Recent findings on nasal microbiome derived from the EHPC 
model suggest that not only establishment of colonisation, as initially was thought, but 
even exposure to S. pneumoniae can confer large changes to the microbiota profile 
directly following pneumococcal exposure (de Steenhuijsen Piters et al. 2019).   
During colonisation, S. pneumoniae interact with the nasopharyngeal microbial 
community, developing both synergistic and antagonistic relationships. Some of these 
interactions have already been described and mainly focus on the relationship between 
pneumococcus and other respiratory pathogens.  An antagonistic relationship has been 
identified between S. pneumoniae and S. aureus that may, in part, be explained by the 
production of pneumococcal hydrogen peroxidase (H2O2), which results in lethal 
bacteriophage induction in S. aureus (Regev-Yochay et al. 2006, Selva et al. 2009). On the 
other hand, pneumococcal colonisation in the nasopharynx has also been associated 
with carriage of two other major nasopharynx-based pathogens, H. influenzae and 
Moraxella catarrhalis. Although there are exceptions, most studies find a positive 
association between the presence of S. pneumoniae and H. influenzae and between S. 
pneumoniae and M. catarrhalis in the human nasopharynx (Mackenzie et al. 2010, 
Pettigrew et al. 2008). The epidemiologic association between S. pneumoniae and H. 
influenzae was recently extended by the observation that their carriage densities are also 
positively correlated (Chien et al. 2013). Interestingly, in many murine and in vitro 
studies, S. pneumoniae and H. influenzae seem to inhibit each other, dependent on the 
order in which they are being given (Lijek and Weiser 2012). 
Many respiratory viruses predispose individuals to bacterial infection through 




pathogens (Avadhanula et al. 2006). Primary infection with influenza virus enhances 
pneumococcal colonisation by liberating host-derived nutrients (Siegel, Roche and 
Weiser 2014) and by decreasing mucociliary clearance (Pittet et al. 2010, Short et al. 
2012). Recent data from an EHPC clinical trial showed that transient infection with live 
attenuated influenza vaccine (LAIV) strains impaired neutrophils activity and monocytes 
infiltration in the human nasopharynx (Jochems et al. 2018), leading to a transient 
increase in pneumococcal density (Rylance et al. 2019). In line with this observation, 
clinical trials in children have shown that LAIV increases the number of colonising S. 
pneumoniae, which would facilitate transmission (Thors et al. 2016).  
 
1.3 Pneumococcal transmission 
A human nasopharynx colonised by pneumococci acts as the reservoir and source 
of pneumococcal transmission from individual to individual. Pneumococcal transmission 
is very common between and from young children, as their nasopharynx is readily 
colonised with high densities and their social behaviour involves intimate contact with 
others. Also, rhinorrhoea, frequently caused by respiratory viruses, is common in 
preschool children. Clinical surveys in day-care attending children demonstrated a 
relationship between secretion volume and pneumococcal colonisation density 
(Rodrigues et al. 2013).  Climatic conditions seem to affect pneumococcal transmission, 
as higher transmissibility was found during the cooler and drier months, when airway 
secretions are more copious and is more likely to occur in conjunction with viral 
infections of the upper respiratory tract (Numminen et al. 2015, Musher 2003).  
Apart from day-care centres, pneumococcal colonisation and contagion have been 
reported to occur under the same conditions in military camps, shelters for the 
homeless, prisons, and nursing homes (Musher 2003).  Airborne transmission was 
described for the first time in 2010 in a ferret model of co-infection with influenza A 
virus.  The infected ferrets were able to transmit the bacteria to other ferrets in the same 
cage or up to 1m away (McCullers et al. 2010). Prior to this observation, a study of 
prevalence in adults had showed that carriage could be detected in adults twice as often 
when they had an upper respiratory tract infection, implying that acquisition of 
pneumococci was favoured during viral co-infections (Regev-Yochay et al. 2004). Under 




viral URT viral infection is associated with higher colonisation rate post the bacterial 
challenge (Glennie et al. 2015), which may have implication in increased change of 
bacterial shedding and transmission.  
Preliminary data from the experimental human pneumococcal challenge model 
shows that healthy adults, who were not in contact with children, shed bacteria through 
the nasal or oral route and, therefore may acts as pneumococcal reservoir and source 
for transmission to others (Mitsi et al. 2019). Recently, using a pneumococcal model of 
exposure, research within the EHPC group demonstrated that hands contaminated with 
pneumococci can serve as vehicles for transmission, leading to acquisition of 
nasopharyngeal colonisation (Connor et al. 2018).   
Aside from social behaviour, climatic conditions and co-infection with respiratory 
virus, there are also bacterial factors that can promote shedding. The role of capsule type 
and amount of shedding and transmission was tested in a murine model using isogenic 
serotype- switch and cps- promoter switch mutants, showing reduction in shedding and 
transmission compared to wild type, when the capsule was switched. Mutants with 
lower expression of CPS and thinner capsules were shed and transmitted poorly (Zafar 
et al. 2017a). Encapsulation may facilitate shedding by allowing escape from the mucus 
that lines the airway surface, with a thicker capsule or capsule of certain serotypes being 
more effective (Weiser et al. 2018).  
Pneumolysin (ply) is a major pneumococcal virulence factor. It is the single 
pneumococcal cytotoxin, which triggers strong pro-inflammatory host responses. Its 
inflammatory property was tested in a mice model in association with bacterial shedding 
and transmission. Ply-knockout mutant caused moderated URT inflammation and had 
reduced ability to transit to littermates (Zafar et al. 2017b). These findings with Ply 
provide a link between pneumococcal virulence and transmission, suggesting that 
factors such as Ply that contribute to the disease state by enhancing inflammation can 





1.4 Pneumococcal disease and its spectrum  
The “asymptomatic” phase of pneumococcal colonisation is widely considered as 
the essential step that enables transmission to a new host and precedes development of 
pneumococcal disease. As noted above, induction of pro- inflammatory chemokines and 
cytokines, upregulation of target receptors and damage to the respiratory epithelium 
caused by viral infection of the URT increase bacterial loads in the nasopharynx. This 
facilitates bacterial transmission but also increases the likelihood of penetration of host 
tissues and progression to localised (non-invasive) or invasive disease (Figure 1.6).  
 
Figure 1.6. Spectrum and pathway of disease caused by S. pneumoniae. Translocation of S. 
pneumoniae to local tissues (middle ear, nasal sinuses, lungs) causes non-invasive 
pneumococcal diseases. Tissue penetration and access to the bloodstream or meninges leads 
to invasive disease (Image source: WedMD 2014).   
 
 
Pneumococcal spread to local tissues causes simple mucosal infections, such as 
otitis media of the middle ear or sinusitis. S. pneumoniae can also be aspirated into the 
distal pulmonary alveoli. Without effective clearance by the lung mucosal immune 
mechanisms, this results in non-bacteraemic pneumonia, whereby infection is confined 
to the lung mucosa. However, if bacteria spread to normally sterile sites around the 




disease, such as bacteraemic pneumonia and empyema (Jover et al. 2008, Bogaert et al. 
2004). 
 Invasive pneumococcal disease (IPD), including meningitis, can occur independent 
of lung mucosal involvement. It requires breaching of epithelial and/or endothelial 
barriers and penetration of tissues, ultimately providing access to the bloodstream. In 
the case of meningitis, this involves breaching the blood–brain barrier. Invasion mainly 
involves interaction between ChoP moieties and PAFR on the surface of cytokine-
activated respiratory epithelial and vascular endothelial cells, followed by hijacking of 
the PAFR recycling pathway to gain entry (Cundell et al. 1995). There are also marked 
differences in the capacity of specific S. pneumoniae strains to cause invasive disease, 
which highlights the vast genetic and phenotypic heterogeneity of this bacterium. Also, 
the range of pneumococcal disease differs in severity and frequency (Figure 1.7). The 
severity of disease caused by S. pneumoniae, is inversely related to incidence (Jambo et 
al. 2010) and pneumonia dominates the burden of disease caused by this bacterial 
pathogen (Wahl et al. 2018). 
 
 
Figure 1.7. Hierarchic chart of pneumococcal diseases.  Illustration of pneumococcal disease 






Progression to invasive disease is more likely in young children, elderly people and 
patients with specific lifestyle traits and comorbidities (Figure 1.7). In 2015, 
pneumococcal deaths was estimated to be over 500,000 deaths in children under 5 years 
of age worldwide (Wahl et al. 2018). Pneumococcal pneumonia incidence rates vary with 
age, affecting disproportionally young children and the elderly. In resource-rich settings, 
there is a trend of increasing incidence of pneumococcal meningitis in the elderly 
population, which frequently results in death, with higher mortality rates in this than in 
any other age group  (Adler et al. 2017).  
 
1.4.1 The burden of pneumococcal pneumonia 
In 2015, 10 million episodes of childhood pneumococcal pneumonia were 
reported worldwide, with 76% mortality rate in Africa and 36% globally (Wahl et al. 
2018). In numbers, this is translated to approximately 400,000 pneumococcal 
pneumonia deaths in children under 5 years of age in one year (Wahl et al. 2018). In the 
developed world the highest burden of pneumococcal disease arises in the elderly 
population, in which community-acquired pneumonia (CAP) incidence sharply increases 
following the age of 65. In 2014, over 70% of cases of CAP occurred in people aged over 
65 (Daniel et al. 2016). In the United States, an estimated 600,000 episodes of 
pneumococcal CAP occur annually, with a total cost to the society of 4.85 billion dollars 
(Huang et al. 2011). Within Europe, CAP is the leading cause of death due to infection, 
with approximately 90% of deaths due to pneumonia occurring in people aged >65 years. 
Pneumonia places a considerable burden on healthcare resources and society, with 
associated annual costs in Europe estimated at approximately €10 billion, mainly due to 
hospitalisation and lost working days (Torres et al. 2013). Over the next two decades, the 
incidence of CAP is expected to double as the population ages and develops more co-





Figure 1.8. Invasive pneumococcal disease rates per age group. IPD incidence rate per 
100,000 in England and Wales. Reproduced from Public Health England, July 2012. 
 
Other risk factors than age are recognised for CAP, including smoking, alcoholism, 
conditions such as chronic obstructive pulmonary disorder (COPD), immunosuppressive 
conditions and co-infection with HIV. Patients infected with HIV are 25 times more likely 
to develop pneumonia, with CAP being a frequent respiratory complication in HIV 
patients even in the highly active antiretroviral therapy (HAART) era (Cilloniz et al. 2014, 
Klugman, Madhi and Feldman 2007). In HIV infected persons who have advanced 
disease, are not under HAART and with low CD4+ T cell counts, there is a progressive loss 
of control of colonisation and invasion of S. pneumoniae, coupled with the inability to 
resolve pneumonia. Data on the effects of HIV on the physiological functions of alveolar 
macrophages in the lung are conflicting (Jambo et al. 2014). Alveolar macrophages are 
the gatekeeper of mucosal lung tissue integrity, and therefore compromised 
physiological functions can be detrimental for the lung health.  
Pneumococcal pneumonia can be effectively treated with antibiotics. However, 
patients with bacteraemic pneumonia require longer courses of intravenous (IV) 
antibiotics than patients with non-bacteraemic pneumonia (Jover et al. 2008), and 




response plays an important role in regulating the containment of S. pneumoniae within 
the nasopharyngeal cavity or restrain its replication in the lung.  
 
1.5 Innate immunity to S. pneumoniae 
A brisk local host immune response to S. pneumoniae involving phagocytes 
(neutrophils and macrophages), B cells (antibodies against pneumococcal 
polysaccharides and proteins) and T cells rapidly eliminates colonisation, whereas a poor 
mucosal immune response results in protracted colonisation. Both innate and adaptive 
immunity play a role in these host defence responses against S. pneumoniae (Bogaert et 
al. 2004).  
Innate immunity provides the early line of defence against microbes. It consists of 
cellular and biochemical defence mechanisms that are in place even before infection, 
responding rapidly to pathogens that enter to the human body. During pneumococcal 
infection the epithelial cells, through the specialised sets of receptors (pattern 
recognition receptor, PRR), can trigger such innate immunity to prevent pneumococcal 
invasion.  
1.5.1 Mucociliary escalator 
The mucociliary escalator is the layer of fluid, antimicrobial compounds and 
mucins (glycoproteins coated with negatively charged sialic acid) that lines the 
respiratory epithelium from the nasopharynx to the proximal bronchial tree (Knight and 
Holgate 2003, Tilley et al. 2015). The effectiveness of the mucociliary escalator depends 
on hydration, mucins produced by secretory cells and on the coordinated function of the 
ciliated cells that provides the force and direction of the escalator (Tilley et al. 2015). S. 
pneumoniae expresses enzymes that cleave sialic acid, e.g. NanA, in attempt to access 
the epithelium. Inhibition of mucociliary function by cigarette smoke (Nuorti et al. 2000) 
or viral co-infection (Pittet et al. 2010) increases the ability of pneumococcus to establish 
colonisation, be aspirated into the lungs and develop infection within them. Also, ciliary 





1.5.2 Antimicrobial compounds  
Respiratory secretions contain products with antimicrobial functions, inhibiting 
bacterial growth.  Antibacterial compounds include (I) lactoferrin, b) lysozyme and c) a 
wide range of antimicrobial peptides (e.g. defensins and cathelicidin).  
Lactoferrin is an iron binding protein found in nasal secretions and neutrophil 
granules. It sequesters iron -essential for bacterial respiration- and has direct 
microbicidal effects. However, S. pneumoniae is relatively resistant to lactoferrin as the 
latter is bound to the pneumococcal surface by PspA, which blocks its activity (Shaper et 
al. 2004).  Pneumococcus has developed similar restriction mechanisms against the 
action of lysozyme.  
Lysozyme breaks down peptidoglycans (PG) found in the bacterial cell wall. In 
respiratory fluids the major source is probably airway epithelium and associated glands, 
but it is also produced by neutrophils. While lysozyme can restrict the growth of S. 
pneumoniae in vitro, modifications to its cell wall structure render it relatively resistant 
to degradation. These peptidoglycan modifications reduce overall fitness of the 
bacterium, but this is outweighed by the benefits of resistance to the degrading activity 
of lysozyme (Davis et al. 2008). 
Defensins and cathelicidins are two other antimicrobial peptide families that 
contribute to the host defence at mucosal sites. The α defensins, also known as human 
neutrophil peptides (HNP), are small peptides found in neutrophil azurophilic granules, 
whereas β defensins (hBD) 1-4 are all found in respiratory fluids, with hBD2 release 
stimulated by direct activation of epithelial cells, as well as by cytokines such as 
interleukin (IL) 1β and tumour necrosis factor (TNF) (Kota et al. 2008) (Kim, Min et 
al.2010). Respiratory epithelial cells constitutively express hBD1, whereas hBD2 & 3 are 
inducible by S. pneumoniae, and both restrict pneumococcal growth and promote its 
lysis in vitro (Lee et al. 2004, Scharf et al. 2012). The human cathelicidin LL-37, the only 
known human member of cathelicidins, is found in neutrophil-specific granules and 
exhibits broad spectrum microbicidal activities (Ganz 2004). Exemplifying the overlap of 
phagocytic and epithelial host defences, the mRNA for the human cathelicidin has also 
been found in human airway epithelia (Bals et al. 1998). The pneumococcal toxin 
pneumolysin has been shown to induce the release of LL-37 from human lung mast cells, 




In the lung, surfactant protein A and D (SP-A and D respectively) are constitutively 
synthesised and secreted into alveolar lining fluid by type II pneumocytes and non-
ciliated bronchial epithelial cells. SP-A and D bind to exposed mannose and glucose 
residues on the surface of bacteria, leading to agglutination of pathogens, inhibition of 
microbial growth, and increase recruitment of phagocytes. SP-A and D also function as 
opsonins that increase macrophage phagocytosis of S. pneumoniae (Lawson and Reid 
2000). In particular, SP-A has been shown to promote phagocytosis of S. pneumoniae 
mouse alveolar macrophages in vitro  (Kuronuma et al. 2004). Although, it binds to the 
pneumococcus, SP-A does not have to be bound to the organism to enhance 
phagocytosis: “priming” of macrophages with the protein seems to be sufficient 
(Kuronuma et al. 2004). 
C-reactive protein (CRP), an acute-phase protein, has also been detected in the 
upper respiratory tract of healthy individuals and is also elevated during inflammation. 
The concentration of CRP is lower in the respiratory tract than in serum but is sufficient 
to contribute to innate immunity, and is locally produced by epithelial cells (Gould and 
Weiser 2001, Gould and Weiser 2002). CRP has several functions in relation to cell-
surface phosphorylcholine-expressing bacteria (such as S. pneumoniae and Haemophilus 
influenzae), which includes activation of complement by the classical pathway, 
enhancing opsonisation and inhibition of the attachment of bacteria to epithelial cells 
(Gould and Weiser 2002). These functions assist in clearance of colonising pneumococci 
from the upper respiratory tract. 
 
1.5.3 Complement system  
The complement system consists of a series of host proteins found in serum, epithelial 
lining fluid and cell surfaces that form protease cascades. It assists host immunity by 
identifying and opsonising invading pathogens and links the innate and adaptive immunity 
by promoting antigen recognition and improving antibody efficacy. The complement system 
is organised into three pathways known as classical, mannose-binding lectin (MBL) and 
alternative pathways. All converge on the activation of protein C3 to C3b which together 
with its degradation product iC3b, are deposited on the pneumococcal surface as opsonins. 
This deposition strongly stimulates phagocytosis by neutrophils and macrophages via 




termed the classical pathway.  This is the major mechanism by which complement activity 
facilitates the killing of S. pneumoniae (Brown et al. 2002). The classical pathway is also 
important in early lung defence against S. pneumoniae, where pulmonary cells synthesize 
and secrete complement components (Kerr et al. 2005).   
The importance of complement to host immunity against pneumococcus is 
demonstrated by the increased incidence of pneumococcal infections in patients with 
inherited complement deficiencies, such as those with deficiency of the classical component 
C2 who have reduced ability of complement-dependent phagocytosis of S. pneumoniae 
(Yuste et al. 2008). However, the pneumococcus has evolved multiple mechanisms of 
inhibiting complement activity. These mechanisms involve pneumococcal factors, such as 
the capsule and pneumococcal surface proteins (Table 1.2).  
 
Table 1.2. Pneumococcal factors with inhibitory function on complement activity. 
Pneumococcal factor  Function 
Polysaccharide capsule  Inhibition of C3 protein surface binding (Melin et al. 
2010) 
Prevention of C3b conversion to iC3b, and 
subsequent opsonisation via the alternative 
complement pathway (Hyams et al. 2010) 
 
Pneumococcal surface protein A, 
PspA 
Inhibits the deposition of C3 onto the surface of 
pneumococci and interferes with both the classical 
and alternate complement pathways (Ren et al. 
2004) 
 
Competes with the binding of CRP to cell-surface 
phosphocholine and, thus, inhibits complement 
deposition on the pneumococcal surface (Mukerji et 
al. 2012) 
 
Pneumococcal surface protein C, 
PspC 
Binds complement factor H which inhibits the 
alternative pathway C3 convertase and protects 
cells from complement attack  (Dave et al. 2001).  
 
 
Pneumolysin Stimulates the classical complement pathway in the 
absence of pneumolysin-specific antibody, diverting 
the inflammatory response from intact 





1.5.4 Pattern Recognition Receptors (PRRs) 
Upon access to the epithelium, the innate immune system initially recognises S. 
pneumoniae by several pattern-recognition receptors (PRRs). These receptors can 
recognise highly conserved microbial structures known as pathogen-associated 
molecular patterns (PAMPs) and initiate an inflammatory response. PRRs include 
transmembrane Toll-like receptors (TRLs), cytosolic NOD-like receptors (NLRs), DNA 
sensors, scavenger receptors and C-type lectins.  
 
1.5.4.1 Toll-like receptors  
 From the 10-known human TLRs, only three have been described in host defence 
against the pneumococcus. These are TLR2, TLR4 and TLR9.  
➢ TLR2: Amongst the diverse ligands recognised by TLR2 are pneumococcal 
lipoteichoic acid (LTA) (Schroder et al. 2003) and mainly  lipoproteins (LP) 
(Tomlinson et al. 2014). Responses to surface lipoprotein-deficient ∆lgt 
pneumococcal strain, such as macrophages NF-kB activation and TNF-α release, 
are reduced compared to wild-type bacteria (Tomlinson et al. 2014). Structural 
differences in LTA between pneumococcal strains alter their ability to stimulate 
TLR2 in vitro which may contribute to differences in virulence (Draing et al. 2006). 
Overall, our knowledge on the role of TLR2 in protection against pneumococcus 
derives from mice models, where it is involved in both protection against 
pneumococcal colonisation and disease (Paterson and Orihuela 2010).  
 
➢ TLR4: It is best known as a specific receptor for lipopolysaccharides (LPS), but also 
recognises other ligands including pneumolysin (Malley et al. 2003). The role of 
pneumolysin-TLR4 recognition during nasopharyngeal carriage is ambiguous. 
Malley et al. 2003 showed that TLR4 −/− mice have increased colonisation levels 
and heightened risk of invasive disease (Malley et al. 2003). In contrast other 
work described that TLR2, but not TLR4, was necessary for efficient clearance of 
colonisation (van Rossum, Lysenko and Weiser 2005). Furthermore, TLR4 plays 
only a limited role in pneumonia, systemic infection or meningitis. As indicated, 
this is probably due to in part redundancy between different TLRs (Paterson and 





➢ TRL9: It recognises unmethylated cytosine-phosphate-guanosine (CpG) motifs 
present in the bacterial DNA (Ishii and Akira 2006). TLR 9 −/− mice display 
enhanced susceptibility to pneumococcal pneumonia, a phenotype more severe 
than that seen with mice lacking TLR2 or TLR4 (Albiger et al. 2007). Unlike TLRs 2 
and 4, which are on the cell surface, TLR9 is expressed within endosomal 
compartments, thus it may serve to amplify/modulate responses following 
phagocytosis. 
 
1.5.4.2 NOD-like receptors  
NOD1 and NOD2 are intracellular PRRs, acting in the cytosol to recognize and 
respond to bacterial cell wall components. They function via activation of the 
inflammasome, a cytosolic multiprotein complex which activates caspase-1. The latter in 
turn promotes the cleavage, and thus the activation of IL-1β and IL-18, with the active 
cytokines to lead to a downstream inflammatory response. It has been shown that NOD2 
sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment, 
through CCL2 signalling, and hence facilitate clearance of S. pneumoniae colonisation in 
mice (Davis, Nakamura and Weiser 2011).  
1.5.4.3 Scavenger receptors 
Scavenger receptors (SR-A, MARCO, CD36, mannose-receptor) represent a large, 
diverse family of surface glycoproteins expressed predominantly on macrophages, 
dendritic cells and endothelial cells (Hussell and Bell 2014). These PRRs act as phagocytic 
receptors mediating direct, non-opsonic phagocytosis of pathogenic microbes 
(Areschoug and Gordon 2009). Both SR-A and MARCO bind pneumococci, although the 
bacterial features that are recognized are not yet known. Mice lacking either receptor 
have increased susceptibility to pneumococcal pneumonia (Arredouani et al. 2004, 
Arredouani et al. 2006). Also, data from a mouse colonisation model indicate that 
MARCO is an important component of anti-S. pneumoniae responses in the murine 
nasopharynx during colonisation, which amplifies TLR2- and NOD2-dependent NF-κB 
activation and signalling (Dorrington et al. 2013). In addition, MARCO expression on 
alveolar macrophages (AMs) is downregulated after influenza infection, contributing to 




The mannose receptor (CD206) interacts with glycoproteins and glycolipids that 
are found on the surface of pathogens. Recognition of non-opsonised bacteria results in 
the suppression of alveolar macrophages in humans, rats, mice and rabbits — an effect 
that is dependent on the expression of mannose receptors by these cells (Zhang et al. 
2005, Hussell and Bell 2014). This suggests that, unless other receptors are co-ligated or 
the bacteria are ‘flagged’ for immune recognition in some way, signalling through the 
mannose receptor prevents alveolar macrophages from initiating pro-inflammatory 
responses against microorganisms. This may be of benefit in preventing inflammatory 
responses against commensal bacteria in the airways. 
 
1.5.5 Phagocytes  
Professional phagocytes, such neutrophils, monocytes, macrophages and dendritic 
cells, detect foreign particles, such as bacteria, through their surface receptors.  Binding 
of the pathogen to the receptors initiate its internalisation in a phagosome, which 
normally acidifies and fuses with lysosomes in order to destroy the contents. Phagocytes 
are central players in host defence against infection, such as pneumococcal infection.  
1.5.5.1 Neutrophils  
Neutrophils are among the first cells recruited during many stages of S. 
pneumoniae pathogenesis. In mice, neutrophils are recruited during asymptomatic 
nasopharyngeal colonisation (Lu et al. 2008, van Rossum et al. 2005), whereas in healthy 
adults they are abundant in the nose, even in absence of pneumococcal colonisation 
(Jochems et al. 2017). In the lungs, neutrophils are mainly recruited to the alveoli during 
invasive infection. They comprise a crucial component of innate immunity, controlling 
bacterial and fungal infection through a combination of both oxidative and non-oxidative 
mechanisms. The oxidative burst, which generates reactive oxidative species (ROS) 
through an NADPH oxidase system, was long thought of as the neutrophil’s primary 
mode of killing pathogens. Other than ROS, neutrophils also produce a multitude of 
antimicrobial molecules in their granules. The two major granule subsets are the 
azurophilic and specific granules. The azurophilic granules, are the first to fuse with the 
phagolysosome and contain defensins, bactericidal permeability-increasing protein 
(BPI), as well as serine proteases such as elastase, cathepsin G and proteinase 3. Weiser 




cathepsin G and neutrophil elastase, offering an explanation to Chedaki-Higashi 
syndrome (Standish and Weiser 2009). Neutrophils from Chedaki-Higashi syndrome 
patients have a diminished capacity to kill pneumococcus (Root, Rosenthal and Balestra 
1972), pointing out that non-oxidative mechanisms play an important role in neutrophil-
mediated killing. Additionally, in the absence of NADPH oxidase-generated ROS, mice 
tolerate greater numbers of neutrophils in the lung without a concomitant increase in 
lung injury (Marriott et al. 2008). Neutrophils can also produce extracellular traps (NETs), 
which trap pathogens within chromatin structures, and subsequently kill them with 
various antimicrobial proteins (Brinkmann et al. 2004). Pneumococcus, though, shows 
resistance to killing by NETs via the expression of a surface endonuclease encoded by 
endA, which allows pneumococci to degrade the DNA scaffold of NETs and escape (Beiter 
et al. 2006).  
 
1.5.5.2 Monocytes  
Monocytes consist 1-6% of circulating blood cells. They are attracted to inflamed 
tissues through chemokines (MCP-1, RANTES, MIP-1β)(Deshmane et al. 2009), where 
they differentiate into macrophages. In mice it has been shown that pneumococcal 
colonisation leads to TLR2-dependent recruitment of monocytes into the nasal mucosa, 
facilitating clearance of pneumococci (Zhang, Clarke and Weiser 2009). Weiser and 
colleagues have further elucidated the mechanism of gradual pneumococcal clearance 
from the nasopharynx by recruited monocyte/macrophage either colonisation alone 
(Davis et al. 2011) or in the context of influenza co-infection (Nakamura, Davis and 
Weiser 2011). They have shown that digestion of pneumococci by phagocytes results in 
CCL2 release, and CCR2-dependent recruitment of the additional 
monocytes/macrophages to the airway lumen (Davis et al. 2011). During influenza-
pneumococcal infection, this CCL2 auto-feedback loop is inhibited by the synergistic type 
I IFN response and leads to increased pneumococcal density in the mice nasopharynx 
(Nakamura et al. 2011). In agreement with the findings in murine models, a recent EHPC 
study showed that in humans acquisition of pneumococcus in the nasopharynx induces 
recruitment of monocytes (with a peak at Day 9 post the intranasal challenge) and that 
monocyte function was associated with the clearance of colonisation (Jochems et al. 




suggested that live pneumococci trigger Th1-biased response via monocyte production 
of IL-12p40, whereas heat-killed pneumococci trigger a Th17 response through TLR2 
signalling (Olliver et al. 2011). During pneumococcal pneumonia, monocytes are 
recruited to the lungs- although at a later point compared to neutrophils- and contribute 
to bacterial resolution from the pneumonic regions of the lung (Goto et al. 2004). But 
prior pneumonia development, the highly differentiated macrophages of the lung- the 
alveolar macrophages- fight to restrain pneumococcal replication.  
 
1.5.5.3 Alveolar macrophages 
Alveolar macrophages are the most numerous cell type in the alveolar spaces and 
can readily be recovered in high purity (>95%) by bronchoalveolar lavage. Studies 
conducted in murine models have shown that alveolar macrophages derive from fetal-
liver monocytes. The latter migrate to the lung and differentiate into AMs during the first 
weeks of life following exposure to granulocyte-macrophage colony-stimulating factor 
(GM-CSF) produced by alveolar type II epithelial cells (Mass et al. 2016). These fetal 
monocyte-derived alveolar macrophages are long-lived cells and are maintained via self-
renewal (Morales-Nebreda et al. 2015).  
Alveolar macrophages play a critical role in homeostasis, host defence, and tissue 
remodelling (Lambrecht 2006, Svedberg et al. 2019). Strategically located, AMs  function 
as a first line defence of the lung against inhaled microorganisms and damage to these 
cells is an important factor in increased host susceptibility to airborne bacterial infection 
(Gwyer Findlay and Hussell 2012). This is due to expression of numerous cell surface 
receptors and their strong phagocytic and microbicidal capacity (Guilliams et al. 2013). 
Interaction with mannose receptor, SIPRa, CD200R or activation of TGFβR signalling 
result in suppression of AM in humans (Hussell and Bell 2014). On the other hand, 
stimulation of alveolar macrophages through TLR2, TLR4 or TLR9 inhibits IL-10R signal 
transduction and releases these cells from the suppression that is usually mediated by 
epithelial cell-produced IL-10 (Fernandez et al. 2004) (Figure 1.9). Signalling via one TLR 
in AMs markedly changes the pattern of expression of other TLRs on the same cells 





Figure 1.9. Alveolar macrophage surface receptor that promote either cell activation or 
suppress inflammatory responses. Image source: (Hussell and Bell 2014).  
 
 
 Once activated, AMs generally have a greater phagocytic capacity (Hussell and Bell 
2014), release large quantities of ROS and  NO and have higher pro-inflammatory 
cytokine production, such as TNFα, which aid in pathogen destruction (Steinmuller et al. 
2000). Once their phagocytic capabilities are overwhelmed, AMs institute an 
inflammatory response that results in leukocyte chemotaxis (Dockrell et al. 2003). They 
secrete chemokines like CXCL8 (IL-8), CCL2 (MCP-1), and CX3CL1, promote neutrophil 
and monocyte recruitment to the lung; and growth factors such as macrophage-colony 
stimulating factor (M-CSF), which augment monocyte survival.  
AMs also express major histocompatibility complex (MHC) class II antigens ((HLA-
DR,DQ,DP) and exhibit antigen presenting activity, although this is reduced relative to 
pulmonary dendritic cells and interstitial macrophages (Misharin et al. 2013) Flow 
cytometric analysis has shown that human alveolar macrophages are unique, compared 
to macrophages in other tissues, in that they express high levels of CD11c (integrin alpha 




recognition receptors (TLR4, TLR2), as well as receptors for Fcγ (CD64) and SIRP-α (CD47), 
along with receptors for various cytokines, chemokines, and signalling molecules 
(Morrell et al. 2018, Bharat et al. 2016, Yu et al. 2016). Conversely, they are low in 
expression for CD11b (Mac-1), which may reflect their special function of tolerance 
versus immunity. A study of murine pneumococcal infection showed that the initial 
inflammation and its subsequent resolution induced the influx of a population of AMs 
with dramatically increased expression of CD11b (monocyte-derived AMs), which 
continued after the bacterial resolution (Kirby, Raynes and Kaye 2006). 
The polarisation of macrophages into “M1” and “M2” gene expression phenotypes 
has formed a base for partially understanding the complexity of tissue macrophage 
function over the time course of tissue injury and repair (Murray et al. 2014). In 
controlled cell culture conditions, classically activated or M1 macrophages are induced 
by exposure to interferon gamma (IFN-γ) and LPS and appear to be primed towards 
microbicidal functions, i.e. to produce more ROS and more proinflammatory cytokines, 
as well as IL12 and IL23. M2 or alternatively activated macrophages are induced by IL-4 
released from Th2 cells. Their primary role appears to mediate tissue repair, through the 
production of anti-inflammatory cytokines, including transforming growth factor–β 
(TGF-β). In humans, there is no general consensus about whether alveolar macrophages 
in the healthy state are M1- or M2-like in vivo (Hussell and Bell 2014). More recent 
findings from several independent groups suggest that this concept incompletely 
describes and underestimates the complexity of macrophage gene expression in vivo, 
which might include simultaneous expression of M1 and M2 genes during injury and 
repair (Xue et al. 2014). Furthermore, the applicability of this paradigm to human lung 
macrophages is not known. 
 
1.6 Adaptive immunity to the pneumococcus 
Although it needs induction before being able to mount quick responses, the 
adaptive immune system is highly specific, has memory and is comprised of a humoral 





1.6.1 Humoral immunity to S. pneumoniae 
Capsule-specific antibodies produced by activated B cells play an important role 
in protection against disease and potentially against colonisation. Antibodies to the 
pneumococcal capsular polysaccharide are produced following vaccination against 
pneumococcus or through natural exposure after a colonisation episode. In adults, 
pneumococcal colonisation confers complete protection against acquisition of the same 
strain up to one year later, as shown in the EHPC model (Ferreira et al. 2013). Similarly, 
serotype-specific protection against colonisation is present in toddlers for at least several 
serotypes, demonstrating that this also plays a role in children (Weinberger et al. 2008). 
However, studies of anti-capsular immunity have shown that the serotype-specific 
immunity elicited by natural exposure to pneumococci is imperfect, frequently allowing 
repeated colonisations with the same serotype. Three separate studies have found 
evidence of strong immunity for one serotype (individuals who have carried type 14 are 
approximately 90% less likely to carry it again); however, they suggest that such 
immunity for all other serotypes, if it exists, is much less protective (Goldblatt et al. 2005, 
Hill et al. 2008, Weinberger et al. 2008). Additionally, an epidemiological study in 
Bangladeshi infants and young children attributed the observed decrease in the rates of 
subsequent pneumococcal acquisition to their association with the previous 
heterologous carriage, pointing out the importance of serotype-independent immunity 
(Granat et al. 2009).  
Pneumococcal proteins, with highly conserved patterns amongst the 
pneumococcal serotypes, have long been on the target of new vaccines strategies, as 
they could provide serotype independent protection. PspA is considered one of the most 
important antigens capable of inducing a protective immune response. In adults, anti-
protein antibody responses are weak and although experimental pneumococcal 
colonisation elicited serum IgG against 18 proteins, including PspA and PspC, (Wright et 
al. 2012, Ferreira et al. 2013), baseline IgG levels to them did not correlate with 
protection against acquisition of colonisation (Ferreira et al. 2013). Similar to the 
pneumococcal protein, baseline CPS-specific IgG do not correlate either with 
pneumococcal colonisation protection in adults (Pennington et al. 2016). To study the 
role of naturally acquired immunity against invasive pneumococcal disease, a recent 




IgG responses to S. pneumoniae, and suggested that this type of protection depends on 
antibody to protein antigens rather than the capsule (Wilson et al. 2017).  
Among the different antibody classes, IgG seems to have a major role in the 
immunity against pneumococcus post vaccination. Circulating anti-pneumococcal IgG in 
mice previously colonised was the predominant antibody response and associated with 
reduced bacteraemia, whereas antibody knock-out mice sustained lethal bacteraemia 
(Cohen et al. 2011). In bronchoalveolar lavage fluid (BALF), levels of IgG and IgA were 
elevated in the colonised mice and were associated with reduced bacteraemia in the 
lung. In a PCV vaccination trial of young adults, serum levels of IgG to CPS-6B were 
strongly correlated with those measured in the nasal washes four weeks post vaccination 
and resulted in high reduction in  rates of 6B colonisation (Collins et al. 2015, Mitsi et al. 
2017). This reduction in colonisation following PCV vaccination was likely conferred by 
antibody-mediated bacterial agglutination on the mucosal surface that led to bacterial 
sequestration, that may aid mucociliary clearance and prevent acquisition of 
colonisation (Mitsi et al. 2017). In mucosal surfaces, IgA is the dominant antibody, with 
IgA1 making up approximately 90% of the total IgA in the upper and 70% in the lower 
respiratory tract (Burnett 1986).  S. pneumoniae produces protease IgA1, which cleaves 
human IgA1, and thus circumvent killing by this important mucosal immunoglobulin 
(Janoff et al. 2014) . Cleaved fragments of IgA1 facilitate bacterial adherence to the 
respiratory epithelium and can thus even promote colonisation acquisition (Weiser et al. 
2003). Therefore, mucosal (nasal and lung) protection requires other classes of 
immunoglobins such as IgG (Janoff et al. 2014). In the respiratory mucosa, it is unclear 
yet whether immunoglobulin to S. pneumoniae measured in mucosal (lung and nasal) 
secretions are locally synthesised by plasma cells or diffuse from vascular compartments 
via the peripheral circulation.  Interestingly, sampling of the nasal mucosa pre and after 
experimental pneumococcal colonisation revealed that B cells were depleted from the 
nasal mucosa upon pneumococcal colonisation and this observation was associated with 






1.6.2 T cell mediated immunity to S. pneumoniae  
Cellular adaptive immune responses are driven by T lymphocytes, which recognise 
internalised antigen presented on MHC II molecules. CD4 expressing helper T cells 
secrete cytokines to affect other cells in the local milieu, while CD8 expressing cytotoxic 
T cells induce apoptosis of host cells infected with intracellular pathogens. In adaptive 
immunity, the presentation of antigens to naive T cells in lymph nodes by dendritic cells 
drives the activation of T cells and directs their development into specific effector T cells 
or cells with a memory phenotype. 
 
1.6.2.1 T-helper 1 mediated immunity 
T-helper 1 (Th1) are a subset of CD4+ T cells that initiate pro-inflammatory 
responses, which increase phagocytosis and intracellular killing. There are contradictory 
reports on the role of the Th1 cytokine IFN-γ in protection against pneumococcal 
infection  (Rubins and Pomeroy 1997, Rijneveld et al. 2002, Nakamatsu et al. 2007, Sun 
et al. 2007, Sun and Metzger 2008). However, these studies used murine models, and 
human Th1 responses remain poorly understood. Interestingly, Kemp et al. found that 
IFN-γ-producing T cells disappear from the circulation in patients with pneumococcal 
pneumonia or bacteremia, suggesting that these cells are engaged in the in vivo immune 
response (Kemp et al. 2002).  Furthermore, it has been demonstrated that peripheral 
blood mononuclear cells (PBMCs) from healthy adults living in a region with a high 
incidence of pneumococcal carriage and disease respond to pneumococcal antigens with 
both IFN-γ and IL-17 production, indicating that exposure to pneumococci results in T 
cell-mediated immunological memory (Mureithi et al. 2009). As mentioned earlier, live 
pneumococci trigger a Th1-biased response in vitro (Olliver et al. 2011).  Furthermore, 
Th1 cells induce B cell isotype switching to IgG2 antibody, which correlates with 
increased phagocytic ability in mice (Lefeber et al. 2003). Despite these evidences, it is 
not known whether Th1 responses improve adaptive immune mediated protection 






1.6.2.2 T-helper 2 mediated immunity  
A child's immune system in the first few years of life is Th2-skewed so as to avoid 
inflammation-induced immunopathology (Adkins, Leclerc and Marshall-Clarke 2004, 
Schaub et al. 2008). The Th2 subset produces IL-4, IL-5 and IL-13, which drives B-cell class 
switching to IgG and IgE antibody production (Leiva et al. 2001, Mosmann and Sad 1996). 
Dysregulation of Th2 responses are associated with allergy and predispose for 
respiratory conditions such as asthma. House bust mouse-sensitised children have early 
defective antibody responses to S. pneumoniae and H. Influenzae that are associated 
with asthma development (Hales et al. 2012). However, a distinct IL-4 signature in the 
lungs of a mice with pneumococcal pneumonia highlighted a Th2 environment as a risk 
factor for infection (Kang et al. 2009). 
 
1.6.2.3 T-helper 17 mediated immunity  
Th17 cells have pathogenic properties, but not all actions by Th17 cells are 
deleterious; they have been shown to confer protection against infections with 
extracellular bacteria such as S. pneumoniae. Th17 cells secrete the pro‐inflammatory 
cytokine IL‐17, which is essential for recruitment and activation of neutrophils and 
macrophages to the nasopharynx (Marques et al. 2012).  
Many studies support a key role for Th17 responses in preventing or reducing 
pneumococcal carriage mainly in mouse models, whereas in human findings are 
contradictory (Lundgren et al. 2012, Lu et al. 2008, Zhang et al. 2011, Hoe et al. 2015). In 
mice, Malley and colleagues demonstrated that CD4+ T cells protect against nasal 
colonisation through antibody-independent acquired immunity (Malley et al. 2005). The 
importance of IL‐17‐secreting Th17 cells has been highlighted by the finding that these 
cells orchestrate recruitment and activation of neutrophils, monocytes and macrophages 
to sites of inflammation in the upper respiratory tract, leading to the clearance of 
pneumococci (Zhang et al. 2009). Although systemic and mucosal antibodies also 
contribute, the protection against lung infection afforded by prior colonisation is lost in 
the absence of CD4+ T cells or IL‐17 (Wilson et al. 2015). Importantly, it has been found 
that the site of subsequent infection determine the basis of protection; Th17 responses 
being critical against lung infection whereas antibodies are needed against invasive 




pneumococcal infections seems to be diminished or lost when preceded by a viral 
infection such as influenza (Kudva et al. 2011). The reasons for this are not fully 
understood.  
In humans, IL‐17A is produced following in vitro stimulation of tonsillar and 
peripheral blood mononuclear cells with pneumococcal antigens such as pneumolysin 
and whole cell antigen (Lu et al. 2008, Mureithi et al. 2009, Schmid et al. 2011). IL-17A 
increased pneumococcal killing by human neutrophils both in the absence and in the 
presence of antibodies and complement, but this protective affect was abrogated in the 
absence of IL-17A receptors, as shown in mutant mice in the same study (Lu et al. 2008). 
In children findings on Th17 responses in response to colonisation are conflicting. Studies 
have shown that high IL‐17 concentrations are associated with low pneumococcal 
nasopharyngeal carriage density in children (Hoe et al. 2015). In Gambia- an area with 
very high pneumococcal carriage rates- high levels of IL-17 were not associated with the 
absolute interruption of pneumococcal carriage (Mureithi et al. 2009). Comparison of 
Th17 responses to S. pneumoniae between adults and children in two different setting 
(Sweden and Bangladesh) showed differential levels of Th17 responses to pneumococci 
in children and adults between the two countries. Swedish children produced lower 
levels of IL-17A in response to pneumococcal antigens compared to adults, whereas no 
such difference was noted from the samples from Bangladesh, where responses by 
children and adults were both significantly higher than those in Sweden (Lundgren et al. 
2012). In healthy adults, experimental pneumococcal colonisation resulted in an 
increased number of pneumococcal specific, IL-17A secreting CD4+ T cells in both blood 
and lung of the colonised individuals, whereas human alveolar macrophage treatment 
of with exogenous IL-17A augmented pneumococcal killing (Wright et al. 2013).  
 
1.6.2.4 T regulatory T cells 
Regulatory T cells (Treg) play a key role in the control of various aspects of the 
immune response including maintenance of immune tolerance and prevention of 
autoimmunity (Sakaguchi et al. 2006). The cytokine TGFβ drives the differentiation of 
naïve T cells to Tregs (Huber et al. 2004) and they, in turn, limit excessive inflammation 




considered the most specific single marker of Treg, although a combination of 
phenotypic expression of CD4+CD25highCD127low has also been established as a useful 
phenotypic marker for natural Treg (Zhang et al. 2011).  
Neill and colleagues demonstrated elevated TGF-β1 and IL-10 levels in nasal 
washes of Spn colonised individuals post experimental human pneumococcal challenge 
compared to their non-colonised counterparts. Also, mice with low density and 
prolonged carriage episodes were shown to have a higher level of TGF-β1 compared to 
high-density colonised mice (Neill et al. 2014). In young children (<6 years of age), the 
majority of Tregs in the blood are characterised as naïve, whereas over 50% of Treg found 
in adenoidal tissues express the markers CD45RO and CD69, and among them, a 
significant proportion expressing Foxp3highCD25high (Zhang et al. 2011). The latter 
subpopulation is characterised as effector/memory Tregs with potent suppressive 
properties (Sakaguchi et al. 2010). Zhang et al described that children with confirmed 
pneumococcal colonisation during the study period had significantly higher levels of 
effector/memory Tregs in their tonsils, suggesting that local colonisation promotes 
antigen-specific Treg in vivo in local lymphoid tissues adjacent to the site of colonisation 
(Zhang et al. 2011). Later in the same year, another group used pneumococcal specific 
tetramers bound to epitopes of Ply and demonstrated that tonsils from both children 
and adults with recurrent tonsillitis contain high proportions of pneumococcal-specific 
Tregs, implying that pneumococcal-specific Treg become a stable part of the repertoire 
with age (Pido-Lopez et al. 2011). The same study described that CD25hi Treg depletion 
from cultures of tonsil mononuclear cells resulted in high increase in the proliferative 
responses of the remaining CD4+ T cells after stimulation with pneumococcal antigens. A 
few years later, a study described the relation between Th17 and Treg in nasal‐associated 
lymphoid tissue with age, showing that Th1 and Treg are inversely correlated, with 
amounts of Th17 specific for pneumococcus increasing with age and being greater in 
carriage‐negative individuals (Mubarak et al. 2016). In contrast, mice that are resistant 
to invasive pneumococcal pneumonia have significantly more Tregs in their lungs than 
susceptible mice, with this being mediated through TGF‐β signalling (Neill et al. 2012). 
Collectively, these data suggest that maintenance of Th17/Treg balance is critically 





Figure 1.10. Relationship between Th17 and Tregs under normal immune homeostasis and 
under different diseases contexts. Source of image (Hoe et al. 2015) 
 
 
1.6.2.5 TCR-γδ T cell mediated immunity  
γδ T cells are T cells with a distinctive T-cell receptor (TCR) on their surface. They 
are considered to be unconventional T cells and a bridge between innate and acquired 
immunity (Nishimura et al. 2004). The nature of antigens recognised by γδ TCRs is diverse 
and still incompletely characterized. TCR γδ T cells express a wide array of nonclonal 
receptors, including PRRs and receptors to recognise natural killer (NK) cell. They can be 
directly activated through TLRs and C-type lectins (including dectin-1) and indirectly by 
microbial products presented via antigen-presenting cells (Ivanov, Paget and Trottein 
2014). TCR γδ Τ cells appear to modulate the inflammatory response to other organisms 
in the respiratory tract despite being present in low numbers. In a murine model of acute 
Streptococcus pneumoniae-mediated lung inflammation, resolution of inflammation 
following bacterial clearance was associated with a > 30-fold increase in γδ T cell number 
(Kirby et al. 2007). Another study used cytometry by time-of-flight (CyTOF) mass 
cytometry to better characterize the phenotypic response of TCR γδ T cells to S. 
pneumoniae lung infection and found that lung infection caused a significant increase in 
TCR γδ T cells, which expressed high IFN-γ and IL-17A levels (Wanke-Jellinek et al. 2016). 




pneumoniae, which contributed to influenza induced S. pneumoniae infection (Li, 
Moltedo and Moran 2012). γδ T cells are probably also involved into the resolution of 
inflammation by inducing cytotoxic cell death of inflammatory monocytes (Kirby et al. 
2007). However, the mechanism by which S. pneumoniae induces their activation 
remains unclear. 
 
1.6.2.6 CD8 T cells mediated immunity 
CD8 T cells are usually associated with responses to intracellular organisms. 
Genetic mutations in humans affecting transporter associated with antigen processing 
(TAP) proteins required for CD8 function are associated with an increased incidence of 
S. pneumoniae infection (Gadola et al. 2000). In a mouse model of lung infection CD8 
deficient mice had greater levels of bacteraemia with several serotypes of S. pneumoniae 
and poorer survival with serotype 3 (Weber, Tian and Pirofski 2011). The mechanism 
appears to be the role of CD8 (CD8+CD28-) in inhibition of CD4+ T cells (particularly Th17) 
mediated inflammation via the secretion of IL10 and TGFβ (Mertens et al. 2009). In the 
EHPC model, basal levels of CD8+CD161+ T cell clusters measured in nasal mucosal tissue 
were significantly lower in colonised than in non-colonised subjects. Combined with in 
vitro assessment of blood mucosal associated invariant T (MAIT) cells responses post 
pneumococcal stimulation, these data implied a protective role for this CD8 type against 
pneumococcal colonisation. (Jochems et al. 2019) However, the role of CD8 T cells for 
adaptive immunity to S. pneumoniae requires further characterisation. 
 
1.7 Vaccination against S. pneumoniae 
The currently licensed pneumococcal vaccines target the polysaccharide capsule 
and have shown success in decreasing IPD but confer sub-optimal protection against 
pneumonia. They are divided in two categories: a) polysaccharide pneumococcal 
vaccines (PPV) and b) pneumococcal conjugate vaccines (PCVs).  
1.7.1 Polysaccharide pneumococcal vaccine  
 The established 23-valent pneumococcal vaccine (PCV-23) contains purified 
capsular polysaccharides for the following 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 
10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. PCV23 elicits a T-cell-




leads to B cell differentiation into plasma cells and release of anticapsular IgG and IgM in 
adults (Durando et al. 2013), but hardly any class switching, affinity maturation, or 
immunological memory (Rose et al. 2005) (Figure 1.10). PPV are poorly immunogenic in 
young children (Pollard, Perrett and Beverley 2009), and hence are mainly recommended 
for use in adults >65 years old (Adler et al. 2017). A Cochrane review in 2013 concluded 
that PPV23 effectively prevents pneumococcal bacteraemia and meningitis, including in 
the elderly (Moberley et al. 2013). It has minimal effect at the mucosal level and thus has 
not been shown to reduce rates of colonisation. The protective efficacy of this vaccine 
for non-bacteraemic pneumonia remains controversial despite many years of use, and 
there are theoretical concerns about immunological harm resulting from B cell depletion 
(Clutterbuck et al. 2012). 
Conflicting results have been obtained concerning the immunogenicity of the 
pneumococcal polysaccharide vaccine in HIV infected patients. A double-blind, 
randomized, placebo-controlled clinical trial showed that the vaccine was ineffective in 
HIV-1 infected Ugandan adults, aged 15–55 years (French et al. 2000). Invasive 
pneumococcal events were more frequent in the PPV23-vaccinated arm, with a big 
proportion of isolates to be vaccine-specific serogroups.  All-cause pneumonia, but not 
pneumococcal pneumonia, was significantly more frequent in the vaccinated group. 
Collectively, these data triggers thoughts on whether the vaccine might even have been 
harmful in this population. In slight contrast to this, a retrospective case-control study 
performed in the USA demonstrated protection against invasive pneumococcal 
infections among White but not Black HIV-infected adults (Breiman et al. 2000). 
 
1.7.2 Pneumococcal conjugate vaccines 
The pneumococcal conjugate vaccine (PCV) exists in two formulations that target 
either 10 (PCV10) or 13 serotype s (PCV13) (Pollard et al. 2009). Serotypes included in 
PCV10 are 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F. The PCV13 formulation includes the 
additional serotypes 3, 6A, and 19A. PCV13 is currently recommended in immunisation 
schedule for infants in the UK (Public Health England and Department of Health 2018) 
and many other countries. In the PCVs, purified CPS are covalently linked to a carrier 
protein and therefore they induce a T cell-dependent response (Figure 1.11). This type 




improves affinity maturation, class switching, and levels of IgG (Papadatou, Tzovara and 
Licciardi 2019, Clutterbuck et al. 2012). The widespread use of PCVs among children 
sharply decreased the circulation of the vaccine-type serotypes amongst them (Wahl et 
al. 2018). As a result, the incidence of IPD and pneumonia in both vaccinated children 
and unvaccinated adults has reduced dramatically. Most of the overall efficacy of PCVs 
has been attributed to herd immunity for populations at risk, such as elderly and 
immunocompromised and a recent study suggested that preschool-aged children, rather 
than infants, are responsible for maintaining the indirect benefits of PCVs (Weinberger 
et al. 2019).  
 
Figure 1.11. The immune responses to polysaccharide and protein-polysaccharide 
conjugate vaccines. A) Polysaccharides stimulate B cells by cross‑linking the B‑cell receptor 
(BCR) and drive the production of immunoglobulins. This process results in a lack of 
production of new memory B cells. B) The carrier protein from protein–polysaccharide 
conjugate vaccines is processed by the polysaccharide‑specific B cell, and peptides are 
presented to carrier‑peptide‑specific T cells, resulting in T‑cell help for the production of 




1.7.3 Protection against nasopharyngeal colonisation 
Nasopharyngeal colonisation precedes pneumococcal disease; therefore, 
prevention of carriage has been used as a proxy for vaccine efficacy. In the context of 
experimental human pneumococcal colonisation, a 78% reduction in colonisation 
acquisition following intranasal challenge with live 6B was observed in PCV13 vaccinated 
volunteers compared to the control arm (Collins et al. 2015). Within the same study, 
assessment of colonisation rates with a multiplex (lytA and CPS-6B specific gene) qPCR 
assay revealed low density colonisation, identifying additionally colonised participants 
than previously detected with classic culture. The latter findings suggest that the impact 
of PCV13 is likely due to a reduction in colonisation density rather than a reduction in 
the rate of colonisation (German et al. 2019).  
Data from healthy, adult participants enrolled in EHPC studies have also been 
useful to assess naturally circulating serotypes. Samples taken in the first seven years 
following PCV13 introduction in the UK showed that circulating serotypes responsible for 
natural nasopharyngeal colonisation, are mostly non-vaccine types. However, there is an 
ongoing circulation of serotypes 3, 19A and 19F despite their inclusion in the PCV (Adler 
et al. 2019, Moore et al. 2015). Further data from a  UK based study in children under 
the age of five and their household contacts revealed ongoing circulation of serotypes 3 
and 19A, six years after PCV13 introduction (Southern et al. 2018). In particular, Spn3 
vaccine escape has been attributed to Spn3 ability to release capsule and, thus, bypass 
antibody-mediated killing and protection by anti-CPS antibodies (Choi et al. 2016).  
Collectively, these studies imply that PCV13 fails to protect against nasopharyngeal 
colonisation by these serotypes and therefore fails to confer herd immunity against 
them.  
 
1.7.4 Protection against pneumonia   
PCVs confer optimal protection against IPD. The incidence of IPD caused by vaccine 
serotypes declined dramatically following the introduction of PCV7 and this was evident 
in many countries including the UK (Durando et al. 2013). Fall in PCV7 efficacy over time, 
due to serotype replacement, resulted to PCV13 introduction and PCV7 succession.  A 
post licensure study reported a 90% protection against IPD caused by PCV7 serotypes 




protective effect of PCVs against non-bacteraemic pneumonia is less well documented. 
Following the introduction of PCV7 in the UK, incidence rates of bacterial pneumonia and 
empyema from 2006-2008 in children less than 15 years old in England, dropped by 19% 
and 22% respectively. Incidence rates declined across all ages groups, despite 
vaccination being targeted at children under the age of 2 years old, implying the 
generation of herd immunity. However, this data was collected using International 
Classification of Disease version 10 (ICD10) codes and was therefore not specific to 
bacterial pneumonia caused by S. pneumoniae. Data also relied on correct coding by 
physicians (Koshy et al. 2010).  
A five-year prospective cohort study (2008-2013) was conducted in two large UK 
hospitals to evaluate the impact of childhood PCV13 vaccination, against CAP in 
hospitalised adults. This study performed urine multiplex immunoassays and could 
distinguish between pneumococcal vaccine serotypes. It finished three years after the 
introduction of PCV13, therefore possible variations in serotype distribution, in response 
to wide vaccine coverage, were possible to determine. They reported an overall 16% 
decline in pneumococcal CAP per year, with an 88% reduction in the incidence of CAP 
caused by PCV7 serotypes and 30% reduction in the incidence of CAP caused by 
additional PCV13 serotypes. However, the incidence of CAP caused by non-vaccine 
serotypes increased from 2 years after PCV13 introduction.  Changes to serotype 
distribution are shown in Figure 1.12 (Rodrigo et al. 2015). In the Netherlands, a large 
randomised controlled trial (RCT) (CAPITA study) aimed to determine vaccine efficacy for 
vaccine type invasive and non-invasive pneumococcal pneumonia, in adults greater than 
65 years old, receiving either PCV13 or a control vaccination. Although, the study 
reported 45% vaccine efficacy against vaccine-type caused non-bacteraemic CAP and 
75% against IPD, there was no protective effect against all-cause CAP, overall 
pneumococcal pneumonia or mortality (Bonten et al. 2015). In the Gambia, a RCT found 
similar results in infants (6-51 weeks old) receiving a nine-valent PCV. Vaccine efficacy 
was 37% for radiologically confirmed pneumonia, compared to 77% for IPD caused by 







Figure 1.12. Variation in individual serotype numbers by study year among adults with 
pneumococcal community-acquired pneumonia in two UK hospitals (total n=2229 
pneumococcal CAP cases). PCV13 was introduced PCV13 in 2010. Incidence of pneumococcal 
CAP caused by five PCV7 serotypes (4, 9V, 14, 18C and 23F) decreased over the study period. 
The incidence of CAP caused by 6B and 19F increased (not statistically significant). 
Pneumococcal CAP caused by five PCV13 additional serotypes (1, 3, 5, 6A/C and 19A) 
decreased over the study period. However, the incidence of pneumococcal CAP caused by 
7F/A increased. The incidence of CAP caused by non-vaccine serotypes increased from 2012-
2013. Image source: (Rodrigo et al. 2015).  
 
Overall the research shows a discrepancy in direct vaccine efficacy against IPD 
compared to non-invasive CAP. This could reflect diagnostic challenges for 
uncomplicated CAP, as sputum samples are often inadequate and sputum culture has 
poor sensitivity, particularly when antibiotics have been administered (Musher, 
Montoya and Wanahita 2004). Diagnosis usually relies on chest radiography which 
cannot distinguish causative pathogens. Urinary antigen assays are available but may be 
unhelpful in children who are concurrently colonised (Dion and Ashurst 2019). Therefore, 
most often the causative pathogen remains undetected. Other respiratory pathogens 
including viruses are responsible for a significant burden of CAP, and national 
surveillance often depends on ICD10 coding which are nonspecific and may be inaccurate 
(Nouraei et al. 2016).   
Suboptimal vaccine efficacy could also reflect poor humoral immune responses 
to PCV13 at a pulmonary mucosal level. Since there is clinically documented efficacy for 
PCV7, new generation of PCVs can be licensed on the basis of non-inferiority of induced 




conducted in infants, estimated a capsular IgG concentration of 0.35µg/ml, which could 
be used as a correlate of protection against IPD in serum, applied to infants one month 
after vaccination (Siber et al. 2007). However, bronchoscopy is an invasive technique 
which is unethical to conduct in large scale clinical trials and no such level of protection 
has been accepted for anti-CPS IgG in BAL. Therefore, the protective effect of antibody 
responses in the lung is difficult to determine.  
 
1.7.5 Drawbacks of PCVs 
Prevention of pneumococcal infection with vaccination is safe and effective and 
their use prevents from excessive use of antibiotics, which has resulted in antibiotic-
resistant strains. Despite the significant impact of PCVs on invasive disease, in part via 
the conferred herd immunity, which has minimised the spread of pneumococcus within 
the community, there are a number of drawbacks to PCVs.  
1. No broad and suboptimal protection. Protection of the current PCVs is 
limited to a subset of serotypes, of which the prevalence varies 
geographically. Furthermore, two serotypes contained in PCV13: SPN3 and 
SPN19A, have continued to be detected in colonisation studies in fully 
PCV13 vaccinated children up to 2015/16, with no evidence of a decline in 
rates of colonisation for these 2 serotypes (Southern et al. 2018), which 
partially masks PCV13-mediated herd immunity in adults (LeBlanc et al. 
2019) . 
 
2. Serotype replacement. In the era post introduction of PCVs, colonisation 
and disease caused by vaccine-type serotypes have been reduced. 
However, it’s is now well established that non-vaccine type (NTVs) 
pneumococcal serotypes have filled in the gap in the human niche, 
contributing to carriage and disease (Lewnard and Hanage 2019). This 
phenomenon is called serotype-replacement. The effects of replacement 
on public health have varied geographically. Striking differences have 
emerged between the UK and USA, countries that otherwise often 
resemble each other epidemiologically. Similar to other European settings, 




disease, most notably in older adults, mainly driven by PCV7 and less by 
PCV13 introduction of to the paediatric immunisation schedule. Such 
impacts of serotype replacement have not been reported in the USA, 
where incidence of non-vaccine serotype invasive pneumococcal disease 
in young children and older people has been stable since the introduction 
of the same vaccine (Lewnard and Hanage 2019). In addition, serotype 
replacement has resulted in poor matching to serotypes circulating in 
developing countries, which suffer the largest burden of disease (Feikin et 
al. 2013). 
 
3. High cost. The conjugation of capsular polysaccharide with the protein 
carrier, although increases vaccine immunogenicity, has a major impact on 
the vaccine cost. The high cost of PCVs per dose has hampered its 
implementation in many developing countries. However, through GAVI 
Vaccine Alliance nearly 60 GAVI-supported countries have introduced 
pneumococcal vaccines into their routine programmes. The importance of 
sustaining PCV vaccination after transitioning from GAVI support was 
highlighted by a modelling studied in Kenya, which estimated that IPD 
caused deaths will doubled per year in the country within 10 years of PCV 
discontinuation. Importantly, the study estimated that PCV continuous use 
in Kenya post GAVI support period will require an estimated additional 




1.7.6 Novel pneumococcal vaccine development  
Due to the high manufacturing costs of PCVs, combined with the lack of broad 
protection against pneumococcal disease, there is a need of novel vaccination strategies 
to complement current vaccination and treatment options. As a result, different research 
groups work on the development of novel pneumococcal vaccines (whole cell or protein-
based vaccines), with some of them currently in preclinical and clinical trials.  
One such vaccine being tested is the Whole Cell pneumococcal Vaccine (WCV), 




was used in two clinical trials (USA and Kenya) to study safety, dose tolerance and 
immunogenicity (Moffitt and Malley 2016). In healthy US adults WCV was shown to be 
safe and well tolerated; significant IgG responses to pneumococcal antigens were 
elicited, including PspA and pneumolysin. A third Phase 2 trial of the WCV have been 
completed in Kenyan adults and toddlers who are also receiving PCV immunisation 
(ClinicalTrials.gov Identifier: NCT02097472). Results of this trial, which would include 
evaluations of safety, tolerability and impact on pneumococcal carriage are not available 
yet.  
The development of a protein-based pneumococcal vaccine is a topic that has 
attracted the interest of many researchers in the past and present, as immunisation with 
pneumococcal protein antigens could have the potential to induce serotype-
independent protection. Several pneumococcal proteins, such as PspA, PspC, PhtD and 
PsaA, highly conserved among different pneumococcal isolates, have been proposed as 
new vaccine-candidates against pneumococcal infections (Miyaji et al. 2013). Their 
immunogenic properties have been tested in mice administration as single proteins or 
combined. However, their low immunogenicity presents a challenge for formulating 
vaccines, and thus an adjuvant is generally required for inducing sufficient immune 
responses. Molecular adjuvants, such as cytokines, toll-like receptors agonists and 
nucleic acids, can be incorporated into the formulation with the antigen to improve 
immunogenicity (Paranjpe and Muller-Goymann 2014). Lately, the use of delivery 
vehicles, such as nanoparticles, emulsions, and hydrogels, as adjuvant has gained 
attraction (Wang et al. 2015). Such formulations can improve the antigen exposure to 
the immune cells and also improve uptake by the antigen presenting cells. Although 
there are currently no approved intranasal or pulmonary protein vaccines, several 
preclinical formulations using serotype-independent antigens against S. pneumoniae 









1.8 Experimental Human Pneumococcal Challenge Model 
The study of controlled colonisation in healthy volunteers has proven to be 
instrumental to dissect the dynamics of mucosal carriage of bacteria that precedes 
invasive bacterial infection. The described experimental human pneumococcal challenge 
model developed by Prof. Jeff Weiser and his colleagues in United States, where both 
serotypes 23F and 6B were used in dose-escalation studies (McCool et al. 2002). The 
Experimental Human Pneumococcal Challenged (EHPC) model, developed and based in 
Liverpool School of Tropical Medicine (Gritzfeld et al. 2013), is currently the only 
controlled human infection model (CHIM) with S. pneumoniae in the world, whereas its 
establishment in a low income country, Malawi, is ongoing. EHPC is safe and reproducible 
and enables investigation of pneumococcal biology, as well as the human host immune 
responses against the pathogen.  
 Intranasal inoculation of live pneumococcus, serotype 6B, with an average dose 
of 80,000 CFU/100μl leads to approximately 50% colonisation in healthy volunteers and 
its duration resembles that of natural colonisation. Pneumonia or invasive pneumococcal 
disease has never been reported in studies of more than 1500 inoculations and over 300 
research bronchoscopies (Collins et al. 2014) done so far. Up to date the model has been 
utilised to predict efficacy of licenced vaccines, to test new vaccine protein-candidates, 
as a co-infection model, whereas recently has been used to evaluate transmission in 
adults. The endpoint of these clinical trials was the nasopharyngeal colonisation, with 
colonisation rates and pneumococcal density being the primary outcomes.  The model 
has been also instrumental in studying natural protection, the dynamics of the nasal 
microbiome (de Steenhuijsen Piters et al. 2019), and systemic and mucosal immunity in 
the upper and low respiratory tracts, the sites where infection occurs. Given the scientific 
advances and the favourable safety profile of the pneumococcal colonisation model, the 
model has been expanded to explore the susceptibility of at-risk populations including 
people with asthma (ISRCTN16755478), smokers and the elderly (ISRCTN10948363). 
 
1.8.1 The EHPC model as a method to predict vaccine efficacy 
  Using colonisation status as a surrogate for infection, the EHPC model can be 
used to assess the protective efficacy and herd protection potential of new vaccine. As 




in healthy young adults in a randomised controlled clinical trial in protecting against 
nasopharyngeal colonisation (Collins et al. 2015). PCV13 was found to reduce 
significantly the rate of 6B colonisation and density in vaccinated healthy adults (18-
50years of age), using classical culture. The protective effect of PCV remained robust 
after the re-assessment of colonisation status using molecular methods, although 
revealed an increased rate in low-density colonisation (German et al. 2019). The results 
of this RCT paved the way for the use of EHPC model for testing new protein-based 
vaccines, as it has proven safe, efficient and cost-effective in investigating the protective 
effects of the licensed vaccines.  
 The following year, a novel vaccine candidate, the GEN-004 vaccine, was tested 
in the EHPC model. The GEN-004 vaccine, consisting of three antigens identified 
following a proteomic screen for proteins that elicit robust Th17 cell responses 
(Streptococcus pneumoniae proteins SP0148, SP1912, and SP2108), was protective 
against pneumococcal carriage in murine models (Moffitt et al., 2014). This vaccine 
consistently reduced carriage acquisition by 18% to 36% versus placebo, but the 
differences were not statistically significant because the study was powered to detect 
50% reduction (Skoberne et al. 2016). There was no evidence of reduced colonisation 
density or duration up to day 14 following inoculation. However, any Th17 cellular 
responses induced by the vaccine in this study have not yet been reported, which limits 
the conclusions one can draw from the study. 
 
1.8.2 EHPC as a co-infection model 
 Primary viral infection has been associated with increased inflammation and 
higher risk of pneumococcal disease development. EHPC has been used as a virus-
pneumococcal co-infection model and has provided important insights into how viruses 
effect acquisition of pneumococcal colonisation. Using the model, Glennie at al.  showed 
that asymptomatic upper respiratory viral infection in the week preceding inoculation 
increases the risk of becoming colonised. Increased levels of nasal Factor H facilitated 
the adherence of pneumococcus to the human epithelium via PspC (Glennie et al. 2015). 
In another EHPC study, the dynamics of transient influenza virus-pneumococcal co-
infection were investigated in the context of a transient influenza infection caused by 




administered annually in children as a way to prevent seasonal influenza infection. The 
effect of LAIV vaccine on pneumococcal colonisation was tested in two subsequent RCT 
trial with inverted order of LAIV immunisation and pneumococcal challenge. Overall, the 
study showed that antecedent LAIV administration caused a significant, transient 
increase in pneumococcal density (1 log of CFU), whereas the inversed scenario was 
associated with reduced colonisation density and colonisation rates at Day 27, decreased 
AUC, and earlier bacterial clearance (Rylance et al. 2019). Further analysis of the 
immunological parameter demonstrated that inflammation induced by primary LAIV 
administration impaired the function of neutrophils and inhibited the monocytes 
infiltration in the nasal mucosa, resulting in the transient increase of pneumococcal 
density by hindering bacterial clearance (Jochems et al. 2018). On the other hand, 
pneumococcal precedence impaired acute inflammation post LAIV administration and 
affected LAIV immunogenicity (Carniel, Mitsi et al, 2019, unpublished data). Interactions 
of nasal microbiome and pneumococcus were also studied in the context LAIV, 
identifying microbiome profiles that are associated that are with low-density 
colonisation, in particular Corynebacterium/Dolosigranulum-dominated profiles (de 
Steenhuijsen Piters et al. 2019). 
 1.8.3 Advances in immunity against S. pneumoniae and correlates of 
protection 
 Findings derived from studies conducted in the EHPC model have identified 
humoral correlates of protection against nasopharyngeal pneumococcal colonisation. 
Natural exposure to serotype 6B resulted in greater levels of capsular polysaccharide, 
IgG secreting memory B cells to the homologous strain, and was associated with 
protection against acquisition of colonisation (Pennington et al. 2016). In the context of 
PCV vaccination, elevated levels of mucosal IgG to CPS-6B post vaccination blocked 
acquisition of colonisation through bacterial agglutination (Mitsi et al. 2017). In absence 
of vaccination, naturally acquired baseline levels to CPS-6B antibodies do not correlate 
with protection in adults. Establishment of colonisation post the bacterial challenge 
elicits capsular specific antibodies both systemically and in the nasal mucosa, (Ferreira 
et al. 2013, Mitsi et al. 2017, Pennington et al. 2016), and it has been characterised as a 
protective event against re-acquisition of the homologous pneumococcal serotype 




pneumococcal proteins, such as PspA, PspC and pluA (Ferreira et al. 2013), but their role 
in colonisation protection has not been elucidated yet in humans. The current findings 
suggest that naturally acquired humoral Immunity to the capsule is superior to 
pneumococcal proteins in protecting against carriage. 
Furthermore, the model has revealed innate and adaptive cellular responses that 
are implicated in acquisition or clearance of colonisation. It was observed that in the 
human nose neutrophils are already present in high numbers and that pneumococcal 
colonisation leads to only a modest further recruitment (Jochems et al. 2018). Instead, 
colonisation triggered monocytes recruitment to the nasal lumen. Degranulation of pre-
existing neutrophils in the nasal cavity was important for the initial control of carriage, 
whereas monocytes promoted clearance of nasopharyngeal colonisation (Jochems et al. 
2018). The nasal mucosa cellular populations were further studied in the model, using 
advanced resolution techniques, such as CyTOF, and larger scale nasal sampling by taking 
nasal biopsies (Jochems et al. 2019). This study showed that increased responses of 
blood MAIT cells against in vitro stimulation with pneumococcus before the 
pneumococcal challenge associated with protection against establishment of 
colonisation and with increased mucosal MAIT cell populations, suggesting that MAIT 
cells may contribute in the protection against pneumococcal colonisation (Jochems et al. 
2019). 
 Conventional CD4+ T cells have also been investigated in the model. Experimental 
pneumococcal colonisation mediated the induction of pneumococcal-specific, Th17 CD4+ 
T cells, which were elevated in both blood and the lung (Wright et al. 2013). This is an 
important observation but one of the few reports of lung immunity against S. 
pneumoniae derived from the model. The effect of pneumococcal colonisation on other 
cellular populations, with crucial role in guarding the lungs from infection has been 
poorly described. Therefore, the research work presented here has focused on the 
relationship between nasopharyngeal pneumococcal colonisation and lung immune 
responses in healthy adults, examining alterations in innate and adaptive lung immune 
responses and cytokine milieu of alveolar microenvironment. The findings of this work 





1.9 Project Aims and Objectives 
The overall scope of this research project was to investigate whether and to what 
expend nasopharyngeal pneumococcal colonisation influences lung immune responses 
to S. pneumoniae. To address this overarching research question, the project was 
designed around the following aims:  
1. To investigate alveolar macrophage polarisation, shift and other phenotypic 
changes post pneumococcal colonisation 
• Define human AM phenotype and polarisation profile in the 
steady state 
• Validate and compare findings with an age-matching cohort from 
different setting  
• Measure expression levels of key activation markers and 
scavenger receptors on AM surface 
 
2. To test the hypothesis of pneumococcal aspiration in the lungs during 
nasopharyngeal colonisation 
• Search for evidences of pneumococcal presence in the lungs, in the 
form of intact cells, fragments or pneumococcal DNA 
• Correlate nasal pneumococcal density with levels of pneumococcal 
DNA detected in the kung 
 
3. To investigate the effect of colonisation on lung innate immune responses  
• Assess AM opsonophagocytic capacity post in vivo exposure to 
pneumococci  
• Elucidate the mechanism that augments AM opsonophagocytic 
capacity, if present, and assess the duration of this effect 
• Assess whether colonisation initiates inflammatory responses in 
the lung, resulting in neutrophils or monocytes infiltration 
 
4. To investigate the effect of colonisation on lung adaptive immune responses  





•  Validate the findings of a previous EHPC study relative to 
pneumococcal-specific CD4+ Th17 elevated levels in lung post 
colonisation 
• Define whether similar pneumococcal specific responses can be 
detected in other conventional T cells subsets or TCR γδ Τ cells  
• Compare levels of anti-CPS-6B IgG in bronchoalveolar lavages 
























Material and Methods 
This chapter contains all the methodological approaches used throughout this 
project to generate the data presented in the following chapters.  
2.1  Ethical Approval  
All the experimental human pneumococcal challenge (EHPC) studies were in 
compliance with the Good Clinical Practice (GCP) and with the principles set out in the 
Declaration of Helsinki (World Medical, 2013). All studies where approved by local 
Research Ethics Committees (RECs), which are part of the United Kingdom National 
Research Ethics Service (NRES) (Table 2.1). 
Table 2.1. List of experimental human pneumococcal challenge (EHPC) studies related to 
the project and theirs REC reference.  
Title of EHPC study REC Reference  Primary objective 
Mucosal sampling pilot 
study  
15/NW/0146 Assessing the impact of serial nasal 
scraping on carriage rates 
The Effect of Live 
Attenuated Influenza 







To assess the impact of Antecedent LAIV 
administration on carriage rates 
The Effect of Live 
Attenuated Influenza 
Vaccine (LAIV) on EHPC – 
Study B 
To assess the impact of Concurrent LAIV 
administration on carriage rates 
 




To establish a new colonisation model 
with a new strain. A non-vaccine strain 
15B strain was tested in the model, 
following re-challenge with Spn6B at 6 to 





2.2 Studies design 
The results described at the following chapters have been obtained by EHPC studies, 
where S. pneumoniae, serotype 6B (Spn6B) was used in achieving colonisation of the 
nasopharynx. These studies included lung sampling through the technique of research 
bronchoscopy. 
2.2.1 Study design of EHPC 
Healthy, non-smoking, adult volunteers aged from 18-50 years, enrolled in one 
of the EHPC studies (Gritzfeld et al. 2013) which conducted in Liverpool between 2015-
2018. All volunteers had a baseline (Day -5) nasal wash sample, whereby we assessed 
naturally acquired colonisation. On Day 0, volunteers were challenged intranasally with 
a safe dose (80,000 CFU per naris) of live pneumococci, serotype 6B. Participants were 
followed up for 2 to 4 weeks post the challenge (Figure 2.1). Pneumococcal colonisation 
was detected by classical microbiology methods and individuals were defined as Spn 
colonised (carriage+) if any nasal wash culture following experimental challenge grew S. 
pneumoniae, serotype 6B. A subset of Spn colonised and non-colonised participants 
underwent a single time point research bronchoscopy, at any day between 21 to 203 
days post the intranasal pneumococcal inoculation. Spn colonised individuals received 3 
doses of amoxicillin at the end of the clinical trial (at day 14 or 27 or 29) prior to the 
bronchoscopy (Figure 2.1).  
 
Figure 2.1. Study design of EHPC studies which included lung sampling through research 
bronchoscopy. Intranasal pneumococcal challenge at D0 with follow-up visits. Bronchoscopy 





2.3 Ethics statement   
All volunteers gave written informed consent and research was conducted in 
compliance with all relevant ethical regulations. Ethical approval was given by the North-
west National Health Service Research Ethics Committee (REC). Ethics Committee 
reference numbers: 15/NW/0146, 14/NW/1460 and 15/NW/0931 and Human Tissue 
Authority licensing number: 12548. 
 
2.4 Clinical procedures  
 The intranasal pneumococcal challenge and the samples collection during the 
clinical trials involves a number of procedures, which are described in detail below.  
 
2.4.1 Nasopharyngeal inoculation  
Intra-nasal inoculation with S. pneumoniae was carried out by a trained clinical 
staff. The inoculation was performed while the volunteer was seated comfortably in a 
semi-recumbent position. With the head tilted back slightly, the tip of a P200 pipette was 
inserted just inside the nasal cavity and 100 μl of the bacterial inoculum was slowly 




Figure 2.2. Inoculation of the nasal mucosa with live S. pneumoniae. Live pneumococci were 
installed in the nasal cavity of each volunteer with the use of pipette and both nostrils were 







During the inoculation, it was important that the pipette tip did not come in 
contact with the nasal mucosa, as a disruption in the integrity of the epithelium could 
result in bacteria entering the bloodstream. It was also important that the inoculum was 
not expelled too far back in the nasal cavity as it would run down the throat and be 
swallowed instead of remaining in the nasopharynx. The inoculation was repeated for 
the other nostril and then the volunteer remained in the semi-recumbent position for 10 
minutes without sniffing or blowing the nose. 
 
2.4.2 Nasal wash sampling method  
Nasal wash was used to sample the nasopharynx of volunteers. Samples were 
collected one week before inoculation and at several time points post inoculation (Figure 
2.1). A volunteer was seated comfortably, and the head was tilted back 30° from the 
vertical. The volunteer was then asked to take a deep breath in and hold their breath 
whilst pushing their tongue up and backwards against the roof of the mouth. A syringe 
filled with 20 ml of sterile saline was inserted into the anterior nasal space and 5 ml of 
saline was expelled. The volunteer then leaned forward immediately and expelled the 
fluid by exhaling rapidly through the nose into a foil bowl (Figure 2.3). The procedure 
was repeated three more times so that each naris had been washed twice and a total of 
20 ml was used. Following collection, the samples were pooled in a centrifuge tube and 
transported to the laboratory at room temperature.  
 
 
Figure 2.3. Nasal wash sample collection. A syringe filled with 20 ml of sterile saline was 
inserted into the anterior nasal space and 5 ml of saline was expelled. The volunteer then 
leaned forward and expelled the saline by exhaling rapidly through the nose into a foil bowl. 




2.4.3 Nasopharyngeal sample collection and processing 
After the treatment with antibiotics (only the pneumococcal colonised group) and 
during the preparation for the bronchoscopy, a nasopharyngeal swab (NPS) and an 
oropharyngeal swab (OPS) was collected in a medium containing skim milk, tryptone, 
glucose and glycerine (STGG) per volunteer to assess the clearance of pneumococcal 
colonisation. As, pneumococci usually reside the posterior of the human nasopharynx, 
this was the most suitable sampling method.  
 
Figure 2.4. Collection of NPS and OPS prior the bronchoscopy. NPS and OPS were collected 
to assess clearance of pneumococcal colonisation in the nasopharynx of the volunteers on 
the day of the bronchoscopy. Picture that demonstrates collection of NPS was adapted form 
NEJM Procedure (Collection of Nasopharyngeal Specimens with the Swab Technique). 
 
2.4.4 Bronchoscopy 
In preparation for the bronchoscopy, participants received local anaesthesia using 
topical lidocaine gel and spray, with further 4% lidocaine administered to the larynx and 
2% lidocaine to the bronchial tree via the scope. Using a single use, flexible bronchoscope 
(Figure 2.5), warmed 0.9% saline was instilled to the right middle lobe in sequential 
aliquots (40-50 ml). Bronchoalveolar lavage fluid (BAL) was aspirated into a sterile 
syringe using gentle manual suction. BAL yields were recorded, and the samples were 
transported immediately to the laboratory on ice (Figure 2.5). The volunteers’ heart rate, 
blood pressure and oxygen saturations were continuously monitored during the 
procedure, with supplemental oxygen given by nasal cannula. All procedures were 
carried out in a research ward by a senior bronchoscopists, experienced in obtaining BAL 




    
Figure 2.5. Bronchoscopy and bronchoalveolar lavage sample collection. Bronchoscope was 
inserted through the nasal route and warm saline was instilled into the right middle lobe. 
BAL fluid was collected in sterile tubes and transferred on ice.  
 
2.5 Laboratory procedures 
 Bacterial stocks for either inoculation or in vitro assays and BAL sample 
processing where the core laboratories procedures used in this study.  
2.5.1 Pneumococcal growth conditions for in vivo administration 
A clinical pneumococcal isolate of serotype 6B, strain BHN418 (a gift of Prof. P 
Hermans, Radboud University Nijmegen, Netherlands) grew under aseptic conditions 
and was used for intranasal challenge in healthy, non-smoking adults, aged 18 to 50 
years. The strain was initially cultured on Columbia Blood Agar with horse blood (Oxoid) 
and incubated at 37°C overnight in 5% CO2.The following day a “parent” bead stock was 
made by scraping all the overnight growth from the blood agar plate and was added into 
a cryovial containing ceramic beads and cryo-preservative fluid (Technical Service 
Consultants Ltd.). Vials were stored at -80°C and were tested for purity and colony 
uniformity before being used to prepare the inoculum stocks. These “parent” stocks (also 
called as seed stock) were used to prepare all subsequent inoculation stocks. 
 
2.5.2 Inoculum stock preparation 
Preparation of inoculum stocks was carried out in a fumehood, using a dedicated 
incubator and set of pipettes.  A loopful from the “parent” bead stock was streaked for 
heavy growth onto a blood plate, ensuring that the entire plate was covered. The plate 




vegetable-based growth medium- Vegitone Infusion broth (Fluka, Sigma-Aldrich, 
Missouri, USA) was use for the liquid growth phase of the inoculum, as it was crucial that 
no animal products were administered to the volunteers. The bacterial culture was 
incubated at 37°C, 5% CO2 (no shaking) until mid-log phase was reached (0.30-0.35 OD 
measured at 600nm), following centrifugation at 3345g for 15min. Supernatant was 
discarded, whereas the bacterial pellet was resuspended in fresh Vegitone broth plus 
20% v/v glycerol (Sigma-Aldrich, glycerol for molecular biology). After thorough mixing, 
1ml aliquots were prepared and stored at -80°C. Within a week after freezing, the 
concentration of each stock was quantified by applying the Miles and Misra method on 
two to three stock aliquots (M&M, see section 2.5.4) to ensure reproducibility. Each 
inoculum stock (1ml vial was used per inoculum session) was diluted in sterile phosphate 
buffered saline (PBS) from known concentration to the administrated inoculum dose, 
which was fixed at 80,000 CFU/100ul per nostril across the above mentioned EHPC 
studies (Table 2.1).  
 
2.5.3 Bacterial strains and growth conditions for in vitro assays 
The challenge strain (serotype 6B, BHN41) was also used in in vitro assays, such as 
alveolar macrophages opsonophagocytic killing assay (OPA) and cell stimulation assays 
in a heat-inactivated form. For the purposes of these experimental assays, the 
pneumococcal strain was cultured as described above but in Todd Hewitt broth 
supplemented with 0.5% yeast extract (THY) until early log phase.  Other bacteria used 
in the OPA were two gram positive (Streptococcus pyogenes and Staphylococcus aureus) 
and one gram negative (Escherichia coli). S. pyogenes (MGA315) was cultured from a 
single colony in Brain Heart Infusion (BHI) broth overnight at 37oC with 5% CO2.  S. aureus 
(human isolate from EHPC trial) and E. coli (NCTC86) were cultured in BHI and Luria Broth 
(LB), respectively, from a single colony overnight, on a shaking rotor at 37oC with 
aeration. All bacterial stocks were grown till the early log phase. After addition of 20% 
v/v glycerol, they were aliquoted to 1ml vials and stored at stored at -80oC until further 






2.5.4 Quantification of bacterial stock – Miles and Misra method 
A modification of the Miles & Misra method was used to perform viability counts 
on the bacterial stocks prior use in the experimental assays or on the inoculation Spn6B 
stocks (Miles, Misra and Irwin 1938). Blood or LB agar plates were divided into six 
sections, which were labelled from 1 to 6 (Figure 2.6). In a 96 well U-bottom plate 
(Corning Inc.), 20 μl of bacteria was added to 180 μl of sterile PBS and serially diluted 
(10-fold) until a dilution of 106 was reached. Three drops of 10 μl from each dilution were 
placed on the corresponding section of the plate and allowed to dry. The plate was then 
inverted and incubated overnight at 37°C, 5% CO2. The next day, visible colonies in each 
dilution section were counted and recorded (Figure 2.6).  
 
 
Figure 2.6. Miles and Misra bacterial quantification. Three 10 μl drops from a serial dilution 
were placed on the corresponding dilution section of the plate. The plate was then inverted 
and incubated overnight at 37°C, 5% CO2. Individual colonies can be counted in the 5th and 
6th dilution.  
 
The final concentration of the bacterial stock was calculated using the following 
equation. (x= number of total colonies counted in a dilution section, 10x = dilution factor). 





2.5.5 Nasal wash sample processing  
Nasal wash samples were processed using our published method (Gritzfeld et al. 
2013). The collected samples were transferred to the laboratory within 1 hour after 
collection and centrifuged at 4,000g for 10min. The pellet was separated from the 
supernatant and was resuspended in 100μl of STGG. 20μl of suspension were plated 
directly on a horse blood agar plate supplemented with 4μg/ml gentamycin (Sigma). 
Additionally, 10μl were serially diluted 4 times in a 96-well plate and Miles & Misra 
quantification method was performed on a gentamycin-enriched blood agar plate to 
determine the pneumococcal density (section 2.5.4).  
 
2.5.6 Nasopharyngeal and Oropharyngeal swab sample processing  
The collected nasopharyngeal and oropharyngeal samples were plated directly on a 
gentamycin-enriched blood agar plate. The swab was placed back in the tube and the 
sample was frozen at -80oC until DNA extraction.  
 
2.5.7 Bronchoalveolar lavage processing 
BAL samples were processed as previously described (Mitsi et al. 2018, Zaidi et al. 
2017).  During the bronchoscopic procedure, the BAL fluid was collected in several 
sterile, plastic, non-adhering, 50ml tubes and stored on ice. BAL samples were 
transferred to the lab and were processed within 30min from the collection time. The 
whole BAL sample was filtered using a 70μM filter (Thermofisher) placed on the top of a 
250ml sterile conical flask. This enabled the combination of subsequent BAL fractions, 
generating a homogeneous lavage fluid.  Then, the combined BAL fluid was re-distributed 
to 50ml falcon tubes and centrifuged at 400g for 10 min at 4°C. The supernatant was 
removed and kept at -80oC till further use. The cell pellets were resuspended in cold 




Neomycin and Streptomycin- PNS, Sigma-Aldrich) and combined in one tube. The 
centrifugation step was repeated once, and the final cell pellet was resuspended in cold 
RPMI, plus 1% PNS and 10% heat-inactivated, fetal bovine serum (HI-FBS, Gibco) 
(hereafter referred to as complete RPMI). Viability cells count was performed in each 
BAL sample, using trypan blue in raw material and a haemocytometer. This method 
allowed us to differentially count alveolar macrophages (AM) and lymphocytes (Figure 
2.7). BAL samples yielded a median 5.81 x 106 cells/ml (IQR: 5.81 x 106 – 7.81 x 106 
cells/ml), from which approximately 80% was constituted by AM (median: 4.5 x 106 
AM/ml, IQR: 2.65 x 106 - 6.5 x 106 AM/ml). Following counting, the cell concentration was 
adjusted to 5 x 105 AM/ml, following seeding of 2.5 x 105 AMs per well in a 24-well plate 
(Corning) and incubated overnight. In BAL samples with high cell yield, a faction of cells 
was spun down at 400g for 10 min and the cell pellet was resuspended in cryo-
preservative medium (CryoABC, Immunospot), following gradual freezer in -80oC and 
liquid nitrogen tank for further use. 
 
 
Figure 2.7. Microscope image of whole BAL differential staining. Alveolar macrophages 
represent the most abundant lung cellular population (adherent cells), whereas lymphocytes 




occasionally present in the healthy human lung. Additionally, the presence of bronchial 
epithelial cells in the BAL sample is not very common. Image source: (Collins et al. 2014) 
 
2.5.8 Alveolar macrophages isolation  
AMs were routinely separated from other cell populations by seeding and 
adherence on 24-well plate (Greiner Bio-One, Kremsmünster, Austria) (Wright et al. 
2013). After 4 hours adherence step, the non-adherent fraction was removed. AM 
remained adherent on the 24-well plate and the culture was replenished with warm 
complete RPMI, following overnight incubation at 37oC with 5% CO2. A spare well of 
seeded AM was used for assessment of their viability prior to functional assays. 250ul of 
2.5mM EDTA in cold RPMI was added in the well to accelerate AM detachment from the 
plastic surface, following viability assessment by Trypan blue staining. In experiments 
where a highly pure AM population (95% purity based on the cell sorter counts) was 
required, AMs were purified from the whole BAL sample (half BAL cell pellet used) 
through cell sorting (FACS ARIAIII cell sorter, BD Biosciences), using a combination of cell 
surface antibody markers for a range of lung cell population (Table 2.2). Gating strategy 
followed for AM sorting is illustrated on Figure 2.8. In addition, the characteristic size 
and granularity of AM further enabled the identification of this major lung population 
and resulted in a highly pure AM extract after the cell sorting. The isolated AMs were 
counted under the microscope (median: 1.1 x 106 AM/ml, IQR: 0.8 x106 – 1.7 x106 AM/ml) 
and seeded on 96-well plate at the concentration of 2.5 x104 per well, following 










Figure 2.8. Gating strategy of alveolar macrophage sorting. Alveolar macrophages were sorted through negative selection from other lung cell 





2.5.9 BAL lymphocytes isolation 
BAL lymphocytes were routinely separated from AMs post the 4 hours adherence 
step. Then, the cells were centrifuged at 400g for 5min, resuspended in complete RPMI 
and seeded in 96-well plates at equal concentrations of 600,000 to 1 million cells. In 
some experiments, isolated CD4+ T cells were used. CD4+ T cells were isolated from fresh 
whole BAL sample post cell staining with a combination of key cell surface antibody 
markers (Table 2.2) and following sorting using a FACS ARIAIII cell sorter.  
Table 2.2. Conjugated antibodies used for sorting of human alveolar macrophages and 
CD4+ T cells from whole BAL sample.  This panel was used in results of Chapter 4.  
Marker Fluorochrome Clone Reference 
TCR-γδ FITC 11F4 304006 
CD4 PerCPCy5.5 SK3 344608 
CD16 PECy7 3G8 302016 
CD66b APC G10F5 305118 
CD3 APC-Cy7 SK7 344818 
Live and Dead BV510 NA L34957 
CD56 BV711 NCAM 563169 
CD8 BV785 SK1 344734 
 
 
2.6 Experimental assays 
The functional, molecular, flow cytometric assays and immunoassays used in 
this project are described in more details below.  
2.6.1 Alveolar macrophage opsonophagocytic assays (OPA) 
AMs opsonophagocytic capacity was evaluated as previously described with minor 
modifications (Wright et al. 2012). Live S. pneumoniae serotype  6B  (inoculation strain) 
or S. pyogenes or S. aureus or E. coli  were opsonized in a 1∶16 final dilution of human 
intravenous immunoglobulin (IVIG, Gamunex, Grifols Inc, Spain) in HBSS +/+ (with Ca2+ 




incubated with an opsonised bacterial strain in Opsonisation Buffer B (HBSS +/+ plus 1% 
gelatine solution and 5% FBS) and 10% baby rabbit complement (Mast Group, UK) at 
37oC on a shaking rotor for 60min. Following incubation, 10 µl of reaction mixture was 
plated, in triplicate, onto blood agar (Oxoid) or Luria-broth agar plates and incubated at 
37°C, 5% CO2 overnight. Colony forming units (CFUs) from cell supernatants were 
counted the following day. Multiplicity of infection (MOI) used was 1 :100 for all the 
gram-positive bacteria. Opsonophagocytic killing assay for the gram-negative (E. coli) 
was modified as described elsewhere (MOI= 1:20 for 30min and 7% baby rabbit 
complement) (Abbanat et al. 2017).  
In the assays where cell-sorted AMs were infected with opsonised Spn6B, the MOI 
was modified to 1:20 due to increased loss of cells during the high-throughput cell 
sorting. These experiments included a condition, in which purified AMs were co-cultured 
with autologous CD4+ T cells (isolated from the same BAL sample through cell sorting). 
The CD4+ T cells were added on the top of AMs, just before the uptake assay, in 1:5 ratio 
(CD4: AM).  
In some experiments AMs were stimulated with 2ng/ml, 20ng/ml, 200ng/ml and 
2,000ng/ml of recombinant IFN-γ (Bio-techne). The different concentrations of IFN-γ 
were added to the cells during the preparatory steps of opsonophagocytic assays. No 
cells pre-treatment with recombinant IFN-γ occurred. Additionally, in the experiments, 
the IFN-γ receptor 1 (IFN-γR1) was neutralised, using anti-human IFN-γR1 (Bio-techne). 
The monoclonal antibody was added in AMs culture at the concentration of 0.15μg/ml 
in the presence of up to 2ng/ml recombinant IFN-γ (Neutralization Dose as per 
manufacturer instructions) 30min prior to IFN-γ addition.  
Due to the lack of reading of lysosome acidification within AMs, the term 
pneumococcal/bacterial uptake rather than killing was used. The assays results were 
calculated using the equation: “Bacterial uptake (%) = 100 – [(100*Condition)/Control] “, 
where ‘Condition’ represents the average of CFUs recovered from each experimental 
condition and ‘Control’ represents the average CFU recovered from the bacterial dose 





2.6.2 Bacterial DNA extraction from BAL samples and quantification of 
pneumococcal DNA by qPCR 
The extraction of bacterial DNA from the BAL, OPS and NP swab samples was 
performed, using our published protocol with minor modifications (Connor et al. 2018).  
15ml of uncentrifuged BAL or 200ul of NP and OP sample were separated from total 
sample and centrifuged at full speed for 15min. Following centrifugation, the 
supernatant was discarded, and DNA was extracted from the pellet using the Agowa kit 
for bacterial DNA extraction. The extracted DNA was eluted in a volume of 63ul of elution 
buffer. DNA purity and quality were assessed by a spectrophotometer (Nanodrop ND-
1000, Thermo Fisher Scientific).  
Presence of pneumococcal DNA in BAL samples was determined using primers and 
probe specifically designed for 6B serotype, targeting on a capsular polysaccharide gene 
known as wciP, the rhamnosyl transferase gene. The primers and probe sequences were: 
forward primer 5’- GCTAGAGATGGTTCCTTCAGTTGAT- 3’; reverse primer 5’- 
CATACTCTAGTGCAAACTTTGCAAAAT- 3’ and probe 5’- [FAM] ACT GTC TCA TGA TAA TT 
[MGBEQ] -3’ as previously published (Tarrago et al. 2008). Primers and probe used in 
their optimised concentrations, 900nM primers and 200nM TaqMan MGB probe per 
reaction. A non-template control and a negative control per DNA extraction were 
included in every run. DNA was amplified with the real-time PCR System (Agilent 
Technologies, Statagene Mx3005P) by using the following cycling parameters: 95oC for 
10 min, followed by 40 cycles at 95oC for 15 sec and 60oC for 1 min. A standard curve of 
a 10-fold dilution series of genomic DNA extracted from Spn6B was used. The genomic 
DNA was extracted using the Qiagen Genomic-tip 20/G Kit (Qiagen) and quantified by 
nanodrop.   The conversion from weight pneumococcal DNA to number of DNA copies S. 
pneumoniae was based on the weight of one genome copy TIGR4 calculated by the 
genome length in base pairs times the weight of a DNA base pair (650 Dalton). The lower 
limit of detection (LLOD) of the method was set at 40 cycles. Amplification values >40 
were considered negative. A sample was considered positive if at least two of three 






2.6.3 Confocal microscopy assays 
Confocal microscopy was used for visualisation of pneumococci is association with 
AMs. In these experiments, fresh lung cells were stained in vitro, fixed on slides and 
observed under the microscope “in house”, whereas frozen cells were sent to an 
independent laboratory.   
Fresh BAL cells were washed and stained for surface markers (anti-CD14 Texas Red 
and CD45-magenda).  Cells were permeabilised and incubated with anti-6B 
pneumococcal antisera or anti-23F pneumococcal antisera (negative control) for 30 
minutes on ice and then secondary-conjugated antibody (anti-rabbit 488) for 30 more 
minutes. After washing, cells were cytospun onto microscope slides and allowed to air 
dry. DAPI solution was applied directly on the spun cells for 5 minutes. After washing, 
samples were mounted using Aqua PolyMount (VWR International) with a coverslip onto 
the microslide. The entire cytospin for each sample was manually viewed by microscopy 
for detection of pneumococci. Multiple fields of view (>3) were imaged for each sample. 
Images were captured using an inverted Tissue FAXS Zeiss Confocal Microscope. Z stacks 
were recorded at 1μm intervals at either 40x oil or 63x oil objectives. The confocal 
microscope operator was blinded to the colonisation status of the volunteer at the time 
of sampling.  
Thawed BAL samples were fixed in phosphate-buffered saline (PBS) containing 4% 
v/v EM grade formaldehyde (Sigma) for 20 min at room temperature (RT) before 
incubating 10 min with PBS containing 0.1% v/v TritonX-100 to permeabilise the cells. 
Readily, samples were incubated for 30 min in blocking solution (PBS containing 5% v/v 
goat serum) and then, incubated for 1 h with primary antibodies diluted in blocking 
solution, washed three times with PBS and incubated again for 45 min with secondary 
antibody solution. Then, samples were washed three times with PBS and once with water 
before adding the mounting medium containing DAPI (Thermoscientific ProLong Gold 
Antifade Mountant) and closing the slides with coverslips. Anti-pneumococcal capsule 
anti-6B serum (Statens Serum Institute) was used to stain bacteria. Macrophages were 
labelled using anti-human CD169 (Thermoscientific). Combinations of Alexafluor 
conjugated antibodies from Thermoscientific were used as secondary antibodies (488 
and 568nm with different host specificity). An Olympus FV1000 confocal laser scanning 




ImageJ (http://imagej.nih.gov/ij/) was used for image processing. For the bacterial 
localisation studies, Alexafluor 633-conjugated Wheat germ agglutinin was used prior to 
membrane permeabilization. Z-stack was created from microscope images, elaborated 
using Huygens Essential deconvolution software version 16 (Scientific Volume Imaging, 
Netherlands) and viewed in Imaris 3D reconstruction software 9.4 (Bitplane, 
Switzerland). 
 
2.6.4 Flow cytometry assays  
In each flow cytometry assay, the corresponding cell population was stained with 
predetermined optimal concentration of fluorochrome-conjugated monoclonal 
antibodies against human cell surface proteins or intracellular cytokines. 
2.6.4.1 AM, monocytes and neutrophil immunophenotyping 
Myeloid lineage cells were immunophenotyped using monoclonal antibodies for 
key surface markers. Whole BAL cells (1 x 106 cells) were stained with 1:50 diluted Aqua 
Viability dye (LIVE/DEAD® Fixable Dead Cell Stain kit, Invitrogen, UK) for 15 min on ice, 
following staining with  a combination of antibodies- anti-CD45 FITC, anti-CD80 APC-H7, 
anti-CD86 PE, anti-CD206 PE-CF594, anti-CD14 PerCP Cy5.5, anti-CD16 PE Cy7, anti-
CD163 APC, anti-CD11b AF700, anti-CD11c PB, anti-CD64 BV605 and anti-HLADR BV785 
(Table 2.3)- for additional 15min on ice in the absence of light. Then the cells were 
washed with 2ml of cold PBS and centrifuged at 400g for 10min at 4oC. The cell pellet 
was resuspended in 200ul cold PBS and the samples were acquired on a FACS ARIA III 
sorter/cytometer (BD Biosciences) and analysed using Flowjo version 10 (Treestar). BAL 
samples with macroscopically visual red blood cell contamination were excluded from 









Table 2.3. Conjugated antibodies and viability dye used for alveolar macrophage and 
monocyte immunophenotyping in BAL samples. This panel was used in results of Chapter 3 
and 4. 
Marker Fluorochrome Clone Provider Reference 
CD45 FITC HI30 Biolegend 304006 
CD86 PE IT2.2 Biolegend 305438 








CD16 PECy7 3G8 Biolegend 302016 
CD163 APC GHI/61 Biolegend 333610 











CD11c BV421 Bu15 Biolegend 337212 




CD64 BV605 10.1 Biolegend 305034 
HLADR BV785 L243 Biolegend 307642 
 
2.6.4.2 AM stimulation with HI-Spn6B and IFN-γ 
In this assay, AM macrophages were treated with 10-fold increased recombinant 
IFN-γ (Bio-techne), plus 5μg/mL heat inactivated Spn6B (HI-Spn6B). The latter was 
prepared from Spn6B bacterial stock 1ml aliquots, which were heated at 56oC for 30min. 
The assays include an unstimulated condition, where cells were left unstimulated, as well 
as a condition that include stimulation with Spn6B but not IFN-γ.  In more details, 1 
million of BAL cells per condition, resuspended in complete RPMI, were added in 24-well 
plate and incubated overnight at 37oC, 5% CO2. Non-adherent cells were removed, and 
AMs were washed 3x with pre-warmed plain RPMI, following stimulation with 10x 
increased concentration of IFN-γ (2ng/ml, 20ng/ml, 200ng/ml and 2,000ng/ml) for 
30min. Post the cytokine stimulation, cells received 5μg/ml of HI-Spn6B and were 




controls were included per volunteer. Cytokines were retained within alveolar 
macrophages by the addition of the GolgiPlug (BD Biosciences)- a protein transport 
inhibitor, containing Brefeldin A- and were incubated at 37oC, 5% CO2 for 2 more hours.  
Cell Permeabilisation and fixation step: Post incubation time, AMs were washed with PBS 
and detached from the wells by adding of 2.5mM EDTA solution. Cells were collected in 
FACS tubes and pelleted (400g for 10 min centrifugation) and resuspended in 1ml 
Perm/Fix buffer, following 30min incubation in the dark. Then the cells were washed 
twice with 2mls of Perm wash, following staining for human AM surface markers - anti-
CD169-PE, anti-CD14 PerCyP5.5, CD206 PE-CF594 and CD45 Pacific Orange, whereas for 
intracellular staining anti-TNF-α BV605 was used (Table 2.4) for 45min. Post staining step 
incubation time, the samples were washed with 3mls of PBS, spun down at 400g for 
10min and then the cell pellet was resuspended in 200ul PBS. All the samples were 
acquired on a LSRII flow cytometer (BD Biosciences) and analysed using Flowjo version 
10 (Treestar). 
 
Table 2.4. Conjugated antibodies used for intracellular cytokine staining after treatment 








Marker Fluorochrome Clone Provider Reference 
CD169 PE 7-239 Biolegend 346004 
CD14 PerCPCy5.5 MΦP9 BD Biosciences 562692 
CD206 PE-CF594 19.2 BD Biosciences 564063 
CD45 BV510 HI30 Life Technologies MHCD4530 




2.6.4.3 Transcription factors analysis 
1 million of BAL cells were washed with 3 mL of PBS and stained with 1:50 diluted 
Aqua Viability dye (LIVE/DEAD Fixable Dead Cell Stain kit, Invitrogen, UK) for 15min, 
following addition of antibody cocktail against the following surface markers CD3-
APC.cy7, CD4–PerCP5.5, CD8–AF700, CD69–BV650, anti-CD25-PETexasRed and CD45-
BV711 (Table 2.5) for additional 15min on ice in the absence of light. After incubation, 
the cells were washed with 2mls of cold PBS and centrifuged at 400g for 10min at 4oC.  
For permeabilization and fixation, Foxp3/Transcription Factor Staining Buffer Set 
(eBiosciences, San Diego, CA) was used as described at section 2.6.4.2, without the prior 
addition of EDTA. Permeabilised/fixed cells were stained intracellularly for transcription 
factors analysis with anti-T-bet-APC, anti-Gata-3-PE and anti-Foxp3-FITC (table 2.5) for 
30min on ice in the absence of light. All samples were acquired on a LSRII flow cytometer 
(BD Biosciences). 
 
Table 2.5. Conjugated antibodies and viability dye used for analysis of transcription factors 
within T cell subsets. This panel was used in results of Chapter 4. 
Marker Fluorochrome Clone Provider Reference 
CD25 PE/Dazzle M-A251 Biolegend 356126 
CD4 PerCPCy5.5 SK3 Biolegend 344608 
CD3 APC-Cy7 SK7 Biolegend 344818 
CD8 Alexa Fluor 700 SK1 Biolegend 344724 




CD69 BV650 FN50 Biolegend 310934 
CD45 BV711 HI30 Biolegend 304050 










2.6.4.4 INF-γ, TNF-α and IL-17 producing BAL lymphocytes post Spn stimulation  
In these assays, cells were harvested, stained and analysed as previously 
described, with minor modifications (Wright et al., 2013; Wright et al., 2012) to ensure 
accurate reproducibility of previous findings. The previous antibody panel was expanded 
to include tissue resident cell markers, as well as a surface marker for TCR-γδ Τ cells. 
Therefore, non-adherent cells were collected from the BAL samples post an adherence 
step, centrifuged at 400g for 5min, resuspended in complete RPMI and seeded in 96-well 
plates at equal concentrations of 600,000 to 1 million cells per condition. Cells were 
stimulated with 5μg/ml of HI-Spn6B and incubated for 2 hours at 37oC, following addition 
of GolgiPlug (BD Biosciences) and overnight incubation at 37oC, 5% CO2. A non-
stimulated with Spn6B (mock) cell condition was included per volunteer.  After 16 hours, 
the cells were washed with PBS and stained with Violet Viability dye (LIVE/DEAD Fixable 
Dead Cell Stain kit, Invitrogen, UK) and anti-CD3-APCH7, anti-TCR-γδ –PECy7 (BD 
Biosciences, USA), anti-CD4–PerCP5.5, anti-CD8–AF700, anti-CD69–BV650, anti-CD25-
PE.TxsRed, anti-CD103–BV605, anti-CD49a-APC (Biolegend, San Diego, CA). For the 
assessment of intracellular cytokine production, after permeabilization and fixation, the 
cells were stained with the following markers: anti-IFN-γ-PE, anti-IL17A–BV510 and TNF-














Table 2.6. Conjugated antibodies and dyes used for analysis of intracellular cytokine 
production in T cell subsets. This panel was used in results of Chapter 4 and 5. 
Marker Fluorochrome Clone Provider Reference 
CD4 PerCPCy5.5 SK3 Biolegend 344608 






TCR-γδ PECy7 11F2 BD Biosciences 655410 
CD49a APC TS2/7 Biolegend 328314 
CD25 PE/Dazzle M-A251 Biolegend 356126 
CD69 BV650 FN50 Biolegend 310934 
CD103 BV605 Ber-ACT8 Biolegend 350218 
Live and Dead BV421 NA Fisher Scientific L34964 
IL17A BV510 N49-653 BD Biosciences 563295 
TNF-α BV711 MAb11 Biolegend 502936 
INF-γ PE 45.B3 Biolegend 502509 
 
2.6.5 Luminex analysis of Bronchoalveolar lavage fluid  
The acellular BAL fluid (BAL supernatant) was collected post centrifugation of 
whole BAL sample (400g for 10min at 4oC), divided to 1ml aliquots and stored at -80oC 
until analysis. On the day of the analysis frozen BAL fluid samples were concentrated x10 
(1ml of BAL concentrated to 100ul using vacuum concentrator RVC2-18) and acquired 
using a 30-plex magnetic Luminex human cytokine kit (ThermoFisher), following 
manufacturer’s instructions. Analytes measured by the kit are presented on table 2.7. 
Particularly, 30µL of the concentrated BAL fluid was placed on a 96-well plate (U-bottom) 
followed by addition of 30µL of Assay diluent and 30µL of incubation buffer to each well. 
Standard serum sample was serially diluted 1:10 in assay diluent. 60μl of each dilution 
was mixed with 30ul of incubation buffer in the working plate. 15μl of antibody beads 
were added into each well (including standard, sample and blank wells). 45μl of total 
reaction per condition was transferred to the Luminex plate in duplicates. The plate was 




On the following day, the antibody beads were washed twice with 200μl Wash 
Solution while the Luminex plate was attached to a magnet when the washing buffer was 
discarded. Following washing and air drying, 25μL Biotinylated detector antibody was 
added to each well and the plate was incubated for one hour at RT, placed on an orbital 
plate shaker. After the incubation, the beads were washed twice with wash buffer and 
25μL Streptavidin-RPE solution was added to each assay well. The samples were 
incubated for 30 minutes at RT on an orbital plate shaker. After the final incubation step, 
the beads were washed 3 times with wash solution, following addition of 105μl wash 
solution in each well. Samples were acquired and analysed on a LX200 with xPonent3.1 
software following manufacturer’s instructions. Samples were analysed in duplicates and 
BAL samples with a CV > 50 % were excluded. 
 
Table 2.7. Cytokine human magnetic 30-Plex panel. Luminex platform designed for 
quantifying cytokines, chemokines and growth factors in a range of human samples. 
Cytokines Chemokines Growth Factors 
G-CSF Eotaxin EGF 
GM-CSF IP-10 FGF-basic 
IFN-α MCP-1 HGF 
IFN-γ MIG VEGF 
IL-1β MIP-1α  
IL-1RA MIP-1β  
IL-2 RANTES  
IL-2R   
IL-4   
IL-5   
IL-6   
IL-7   
IL-8   
IL-10   
IL-12 (p40/p70)   
IL-13   
IL-15   
IL-17   




2.6.6 Alveolar macrophage gene analysis using Nanostring platform 
AM gene expression was assessed by using Nanostring platform based on our 
previously published protocol (Jochems et al. 2018). Alveolar macrophages from Spn 
colonised and non-colonised volunteers were sorted by FACS ARIAIII cell sorter, as 
described at section 2.26, and stored in Qiazol (Qiagen) at -80C until RNA extraction.  
 
2.6.6.1 RNA extraction from alveolar macrophages 
RNA extraction was performed using the RNEasy micro kit (Qiagen) with on 
column DNA digestion. On the day of RNA extraction, samples were thawed on ice and 
1ml of Qiazol was added to them. The samples were split equally to two tubes and 100ul 
1-Bromo-3-chloropropane was added to each tube. Homogenates were shaken 
vigorously for 15 sec, following centrifugation at 12,000g for 15 min at 4°C. After 
centrifugation the upper aqueous phase was aspirated and transferred to a new sterile, 
RNase-free tube and 1 volume of 70% ethanol in RNase-free water was added in.  Prior 
to sample (homogenate with ethanol) loading on the RNeasy Micro spin column, the 
column was treated with 5μl of carrier RNA (4ng/μl).  Loaded sample on the column was 
centrifuge for 15 sec at 8,000g. The flow-through was collected and this step was 
repeated 3 times. The column washed twice with RW1 buffer, while both DNA and RNA 
were bound to the membrane. DNA was digested by application of DNAse I mix directly 
on the column membrane. Digested DNA was removed through washing steps. The RNA 
was eluted from the column, when RNase-free water was added upon the membrane 
for 5min and RNA collected to a sterile, RNase-free tube after 1min centrifugation at 
12,000g. Extracted RNA was quantified using using Qubit® Fluorometer and nanodrop. 
In addition, extracted RNA was quantified by qPCR targeting B2M gene (Bioanalyzer, 








2.6.6.2 Preparation of cDNA library and Nanostring platform 
 The synthesis of first-strand cDNA was done using VILO superscript. The 
extracted RNA was diluted in RNase-free water to correspond to 100 cells. 4μl (up to 
2.5μg) of diluted RNA were mixed with 1μL SuperScript™ VILO™ MasterMix and 
transferred to a thermocycler, applying the following program parameters: 25oC for 
10min, 42oC for 120min and 85oC for 5min.  
The single cell immunology v2 kit (Nanostring) was used with 20-pre-
amplification cycles for all samples. Hybridised samples were prepared on a Prep Station, 
according to hybridization protocol for nCounter XT CodeSet Gene Expression and 
scanned on a nCounter® MAX (Nanostring). Hybridization reaction took place at room 
temperature for each sample with the following components: 3 μl of Reporter CodeSet, 
5 μl of hybridization buffer, up to 8 μl (25–100 ng) of sample RNA, and 2 μl of Capture 
ProbeSet. Immediately after the addition of Capture ProbeSet, the Capture ProbeSet 
tubes were spun down briefly and placed into the pre-heated 65°C thermal cycler and 
incubated for 16 hours, following 4oC step. The following day nanostring plate was 
scanned by nCounter® MAX (Nanostring).  
Raw counts were analysed using the R/Bioconductor package DESeq2 for internal 
normalisation, which gave lower variance than normalising to included housekeeping 
genes. Differentially Expressed Genes (DEG) were identified using a model matrix 
correcting for repeated individual measurements. Log CPM from raw counts were 
calculated using the ‘edgeR’ package. 2logFold chances were further analysed by the 
‘fgsea’ package, through BMT pathways gene set enrichment analysis.  
 
2.6.7 Levels of IgG to Spn6B capsular polysaccharide in the BAL fluid 
Levels of IgG to CPS-Spn6B were measured in BAL fluid using the standardised 
ELISA method and reagents, as previously described (Goldblatt et al. 2011, Mitsi et al. 
2017). 96-well plates (NUNC maxisorp) were coated with 5 µg/ml of purified 6B capsular 
polysaccharide (Statens Serum Institute) and incubated overnight at 4°C. The following 
day, plates were washed three times with PBS-Tween 0.05% between each step, using a 




Acellular, unconcentrated BAL samples were pre-incubated with 10µg/ml cell 
wall polysaccharide mixture (CWPS Multi, Statens Serum Institute) for 2h before they 
were transferred to pre-coated plates, following 2h incubation at room temperature. 89-
SF reference serum (U.S. Food and Drug Administration) was used as a standard. Bound 
antibodies were detected using goat anti-human IgG conjugated with alkaline 
phosphatase (Sigma-Aldrich) in 1:4000 for 2 hours at room temperature. 0.5 mg/ml of p-
nitrophenyl phosphate (PNPP) was added as a substrate. Optical densities were 
measured at 405 nm using a FLUOstar Omega microplate reader (BMG Labtech, UK). All 
samples were run in duplicates and samples with CV >20% were excluded. Results were 































Phenotype and Polarisation Profile of Human Alveolar 
Macrophages 
 
3.1 Introduction  
The healthy human alveoli are dominated by alveolar macrophages (AM) 
(Wissinger, Goulding and Hussell 2009). These cells play a critical role in regulating 
immune responses (Gordon and Read 2002) and maintaining homeostasis in the lung 
(Wissinger et al. 2009, Snelgrove, Godlee and Hussell 2011). Both functions are of great 
importance in preventing infection, disease and extensive lung tissue damage. However, 
each function requires plasticity within the lung resident macrophage population so that 
pro-inflammatory responses to tissue debris or to innocuous antigens are inhibited, but 
effective immune responses to pathogenic microorganisms are not compromised with 
the local microenvironment to tailor them to the task required. Alveolar macrophage 
plasticity to adapt to changes in their microenvironment is fundamental in retaining the 
lung health (Stout and Suttles 2004). 
Macrophages have been classified into classically activated (M1 mode polarised) 
and  alternatively activated (M2 mode polarised) (Mosser and Edwards 2008, Hussell and 
Bell 2014). Classically activated macrophages are generated in response to IFN-γ, TNF-α 
or activated by Toll Like Receptor (TLR) ligands. They have enhanced antimicrobial 
activity, produce cytokines that are important for host defence and interact with T cells 
to give rise to Th1 and Th17 cells, with the latter producing IL-17, a cytokine that is 
associated with increased neutrophil recruitment (Loke et al. 2007). M1 macrophages 




molecules CD80 and CD86, and the FCγ receptor I, CD64 (Biswas and Mantovani 2010, 
Martinez and Gordon 2014). In contrast to classically activated macrophages, 
alternatively activated macrophages (M2 phenotype) have reduced antimicrobial 
capacity and promote tissue remodelling. IL-4 is an early signal released in response to 
Th2-mediated inflammation (Loke et al. 2007). The presence of IL-4 and IL-13 converts 
macrophages into alternatively activated macrophages, and this is amplified by IL-33 and 
IL-25 produced by epithelial cells, macrophages and Th2 cells (Gordon and Martinez 
2010) in order to promote tissue remodelling (Loke et al. 2007). Alternatively activated 
macrophages produce fewer proinflammatory cytokines and are less efficient at killing 
intracellular pathogens such Mycobacterium tuberculosis (Mosser and Edwards 2008, 
Edwards et al. 2006). The surface-marker expression profile of M2 macrophages includes 
the scavenger receptor CD163 and the mannose receptor CD206 (Biswas and Mantovani 
2010, Martinez and Gordon 2014). In addition, macrophages, generated in response to 
cytokines such as IL-10, produce anti-inflammatory cytokines (especially IL-10 and IL1-
RA) to supress immune responses.  
This categorisation is derived from murine models, and from in vitro polarisation 
of human macrophages using a combination of cytokines. However, whether alveolar 
macrophage polarisation in steady state fits the traditional M1/M2 dichotomy is still not 
well understood.  Human studies using healthy alveolar macrophages are few or do not 
directly address the question to their polarisation. There is an unverified yet assumption 
that human alveolar macrophages do not neatly fit into the current macrophage 
classification by flow cytometric analysis (Habibzay, Weiss and Hussell 2013) (Hussell and 
Bell 2014).   
Therefore, in this study we sought to describe the phenotype and polarisation 
profile of human alveolar macrophages.  To pursue this purpose, we immunophenotyped 
human alveolar macrophages from adults living in two different geographical locations: 
UK and Malawi. The two setting were selected to represent a developed and low-income 
country, respectively. This allowed us to study human AM polarisation in steady state 
and ascertained the stability of the phenotype in two distinct geographical regions and 





3.2 Material and Methods 
Bronchoalveolar lavage samples collected and analysed in the present study 
derived from two different human adult cohorts: a) UK and b) Malawi cohort. UK cohort 
were challenged intranasally with S. pneumoniae serotype 6B, whereas Malawi cohort 
was divided in two groups: i) healthy HIV-1-uninfected and ii) age-matched 
asymptomatic HIV-1-infected volunteers. The latter have never received any 
antiretroviral treatment (ART naïve).  
Common clinical and experimental procedures applied in both cohorts are 
described in more details in Chapter 2 (Material and Methods). Both UK and Malawi 
demographic data and alveolar macrophages immunophenotyping are presenting in full 
details in the current methods section due to slightly differential approach.  
 
3.2.1 UK Cohort:  Experimental human pneumococcal intranasal challenge 
and carriage determination  
Briefly, in the UK, healthy, non-smoking participants aged 18-50 years were 
recruited from an ongoing study of the experimental human pneumococcal challenge 
(EHPC) model (Chapter 2- Figure 2.1/EHPC study 2).  At Day 0 volunteers were inoculated 
with 80,000 CFU of live pneumococci serotype 6B per naris. Pneumococcal colonisation 
was detected by classical microbiology methods and quantified by serial dilution from 
nasal washes performed at days 2, 7, 9 and 27 (Gritzfeld et al. 2013). A subset of 25 
participants, 16 individuals who had become colonized (carriage +) with Streptococcus 
pneumoniae, and 9 who had not (carriage –) underwent a single time-point research 
bronchoscopy in the Clinical Research Unit (CRU) at the Royal Liverpool University 
Hospital (RLUH) between 4 to 7 weeks after the bacterial challenge (Zaidi et al. 2017).  
Demographic data of the UK and Malawi study participants are presented in table 3.1. 








Table 3.1. Demographics of the EHPC study participants- UK. Abbreviations; CFU= colony 
forming units. A single time-point bronchoscopy was performed at any day between 4 to 7 
weeks post the bacterial challenge.  







Median age (range) -years 20 (19-25) 21 (18-31) p>0.05 
Sex (M:F) 
 
4:5 7:9  
Median inoculation dose (range) 






Median duration of carriage 
(range)- days post inoculation 
 
N/A 27.0 (14.0-27.0)  
 
 
3.2.2 Malawi Cohort- Study participants 
The study was conducted at the Queen Elizabeth Central Hospital, a large 
teaching hospital in Blantyre, Malawi. Participants were recruited from the hospital’s 
voluntary counselling and testing (VCT) and antiretroviral treatment (ART) clinics. They 
were adults aged ≥18 years comprising healthy HIV-1-uninfected and asymptomatic HIV-
1-infected volunteers with no clinical evidence of active disease and willing to undergo 
bronchoscopy and bronchoalveolar lavage (BAL) for research purposes (Mtunthama et 
al. 2008). HIV testing was performed on whole blood using two commercial point-of-care 
rapid HIV test kits, Determine HIV 1/2 kit (Abbott Diagnostic Division) and Unigold HIV 
1/2 kit (Trinity Biotech Inc.). A participant was considered HIV-uninfected if the test was 
negative by both kits or HIV-infected if the test was positive by both kits. If Determine 
and Unigold results were discordant, a third rapid test using Bioline HIV 1/2 kit (Standard 
Diagnostics Inc.) was performed to resolve the discordance. None of the participants 
were on ART at the time of recruitment to the study, but all initiated ART after sample 
collection according to the 'test and treat' Malawi national treatment guidelines. 
Exclusion criteria for the study were: current or history of smoking, use of 







  Table 3.2. Demographics of study participants – Malawi  





Median age (range) -years 33 (20-35) 33 (22-35) p>0.05 
Sex (M:F) 7:3 7:3  
Peripheral blood CD4 count 
(cells/μl), median (IQR) 
664 (469-746) 251 (154-356) 0.0001 
White blood cell count (cells/L), 
median (IQR) 
4.4 (3.4-4.8) 4.7 (4.0-6.4) 0.4692 




13.0 (11.3-13.8) 0.0121 
Haematocrit (%), median (IQR) 47.4(41.8-49.7) 38.9(35.2-41.4) 0.0140 
 
 
3.2.3: Intranasal pneumococcal challenge- UK Cohort  
Full details can be found in section 2.4.1 (Nasopharyngeal inoculation) 
 
3.2.4 Bronchoscopy- UK and Malawi cohorts 
The same bronchoscopic procedure was applied in both UK and Malawi. Full 
details can be found in section 2.4.4.  
 
3.2.5 Bronchoalveolar lavage sample processing- UK and Malawi cohorts  
BAL samples collected in UK and Malawi were processed using the same 
methodology described in section 2.5.7.   
 
3.2.6 Alveolar macrophage isolation- UK and Malawi cohorts 
In both sites, alveolar macrophages were separated from the other cell 





3.2.7 Alveolar macrophage immunophenotyping 
Flow cytometry-based immunophenotyping was used to characterise AM 
phenotype obtained from BAL fluid. The expressional levels of key surface markers were 
measured immediately after sample collection. Whole BAL cells (1 x 106 cells) were 
stained with predetermined optimal concentration of flourochrome-conjugated 
monoclonal antibodies against human cell surface proteins.  
At the UK site, cells were stained with Aqua Viability dye (LIVE/DEAD® Fixable 
Dead Cell Stain kit, Invitrogen, UK), anti-CD45 FITC, anti-CD80 APC-H7, anti-CD86 PE, anti-
CD206 PE-CF594, anti-CD14 PerCP Cy5.5, anti-CD16 PE Cy7, anti-CD163 APC, anti-CD11b 
AF700, anti-CD11C PB, anti-CD64 BV605 and anti-HLADR BV785. All the samples were 
acquired on the FacsAria III sorter/cytometer (BD Biosciences). 
 At the Malawi site, the cells were stained with anti-CD45 Alexa Fluor 700, anti-
CD206 APC, anti-CD66b FITC, anti-CD163 Brilliant Violet 421, and anti-CD86 PE Dazzle (All 
Biolegend, UK). Further details of the antibodies are included in Table 3.3.  Flow 
cytometry data were analysed using FlowJo software (TreeStar, USA). Compensation was 
set using CompBeads (BD Biosciences). All samples were acquired on the BD LSRFortessa 
flow cytometer (BD Biosciences).  
Flow cytometry data were analysed using FlowJo software (TreeStar, USA) 
(Figure 3.1 and 3.2). Expression of surface markers was calculated by subtracting the 
Median Fluorescent Intensity (MFI) of the surface marker on the AM population from 
the Median Fluorescent Intensity (MFI) of the surface marker on the Neutrophil 
population (negative control), divided by twice the robust standard deviation of the MFI 










Table 3.3.  Summary of the panel composition at the UK site (no shading) and Malawi site 
(grey shading).  
Marker Fluorochrome Clone Provider Filter Isotype 
CD45 FITC HI30 Biolegend 530/30 IgG1 
CD80 APC-H7 L307.4 BD Biosciences 780/60 IgG1 
CD86 PE IT2.2 Biolegend 585/42 IgG2b 
CD206 PE-CF594 19.2 BD Biosciences 616/23 IgG1 
CD14 PerCPCy5.5 MƟP9 BD Biosciences 695/40 IgG2b 
CD16 PECy7 3G8 Biolegend 780/60 IgG1 
CD163 APC GHI/61 Biolegend 660/20 IgG1 
CD11b AF700 ICRF44 BD Biosciences 730/45 IgG1 
CD11c PB Bu15 Biolegend 450/50 IgG1 
CD64 BV605 10.1 Biolegend 610/20 IgG1 
HLADR BV785 L243 Biolegend 780/60 IgG2a 
Live & Dead BV510 NA Invitrogen 510/50 NA 
CD206 APC 15-2 Biolegend 660/20 IgG1 
CD66b  FITC G10FG Biolegend 530/30 IgM 
CD163 Bv421 GHI/61 Biolegend 450/50 IgG1 
CD45 AF700 2D1 Biolegend 730/45 IgG1 


















Figure 3.1.  Gating strategy used to identify human alveolar macrophages in the UK Cohort. Leucocytes were identified as CD45+, following exclusion of 
doublets and dead cells (precaution was taken not to gate out highly autofluorescent alveolar macrophages). Neutrophils were identified as 
CD45+CD16+CD86- cells. Alveolar macrophage (AM) and lymphocyte populations were identified by their forward scatter (FSC) and side scatter (SSC) 
characteristic properties. Using CD206 and CD86 we separated AM to four subpopulations: CD206loCD86hi, CD206hiCD86hi, CD206hiCD86lo and CD206loCD86lo. 
Neutrophils or lymphocytes were used as the negative population to calculate the degree of expression of AM surface markers CD163, HLA-DR, CD64 and 






Figure 3.2. Gating strategy used to identify human alveolar macrophages in the Malawi Cohort. The same gating strategy applied on the Malawi cohort, 
with a difference of a neutrophil marker. Here we used CD66b to identify neutrophils as CD45+CD66b+CD86-. AM gated as described above and the degree 





3.2.8. Statistical analysis 
Statistical analyses were performed using GraphPad Prism (Version 6, GraphPad 
Software, La Jolla, CA). Two-tailed statistical tests were used throughout the study. Non-
parametric data were not logarithmically transformed, therefore when two non-
parametric groups were compared, a Mann-Whitney or Wilcoxon test was used for 
unpaired and paired groups respectively. Differences were considered significant at p ≤ 




3.3.1 Human alveolar macrophages simultaneously express M1 and M2 
markers in steady state 
Data from the two human cohorts from the different geographical locations, were 
collected independently as part of different ongoing research studies, in which the 
human lung was sampled. The comparison of immunophenotyping data of only the 
healthy adults revealed an identical pattern of surface marker expression by human AM. 
In both cohorts, the majority of AM were characterised as CD206hiCD86hi (Figure 3.3A 
and 3.3C). M1-like phenotype (CD206loCD86hi) and M2-like phenotype (CD206hiCD86lo) 
subsets represented a small proportion (less than 1%) of the total AM population (Figure 
3.3A and 3.3C).  
When we looked at the expression levels of the M2 marker, CD163, in each AM 
subset in both cohorts a similar pattern was revealed. The CD206hiCD86hi subset 
expressed greater levels of CD163, compared to the M1-like and M2-like subpopulations 
(Figure 3.3B and 3.3D). UK samples were further analysed for additional M1 markers 
(CD80, CD64) and an activation marker (HLADR). In these, the CD206hiCD86hi subset 
expressed the highest levels of CD80, CD64 and HLADR expression in comparison to the 





Figure 3.3.     Human AM 
express simultaneously M1 
and M2 markers.   A) 
Percentages of AM subsets 
gated for CD206 and CD86 
and the B) the degree of 
CD163 expression in each of 
the subsets (UK cohort, 
n=25). CD206hiCD86hi subset 
occupies the highest 
proportion and expresses 
the highest levels of CD163 
when compared with the 
other three. C-D) The same 
pattern was observed on the 
AM derived from the Malawi 
cohort, n = 10. Black error 
bars represent median with 
IQRs. Wilcoxon test was used 
for the comparison between 
AM subsets from the same 
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Figure 3.4.  Expressional levels of CD80, CD64 and HLADR on the AM subsets isolated from 
the UK healthy individuals. A) The degree of CD80, B) CD64 and C) HLADR expression was 
compared between the different AM subsets (n=25). These surface markers were highly 
expressed in the CD206hiCD86hi subset. Black error bars represent median with IQRs. 
Wilcoxon test was used in the comparison between AM subsets from the same cohort. 








3.3.2 Colonisation of the human nasopharynx with S. pneumoniae does not 
alter the AM phenotype 
We have previously shown that live intranasal pneumococcal challenge alters the 
alveolar environment by increasing the levels of pneumococcal-specific memory CD4+ 
Th17 cells in the human lung (Wright et al. 2013). We therefore investigated whether in 
vivo exposure to intranasal pneumococcal challenge could alter the AM phenotype. We 
compared experimentally pneumococcal-colonised individuals (Spn colonised following 
inoculation with S. pneumoniae) with non-colonised individuals (cleared the bacterial 
immediately) and we found no difference in M1- or M2-like phenotype between the two 
experimental groups (Figure 3.5).  Specifically, the expression of CD163, CD80, CD64 and 
HLADR measured in the four AM subsets remain at the same levels between non-
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Figure 3.5.  Pneumococcal colonisation does not alter the AM phenotype. AM subsets were 
compared between non-colonised (n=9) and Spn colonised (n= 16) post experimental nasal 
pneumococcal inoculation. The data shows that there was no alteration of AM phenotype 
mediated by nasal pneumococcal carriage. CD206hiCD86hi was the dominant subset with the 
highest CD163 expression amongst the rest. Error bars represent median with IQRs. Data 
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Figure 3.6.  Nasal pneumococcal colonisation does not induce polarisation or higher activation of AM. A-D) Levels of CD163, CD80, CD64 and HLADR 
expression respectively between carriage negative (n=9) and carriage positive subjects (n=16).  There is no significant difference on levels of CD80, CD64 and 





3.3.3 Chronic HIV infection is associated with a lower expression of CD163 
on CD206loCD86hi AM 
Infection with HIV virus disrupts the alveolar cytokine microenvironment (Jambo 
et al. 2017). Here we looked at whether HIV infection- a chronic condition that mainly 
affects the T cell lung population- could polarise and alter the AM phenotype. We 
compared asymptomatic ART-naïve HIV-infected adults with age-matched HIV-
uninfected healthy individuals. Interestingly, in the Malawian population, AM subsets 
from HIV-infected individuals followed the same pattern of subdivision described in 
healthy volunteers.  No difference was found in the proportion of the investigated AM 
subsets between the ART-naïve HIV-infected adults and HIV-uninfected healthy 
individuals (Figure 3.7A). However, the expression of CD163 was significantly reduced in 
the CD206loCD86hi subset in HIV-infected individuals (median 0.47x, IQR: 0.42x- 0.61x) 
(p=0.015) (Figure 3.7B). In the predominant CD206hiCD86hi subset, there was a moderate 
reduction (median 0.66x) of CD163 expression in the HIV-infected group, which however 
was not statistically significant when compared with the healthy age-matched group 
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Figure 3.7. HIV infection reduces the levels of CD163 expression in the CD206loCD86hi A) 
AM subsets are compared between healthy (n=10) and HIV-infected individuals (n=10). AM 
collected from HIV infected subjects follow the same pattern with healthy individuals when 
gated for CD206 and CD86. B) The HIV infection regresses the expression of CD163 in the 





3.4 Discussion  
In this study, we compared the polarisation of AM isolated from human volunteers 
from two distinct geographical locations, UK and Malawi. In the UK cohort, which was 
experimentally challenged with S. pneumoniae intranasally, a single time-point 
bronchoscopy was performed at any day between 4 to 7 weeks post the bacterial challenge. 
We report that in healthy human pulmonary mucosa, AM adopt a hybrid phenotype, 
which shares features of both M1 (CD80, CD86, CD64) and M2 (CD206 and CD163) 
polarised macrophages. The same phenotype has been previously reported on the 
decidual macrophages (resident macrophages of the uterine lining), which exhibit 
characteristics of both pro-inflammatory and tolerogenic macrophages (Quillay et al. 
2015).  
We also found that nasal pneumococcal colonisation, even though it alters CD4+ T 
cell responses in the alveoli (Wright et al. 2013), does not alter the expression of key M1 
and M2 polarisation markers on the surface of AM. This leads to the speculation that a 
nasal pneumococcal exposure episode is either incompetent to modulate AM 
polarisation or its effect is transient and quickly irreversible due to macrophages high 
plasticity (Stout and Suttles 2004). By contrast, chronic HIV infection did affect the 
expression of CD163 on the M1-like AM subset (CD206loCD86hi), with a lower expression 
of CD163 observed in HIV-infected individuals than HIV-uninfected controls. This finding 
is intriguing and may be due to active HIV infection of this alveolar macrophage subset 
(Jambo et al. 2014) which has been shown to strongly repress CD163 expression on 
infected-macrophages (Porcheray et al. 2006). Furthermore, CD163 is shed during 
activation as soluble CD163 (sCD163)(Burdo et al. 2011) and this might in part explain 
the reduction of CD163 on the surface M1-like AM in HIV-infected individuals. However, 
even with in vivo exposure to pneumococci or HIV, the CD206hiCD86hi AM subset 
remained the major population, and this ascertains the stability of this phenotype. 
A potential weakness of the current study is the small number of markers used in 
both cohorts, which may have inhibited the identification of more stark changes 
associated with AM polarisation. Studies have highlighted a number of factors that may 
affect polarisation of human macrophages in vivo and have suggested the development 
of a standardised way of assessing human alveolar macrophage polarisation(Murray et 




markers for cytokines and transcription factors expression (IL6, IL1b, IL8, TGF-b1 IR5, 
pSTAT1) and markers for monocyte-deriving macrophages (CD209 or VSIG4) would 
benefit the study by increasing resolution and enabling the identification of additional 
macrophage sub-population in the human lung. Future studies that will involve in depth 
phenotyping of the human alveolar macrophages would assess the complexity of this 
unique type of human macrophages and how they respond to cues provided by the local 
tissue microenvironment in the lung. It is currently unknown whether the time-point interval 
between pneumococcal challenge and bronchoscopy have influenced the findings of the 
current study. Future studies that will aim to sample the human lung immediately after the 
completion of the follow-up visits and antibiotic treatment may allow us to detect more 
profound and dynamic alterations in alveolar macrophage phenotype and polarisation 
profile.  
Our data provides strong evidence suggesting that not all macrophages fall into 
M1 and M2 subsets. The major AM population in steady state expresses a duo M1/M2 
phenotype. This phenotype is present in individuals from two distinct geographical 
location and is stable even after exposure to stimuli known to alter the alveolar 
environment.  This is consistent with recent call for a rethink of the M1/M2 macrophage 
paradigm (Hussell and Bell 2014). It is possible that the lack of stark polarisation is helpful 
in maintaining a healthy balance between immune tolerance and protective immunity in 
the alveolar space. However, whether other tissue macrophages, beyond decidual and 
alveolar macrophages, exhibit similar phenotypes in vivo warrants further investigation. 
As the clear majority of alveolar macrophages combine M1 and M2 features in steady 
state, such a phenotype that may allow brisk and adaptive responsiveness to multiple 

















Heightened human alveolar macrophage 
responsiveness to Bacterial Pathogens post 
nasopharyngeal pneumococcal colonisation 
 
4.1 Introduction  
Human and murine studies have mainly focused on examining the effect of 
nasopharyngeal pneumococcal colonisation on adaptive immune responses of lung 
mucosa, due to the potential application of findings on new vaccine designs against 
pneumococcal pneumonia. However, limited data exist on the impact that 
pneumococcal colonisation may have on lung innate immune cells, in particularly 
alveolar macrophages, the predominant lung cell population. 
The alveolar macrophage (AM) – an innate type resident lung cell- is an integral 
component of lung immunity and its long-lifespan aids function (Marriott and Dockrell 
2007).  Alveolar macrophages are the first cells that combat pneumococci during early 
infection and the main cell population that mediates mucosal responses in the lower 
airways (Gordon and Read 2002). They also play a key role in shaping the adaptive 
immunity through their effects on dendritic cells and T cells (Lambrecht 2006). In murine 
models, it has been shown that AMs are mainly self-maintained, although during lung 
insult or as a result of ageing (Morales-Nebreda et al. 2015) differentiation of peripheral 




macrophage (GM)-CSF-dependent manner contributes to their replenishment 
(Hashimoto et al. 2013, Guilliams et al. 2013). 
A clear understanding of the mechanisms that underlie brisk but controlled lung 
immune responses at early stages of the infection is essential to inform us why high rates 
of pneumonia persists in the high-risk groups (infants, elderly and 
immunocompromised). Although, current immunisation strategies to pneumococcal 
disease target exclusively B cell dependent immunity, the recently described memory 
properties of innate cells, such as natural killer (NK) cells, monocytes (Netea et al. 2016, 
Quintin et al. 2014, Cheng et al. 2014) and most recently murine alveolar macrophages 
(Yao et al. 2018),  indicate that innate immunity could be considered as a promising 
alternative or complementary vaccine target.  
To investigate the association between nasopharyngeal pneumococcal 
colonisation and lung innate mucosal immune responses, we utilised our safe and 
reproducible experimental human pneumococcal challenge model. This model has been 
successfully used in the past to identify immune responses and correlates of protection 
against pneumococcal colonisation (Mitsi et al. 2017, Pennington et al. 2016, Ferreira et 
al. 2013), and also as a surrogate of protection and carriage density for testing novel 
pneumococcal vaccines. We showed for the first time that nasal human colonisation in 
absence of disease leads to pneumococcal aspiration to the lower respiratory tract, 
which enhanced AM opsonophagocytic capacity against a range of bacterial respiratory 
pathogens likely through an interferon-γ (IFN-γ)-mediated mechanism.  
 
4.2 Material and Methods 
 Innate cellular responses to pneumococcus were measured in healthy, non-
smoking, adults aged from 18-50 years old who participated in one of the three 
consecutive experimental human pneumococcal clinical trials conducting in Liverpool 
between 2015 and 2018 (Figure 4.1). Colonisation status was assessed by classical 
microbiology and molecular methods (lytA qPCR) on nasal wash samples. At the end of 
the follow-up visits (either D14 or D29 depending the EHPC study) Spn colonised 
individuals receive three courses of amoxicillin. In total 72 healthy young adults- 35 non-




research bronchoscopy at any day between Day 29 to Day 203 after the bacterial 
challenge (Day 0) (Figure 4.1). This procedure allowed us to sample the lung mucosa and 
compare AM function, cross-talk between AM and CD4+ T cells, as well as cytokine milieu 
in both experimental groups.  The time frame of BAL samples collection was deliberately 
selected to differ between studies, as this enabled us to investigate the duration of 
pneumococcal-mediated effects on the lung immunity (Figure 4.1).  
Full details of the methods used to produce the data presented within this chapter 
are given in Chapter 2. Some method details more relevant to this chapter have been 
included in for ease of reference.  
 
Figure 4.1. Study design. Defined time-period of BAL samples collection from Spn colonised 
(carriage+) and non-colonised (carriage-) individuals within three independent experimental 
human pneumococcal challenge (EHPC) studies. Individuals were purposively sampled 
according to colonisation state. After the final nasal wash (day 27, 17 or 29 based on study), 
Spn colonised individuals received a three-day course of antibiotics. Total BAL sample size, 
n= 72 (35 carriage negative and 37 carriage positive individuals).  
 
4.2.1 Ethical approval and BAL consent 
All volunteers gave written informed consent for the bronchoscopy and research 
was conducted in compliance with all relevant ethical regulations. Ethical approval was 
given by the North-west National Health Service Research Ethics Committee (REC). Ethics 





4.2.2 Inoculum stock preparation and inoculation  
All volunteers received intranasally a dose of 80,000 CFU/100μl of live Spn6B per 
nostril at D0 (Figure 4.1). Full details of inoculum stock preparation and inoculation 
procedure can be found in sections 2.5.2 and 2.4.1. respectively.  
 
4.2.3 Nasal wash processing  
 Full details of nasal wash sample processing can be found in section 2.5.5. 
4.2.4 Nasopharyngeal and oropharyngeal samples processing  
 Full details of NPS and OPS samples processing can be found in section 2.5.6. 
 
4.2.5 Bronchoalveolar lavage processing 
Full details BAL sample processing can be found in section 2.5.7. 
 
4.2.6 Alveolar macrophages isolation 
Alveolar macrophages used to generate the results presented in this chapter 
were isolated either using an adherence step or were purified from the whole BAL 
sample through cell sorting (FACS ARIAIII cell sorter, BD Biosciences). Full details can be 
found in section 2.5.8. 
 
4.2.7 Lung lymphocytes isolation 
Lymphocytes from BAL samples were separated from alveolar macrophages after 
adherence of the latter on a 24-well plate or were purified from the whole BAL sample 
through cell sorting (FACS ARIAIII cell sorter, BD Biosciences). Full details can be found in 
section 2.5.9. 
 
4.2.8 Bacterial strains and growth conditions for in vitro assays 
A live stock of S. pneumoniae, serotype 6B (the challenge strain) was used in 
uptake assays, whereas a heat-inactivated stock was used in lymphocyte or alveolar 




pyogenes and Escherichia Coli strain were also used in uptake assays. Full details of 
bacterial strain and their growth conditions can be found in section   2.5.3. 
 
4.2.9 Opsonophagocytic Assays (OPA) using alveolar macrophages 
All the versions of OPA assays used to generate the results presented in this 
chapter are described in full details in section 2.6.1. 
 
4.2.10 Bacterial DNA extraction and qPCR 
DNA was extracted from whole BAL, OPS and NPS samples, following qPCR 
analysis for the detection and quantification of pneumococcal DNA in these samples. The 
optimised qPCR protocol was specifically designed for the detection of the challenge 
strain (spn6B), targeting on a capsular polysaccharide gene known as wciP, the 
rhamnosyl transferase gene. Full details can be found in section 2.6.2.  
 
4.2.11 Confocal microscopy assays 
Full details of the confocal microscopy assays used to generate the results 
presented in this chapter can be found in section 2.6.3.  
4.2.12 Flow cytometry-based assays 
Full details of the different flow cytometry-based assay, as well as the 
combination of conjugated antibodies used per assay can be found in section 2.6.4.  
4.2.13 Luminex analysis of BAL fluid 
Full details of cytokine analysis in BAL fluid can be found in section 2.6.5.  
4.2.14 Alveolar macrophage gene analysis using Nasostring platform  






4.2.15 Statistical analysis 
Statistical analyses were performed using GraphPad Prism (Version 6, GraphPad 
Software, La Jolla, CA) and R software (version 3.5.1), including Bioconductor packages. 
Two-tailed statistical tests were used throughout the study. If two parametric groups 
were compared, a two-tailed t test was used for unpaired and paired groups. If two non-
parametric groups were compared, a Mann-Whitney or Wilcoxon test was used for 
unpaired and paired groups respectively. If three or more non-parametric paired groups 
were compared, a Friedman test was used. For gene expression and Luminex analysis p 
values were corrected by applying multiple correction testing (Benjamin-Hochberg). To 
quantify association between groups, Pearson or Spearman correlation test was used for 
parametric or non-parametric groups, respectively. Differences were considered 
significant at p ≤ 0.05 (*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001). 
 
4.3 Results 
Here we combined the experimental human pneumococcal challenge model 
with the use of research bronchoscopy to investigate whether and how nasopharyngeal 
pneumococcal colonisation affects the alveolar macrophage function in healthy adults.  
 
4.3.1 Experimental nasal pneumococcal colonisation enhanced alveolar 
macrophage responsiveness to respiratory pathogens 
Antecedent pneumococcal colonisation was associated with 11.4% increase in alveolar 
macrophage (AM) capacity to take up pneumococci in vitro. AM opsonophagocytic 
capacity (OPA) ranged from 58.5% to 81.6% in the non-colonised group (carriage-) and 
from 69.7% to 90.7% in the Spn colonised (carriage+) (p=0.005, Figure 4.2A). The 
increased AM OPA in the carriage+ group was reproducible between studies and 
persisted for approximately 3 months following the intranasal pneumococcal inoculation 
(Figure 4.2B). Later after challenge (120-203 days), uptake was similar between the two 
groups, although we were insufficiently powered to detect any statistical differences 































Figure 4.2. Enhanced alveolar macrophage opsonophagocytic capacity post nasal 
pneumococcal colonisation. A) Percentage of pneumococcal uptake by AM post in vitro 
infection in carriage- (n=35) and carriage+ (n=37) group. **p=0.005 by Mann-Whitney test. 
Multiplicity of infection (MOI) used was 1: 100. B) Chronological representation of all BAL 
samples (n=72) collected from one to six months post intranasal pneumococcal inoculation 
divided into three consecutive time periods. T1: ***p= 0.001, T2: **p= 0.003 and T3: p= 0.82 






We also sought to examine whether this enhanced activity was specific to 
pneumococcus or whether AM responses to other pathogens were similarly increased. 
AMs from Spn colonised individuals had greater capacity to take up the respiratory 
pathogens Streptococcus pyogenes and Staphylococcus aureus (increased by 18% and 
11%, respectively) when compared with AMs isolated from non-colonised individuals 
(p=0.009 and p=0.038 respectively, Figure 4.3). For the gram-negative bacterium 
Escherichia coli there was a non-significant increase in AM OPA in the carriage+ group 
(median: 20.6% increase, p=0.067, Figure 4.3). 
 
 
Figure 4.3. Alveolar macrophages increase responsiveness to take up other bacteria post 
nasal pneumococcal colonisation. Percentage of bacterial uptake by AM post in vitro 
infection with Spn6B or S. aureus or S. pyogenes or E. coli. **p= 0.009, **p= 0.009, *p= 0.038 
and p=0.067, respectively by Mann-Whitney test. Boxplots and individual subjects are 
depicted with Carriage- in black dots and Carriage+ in red dots. BAL samples were collected 






4.3.2 Micro-aspiration and evidences of pneumococcal presence in the 
lungs  
It is widely assumed that pneumococcal aspiration occurs and leads to bacterial 
entrance in the lower airways, with the potential to develop subsequent pneumonia in 
the high-risk groups. While pneumococcal aspiration has been linked with nasal 
pneumococcal density in pneumonia cases (Albrich et al. 2012), it has never been 
previously described in the absence of disease. To investigate whether pneumococcus is 
the stimulus of the enhanced AM responses in the pulmonary mucosa post nasal 
colonisation, we sought to find evidence of presence of the pneumococcal challenge 
strain (6B serotype or Spn6B) in the alveolar spaces.  
For the detection of pneumococcus in the BAL samples, we utilised both classical 
microbiology and molecular methods targeting a capsular polysaccharide gene specific 
to Spn6B (wciP- the rhamnosyl transferase gene). Whole DNA was extracted from 43 
EHPC participants who had research bronchoscopy within a short period (29-50 days) 
post their nasal pneumococcal challenge.  Spn6B DNA was detected in the BAL of 41% 
(9/22) of Spn colonised individuals (Table 4.1), 1 to 3 weeks following the clearance of 
nasal colonisation. None of the non-colonised individuals had detectable Spn6B DNA in 
their BAL sample. Additionally, BAL samples collected from volunteers between 50-120 
days post challenge were negative for presence of Spn6B DNA, irrespective of 
colonisation status. Nasal pneumococcal density positively correlated with the copies of 
Spn6B DNA detected in BAL samples (Figure 4.4A).  Spn colonised individuals differed in 
both density and duration of the colonisation episode (Figure 4.4B). In addition, sampling 
of the nasopharynx by nasopharyngeal (NP) swabs was performed in a subset of subjects 
prior to the bronchoscopy, in order to ensure that colonisation had been interrupted the 
day of the lung sampling. Whereas no live SPN6B was detected in any NP sample after 
culturing and qPCR against Spn6B capsule, two participants had SPN6B growth on agar 
plate after platting of BAL supernatant (Table 4.1). qPCR data confirmed the presence of 
6B DNA in the whole BAL of the same two participants. Moreover, sorted AM capacity to 







Methods of spn6B DNA detection in BAL and NP Carriage pos. Carriage neg. 
Spn6B detected in the BAL by qPCR 9/22 (41%) 0/21 (0%) 
Live Spn6B detected in BAL by culturing  2/16 (12.5%) 0/10 (0%) 
Spn6B DNA detected in the NP and OP swabs by qPCR 0/12 (0%) 0/10 (0%) 
Live Spn6B detected in NP and OP swabs by culturing        0/12 (0%)       0/10 (0%) 
 
Table 4.1. Methods of Spn6B detection in lung and nose the day of research bronchoscopy. 
Spn6B DNA was detected in 41% of carriage positive volunteers (9 in 22 carriers) by qPCR 
targeting a Spn6B specific capsular polysaccharide gene. Spn6B DNA was not detected in any 
(0/21) non-colonised subjects. BAL samples were plated on blood agar plate and 
pneumococcal growth was observed in 12.5% (2/16) carriage positive volunteers, whereas 
there was no growth for any the carriage negatives (0/10). Nasopharyngeal (NP) and 
oropharyngeal (OP) swabs were taken prior to the bronchoscopy from 22 participants. 
SPN6B was not detected in any NPS or OPS sample after culturing or qPCR analysis. BAL 
samples were collected between 29 to 49 days post challenge.  
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Figure 4.4. Evidences of pneumococcal presence in the lung of nasopharyngeal Spn 
colonised individuals. A) Positive correlation between the nasal pneumococcal density, 
expressed as the Area Under the Curve (log AUC) and the copies of pneumococcal DNA 
(Spn6B) detected in the BAL fluid of carriage+ individuals. r= 0.71, *p=0.029 by Pearson 
correlation test. B) Duration and density of nasal colonisation per individual with detected 
Spn6B DNA in the BAL fluid (9 in 22 Spn colonised). The end of each coloured line indicates 




Figure 4.5. Nasal pneumococcal density is associated with increased AM capacity to take 
up pneumococci. Positive correlation between the nasal pneumococcal density (log AUC) 
and sorted AMs opsonophagocytic activity (n=13). Pearson correlation test results and linear 




Utilising confocal microscopy and anti-sera against the polysaccharide capsule of 
serotype 6B, we confirmed the relationship between nasal colonisation and presence of 
pneumococcal particles in the lung. Pneumococcal cells were found associated with the 
surface of AMs or internalised by them; a phenomenon only observed in Spn colonised 
volunteers (Figure 4.6A-C).  
 
 
Figure 4.6. S. pneumoniae in association with alveolar macrophages.  A-C) Representative 
images taken by confocal microscope showing: A) pneumococci around AMs and B) 
internalised pneumococci by AMs derived from Spn colonised individuals. CD45-magenda or 
CD14-red, nucleus-blue (DAPI) and Spn6 capsule-green. Scale bar= 2μm. Inset panels 
represent Z-stack images of the cell with internalised pneumococcus. C) 3D reconstruction 
of deconvolved Z-stack confocal images of alveolar macrophages. The samples were stained 
with either wheat germ agglutinin (on the left; magenta) or anti-CD169 monoclonal antibody 









4.3.3. CD4+ Th1 skewed responses rapidly prime AMs 
To investigate whether the observed augmented AM capacity to take up 
pneumococci in vitro was dependent on lung lymphocytes, we co-incubated AMs with 
autologous CD3+CD4+ T cells during in vitro infection with Spn6B. The presence of 
CD3+CD4+ T cells enhanced the basal AM opsonophagocytic capacity in both non-
colonised (1.6-fold, p<0.0001) and Spn colonised individuals (1.8-fold, p<0.0001) (Figure 
4.7). AM opsonophagocytic capacity differed between the two groups at baseline (prior 
to lung-derived autologous CD3+CD4+ T cell addition) and remained higher in Spn-
colonised when autologous CD4+ T cells were present (Figure 4.7).  
To elucidate the mechanism underlying this increased boosting of AM function by 
CD4+ T cells from Spn colonised individuals, we stained lung lymphocytes intracellularly 
for T-box transcription factor expressed in T-cells (T-bet), GATA-binding protein-3 (GATA-
3) and Forkhead box P3 (FoxP3) transcription factors. The gating strategy used to identify 
the proportion of CD4+T-bet+, CD4+GATA-3+ and CD4+FoxP3+ T cells among the total lung 
CD4+ T cells is shown on Figure 4.8. 
  In the Spn colonised group the levels of CD4+ T-bet expressing cells were twice as 
high than in the non-colonised group (p= 0.003), indicating Th1-polarisation (Figure 4.9). 
There were no significant differences in the levels of neither CD4+ GATA-3 expressing nor 

















Figure 4.7. AMs crosstalk and priming by autologous CD4+ T subsets. Comparison of 
phagocytic activity between sorted AM and sorted AM plus autologous BAL isolated 
CD3+CD4+ T cells from both carriage- (n=11) and carriage+ (n= 13). MOI=1:20. AM and CD4+ 
T cells were used in a 10:1 ratio. ****p< 0.0001 in both groups by paired t-test. Comparison 
of AM basal opsonophagocytic activity between the two groups. *p= 0.018 by unpaired t-
test with Welch’s correction. Comparison of AM opsonophagocytic activity in the presence 
of lung CD4+ T cells between carriage- and carriage+ group. **p= 0.001 by unpaired t-test 
with Welch’s corrections. Boxplots and individual subjects are depicted with carriage- in 





Figure 4.8 Transcription 
factors expression in 
CD4+ T cells. Gating 
strategy of CD3+CD4+ T 
cells for the 
transcription factors T-
bet, GATA-3 and FoxP3 
expression for one 
representative 
volunteer. Fluorescence 
Minus One (FMO) 
controls were used to 








Figure 4.9. Th1 polarisation of lung CD4+ T cells in the pneumococcal colonised group.  
Intracellular staining of CD4+ T cells for T-bet, GATA-3 and FoxP3 transcription factors, 
expressed as percentage of CD3+CD4+ BAL lymphocytes. **p= 0.003, p= 0.85, p= 0.33 
respectively by unpaired t-test with Welch correction test. Boxplots and individual subjects 
are depicted with carriage- in black dots and carriage+ in red dots.  
 
In parallel, lymphocytes from both Spn colonised and non-colonised volunteers 
were stimulated with pneumococcal antigen (Heat Inactivated-Spn6B).  Cytokine (IFN-γ, 
Tumour necrosis factor a [TNF-α] or Interleukin 17A [IL-17A]) producing CD4+ T-cells were 
subsequently detected by flow cytometry (Figure 4.10). Alveolar macrophages OPA 
correlated with cytokine producing CD4+ T cells, classified as spontaneous (unstimulated) 
or pneumococcal-responding cells (Figure 4.11). Increased levels of IFN-γ producing CD4+ 
T cells, both pneumococcal-specific and spontaneous responding, positively correlated 
with AMs ability to take up live pneumococci in vitro. (Figure 4.11A). On the other hand, 
AMs OPA correlated positively with only the pneumococcal-specific TNF-α producing 
CD4+ T cells (Figure 4.11B), whereas IL-17A producing CD4+ T cells did not correlate with 
AMs OPA in any condition (Figure 4.11C). 
Together, these results indicate that skewing of CD4+ T cells and production of 





Figure 4.10. Gating strategy of cytokine (INF-γ, TNF-α and IL-17A) producing T cells 
following overnight stimulation with HI-Spn6B. Cytokines production were defined by 
intracellular staining. Gates from one representative volunteer are shown. Fluorescence 







Figure 4.11. Correlations of AM opsonophagocytic activity with CD4+ Th1 and Th17 
responses.  A) From left to right are illustrated significant correlations between the levels of 
IFN-γ expressing CD4+ T cells at baseline (non-stimulated), total IFN-γ expressing CD4+ T cells 
post stimulation with HI-Spn6B and the Spn-specific responding CD4+ T cells (non-stimulated 
condition subtracted from Spn-stimulated condition) with alveolar macrophage OPA. 
Spearman Rho and p values are shown. B) Significant correlation of Spn-specific, TNF-α 
expressing CD4+ T cells with AM OPA. Spearman Rho and p value are shown. C)  From left to 
right are illustrated the levels of IL-17A expressing CD4+ T cells at baseline and the levels of 
total and Spn-specific, IL-17A expressing CD4+ T cells in association with AM OPA. No 
significant correlations. Spearman correlation test results and linear regression line with 95% 




4.3.4 Alterations of lung cytokine milieu post nasal colonization and the 
effect of IFN-γ on AM opsonophagocytic capacity 
The alveolar microenvironment is crucial for cell signalling, shaping how local cells 
respond to different stimuli (Hussell and Bell 2014).  To assess alterations of the alveolar 
cytokine milieu induced by nasal pneumococcal colonisation, we measured levels of 30 
cytokines and chemokines in the BAL fluid retrieved from both Spn colonised and non-
colonised individuals (Figure 4.12A). Three cytokines had higher detectable levels in the 
BAL fluid of Spn colonised group:  GM-CSF (p=0.032) and the pro-inflammatory cytokines 
IFN-γ (p=0.047) and IFN-α (p=0.043) (Figure 4.12B), although statistical significance was 
lost upon correcting for multiple testing. Full list of the 30 cytokines compared between 
the two groups will be found in Appendix (Table I).  
 












Figure 4.12. Lung cytokine milieu and alterations mediated by nasal colonisation. A) 
Heatmap of the 30 cytokines levels, expressed as log10 median (pg/mL), measured in the 
BAL fluid (carriage-; n=20 and carriage+; n=22). B) Levels of significantly different cytokines 
between the two groups, expressed as pg/ml. GM-CSF, IFN-γ and IFN-a with *p= 0.032, 
*p=0.047 and *p=0.043 respectively, analysed by Mann-Whitney test. Boxplots and 




To address the role of increased secretion of IFN-γ, a prototypic Th1 cytokine, in 
the pulmonary airspaces and its effect on AM function, we primarily neutralized the IFN-
γ receptor 1 (IFN-γR1), a subunit of the heterodimeric IFN-γ receptor found on 
macrophages. IFN-γ binds directly on IFN-γR1, with latter to play an essential role in the 
IFN-γ pathway that is required for the cellular response to infectious agents (van de 
Wetering et al. 2010). Directly before the OPA, AMs were stimulated with exogenous 
IFN-γ, either with a concentration that would reflect better the average in vivo levels of 
IFN-γ in the lung lining fluid of Spn colonised group (0.4ng/ml) or with 2ng/ml. Sole 
addition of IFN-γ enhanced significantly the AM capacity to take up pneumococci in both 
concentrations (median: 1.37-fold change using 0.4ng/ml and 1.45-fold change using 
2ng/ml of recombinant IFN-γ). Blocking of IFN-γ binding receptor prior to IFN-γ addition 
inhibited the stimulatory function of the cytokine upon AM (Figure 4.13). We 
investigated further the role of IFN-γ upon AM activation by stimulating them with 10-
fold increasing concentrations of exogenous IFN-γ. The lowest tested titres of IFN-γ (2 
and 20ng/ml) augmented AMs OPA, resulting both in 1.5-fold increase (1.5x median; 
IQR:1.2x- 2.1x) in AM pneumococcal uptake, whereas no significant increase was seen 
with the highest used concentrations (200 and 2000ng/ml) (Figure 4.14A). These results 
were verified when AM response was assessed using a flow cytometric cytokine 
production assay (Figure 4.15). AMs produced increased levels of TNF-α in response to 
stimulation with HI-Spn6B only at the lower pre-stimulation doses of IFN-γ (Figure 
4.14B). The mechanism seems to have a threshold, as demonstrated by the data, with 









Figure 4.13. IFN-γ enhances alveolar macrophage capacity to uptake pneumococci in vitro. 
AM stimulated with 0.4 or 2ng/ml of recombinant IFN-γ (light blue dots) in presence or 
absence of anti-human antibodies against IFN-γR1 (brown dots). Unstimulated AMs used as 





































Figure 4.14. The effect of graduate increase of IFN-γ concentration on alveolar macrophage 
function. A) The effect of 10-fold increasing doses of exogenous IFN-γ (2-2000ng/ml) on the 
capacity of AM to uptake pneumococcus (live Spn6B used, MOI= 1:100). AM isolated from 6 
non-challenged subjects. Individuals samples are depicted and connected by dashed lines. 
** p< 0.003 by Friedman test followed by Dunn’s multiple comparison. B) TNF-α production 
from AMs, pre-treated or not with exogenous IFN-γ (2-2000ng/ml), following stimulation 
with HI-Spn6B. AM isolated from 4 non-challenged subjects. Individuals samples are depicted 










Figure 4.15. Gating strategy followed for cultured alveolar macrophages. AMs were stimulated with HI-Spn6B or HI-Spn6B plus IFN-γ or unstimulated to 




4.3.5 Pneumococcal colonisation may promote monocyte-to-macrophage 
differentiation in the alveolar spaces 
Previously, we have demonstrated that AMs are not altered phenotypically by the 
presence of pneumococcus in the nasopharynx, as defined by classical monocyte 
polarisation surface markers (Mitsi et al. 2018). However, given the increased capacity 
of AM to take up pneumococcus, we extended our assessment to other lung myeloid cell 
populations (monocytes and neutrophils), in order to determine whether recent 
pneumococcal carriage alters the distribution of these cells in the airway. Identification 
of monocytes in the BAL samples using flow cytometry is shown on Figure 4.16, whereas 
the gating strategy followed for neutrophils was previously presented in Chapter 3 
(Figure 3.1). 
Spn colonised individuals displayed significantly greater AM levels (1.2-fold 
increase, p=0.04) and higher AMs/monocytes ratio (2.3-fold increase, p=0.04) in the lung 
compared to non-colonised individuals (Figure 4.17A). On the other hand, monocyte 
levels, both total and CD14hiCD16lo and CD14hiCD16hi subsets, had no significant 
difference between the two groups, despite their trend for increased presence in the 
non-colonised group (Figure 4.17B). Similarly, no difference in neutrophil levels was 
observed between the two groups (Figure 4.17B), indicating that nasal carriage in 








































Figure 4.17. Pneumococcal colonisation may promote monocyte-to-macrophage 
differentiation. A) Levels of monocytes and AMs in the BAL of carriage- (n=8) and carriage+ 
(n=9), expressed as percentage of CD45+ cells. Significant comparison of AM levels and AM: 
Monocytes ratio between the two study groups, * p=0.046 by Mann-Whitney test. Boxplots 
and individual subjects are depicted with Carriage- in black and Carriage+ in red. B) 
Monocytes and neutrophils analysed based on their CD14, CD16 expression.  In monocytes, 
CD16 expressional levels divided them to two subsets, CD14hiCD16lo and CD14hiCD16hi. 




To test whether antecedent pneumococcal colonisation led to monocyte 
differentiation and AM activation, we sought to identify the differential gene signatures 
of Spn colonised and non-colonised volunteers. We isolated AMs by cell sorting from a 
subset of BAL samples and performed NanoString expression analysis of 594 
immunological genes. Gene set enrichment analysis was performed on all genes, ranked 
from high to low expressed in the Spn colonised group compared to the non-colonised 
group, using published blood transcriptional modules (Appendix- Table II) (Li et al., 2014). 
Purified alveolar macrophages from Spn colonised individuals showed an enrichment in 
pathways of cell differentiation and function, revealing under-presentation of 
monocytes surface markers and over-presentation of antigen-presentation markers in 
the Spn colonised group (Figure 4.18). Some of the genes in these sets that were most 
increased or decreased in Spn colonized individuals included: HLA-DQA1, CLEC7A, LY96 
and HLA-DPB1 (antigen presentation module M5.0) and PTAFR, FCGRT and CD4 
(monocyte surface signature-module S4). This finding complements the previous 
observation that nasal colonisation may lead to monocyte-alveolar macrophage 
differentiation. We then looked whether individual AM gene expression was associated 
with colonisation and/or function. Between, the two groups 34 genes were altered, 
although none remained significant after correction for multiple testing (potentially due 
to small sample size of 5 per group) (Appendix-Table III).When the AM OPA per individual 
was compared with gene expression (log counts per million [CPM]) measured for each 
of the 594 genes, 34 genes were positively correlated with AM function to take-up the 
bacteria (Appendix- Table IV). Only four genes were both significantly correlated with 
AM OPA and significantly increased in Spn colonised individuals: T-box 21 (TBX21), ecto-
5'-nucleotidase (NT5E), Carcinoembryonic antigen-related cell adhesion molecule 6 









Figure 4.18.  Enrichment in pathways of differentiation and function in Spn colonised 
group. Top pathways after gene set enrichment analysis for pathways and function applied 
on 2logFC (n= 5 subjects per group). NES presented in gradient colour. Red shades indicate 
pathways over-presented, whereas blue shades pathways under-presented in the carriage 






Figure 4.19. Increased AM opsonophagocytic activity is associated with M1 polarisation in 
AM based on gene expression analysis. Correlations between alveolar macrophage OPA and 
2log CPM of TBX21, NT5E, TLR8 and CEACAM6. Spearman correlation test results and linear 





 In this study we aimed to determine the effect of nasopharyngeal colonisation on 
lung immune responses, focusing on alveolar macrophages and their cross-talk with cells 
of adaptive immunity. Using our experimental human pneumococcal challenge model, 
we demonstrated that prior nasopharyngeal pneumococcal colonisation results in 
bacterial aspiration to the lower airspaces, leading to increased AM opsonophagocytic 
capacity against both pneumococcus and other bacterial pathogens. Aspirated 
pneumococci most likely act as the stimulus that leads to enhanced AM responsiveness. 
We observed that autologous lung derivedCD4+ T cells cross-talk enhanced AM basal 
capacity to take up pneumococci in vitro and that higher proportion of Th1 CD4+ T cells 
was found in the BAL samples of Spn-colonised group. Combined with the increased Th1 
cytokine secretion measured in the lung of Spn colonised group, we propose that CD4+ 
T cells affect AM antibacterial function via an IFN-γ dependent manner. Systemic effects 
of colonisation may have also contributed to the heightened lung immune responses. 
However, the systemic profile of immune cells usually does not reflect the mucosal sites, 
due to compartmentalisation (Sathaliyawala et al. 2013). Also, in the past we described 
that the effect of pneumococcal colonisation on cognate T cells is more pronounced in 
the lung than in blood (Wright et al. 2013).  Despite temporary influences from blood, 
the human lung exhibits a unique microenvironment that adapts to environmental 
challenges, and so do AM adapt to accommodate the ever-changing needs of the tissue 
(Hussell and Bell 2014). 
The lung mucosa is not the sterile environment previously thought (Charlson et al. 
2011, Man, de Steenhuijsen Piters and Bogaert 2017). By employing classical 
microbiology, molecular and visualisation methods, we demonstrated that 
pneumococcal aspiration occurs during nasal pneumococcal colonisation, a 
phenomenon that was previously observed only in pneumonia cases (Albrich et al. 2012, 
Greenberg et al. 2011).  The positive correlation between AM opsonophagocytic activity 
and nasal pneumococcal density suggested pneumococcal cell trafficking from the 
nasopharynx to the lung airways. Spn-colonised volunteers received amoxicillin 
treatment prior the bronchoscopy to clear pneumococcal colonisation. This was a pre-
requisite in sampling the human lung without artificially introducing pneumococci, 




might trigger host responses both systemically and at the respiratory mucosal sites. 
Although, it is difficult to assess the direct effect of this intervention on the AM 
responsiveness, our findings indicate that AM function is equally increased in those Spn-
colonised volunteers who had naturally cleared colonisation 1 to 2 weeks prior the 
antibiotic treatment.   
Interestingly, pneumococci were detected inside AMs or isolated alive from the 
BAL sample of Spn colonised individuals when colonisation had cleared a few days prior 
to the bronchoscopy. This observation merits of further investigation of pneumococcal 
survival inside AMs, analytical characterisation of the AM subsets in the health human 
lung and molecular signatures that drives differential AM function. This findings together 
with the recent report that pneumococcus has the ability to survive and replicate within 
murine splenic macrophages (Ercoli et al. 2018), points out for the need to analyse 
human AM to single cell levels. AM subpopulations that retain pneumococci or 
internalise them utilising receptors that could lead to insufficient bacterial lysis could 
stand as potential pneumococcal reservoir. 
The increased opsonophagocytic capacity displayed by AMs was a non-specific 
response to pneumococcal stimulus. AM responded with equal efficacy to both Spn and 
other gram-positive respiratory pathogens in vitro.  By contrast, we did not see 
significant enhancement of AM opsonophagocytic activity (OPA) against E. coli, although 
the small sample size used might have limited the detection of a less pronounced 
difference between the two experimental groups.  
Our observation shares some similarities with the findings of emerging studies on 
“trained immunity” (termed  also as innate immune memory) (Cheng et al. 2014, Saeed 
et al. 2014), which have shown  the increased responsiveness of innate immune cells to 
microbial stimuli, caused by epigenetic changes post their activation by varying stimuli 
(e.g. Candida albicans infection, Bacille Calmette-Guerin [BCG] or measles vaccination). 
Similar to our observation, this augmented functional state persisted for weeks to 
months, and moreover it conferred resistance to reinfection or heterologous infection 
(Netea et al. 2016, Kleinnijenhuis et al. 2012, Netea, Quintin and van der Meer 2011, 
Quintin et al. 2014). Further controlled human infection studies, including pre- and post- 
pneumococcal challenge BAL sampling and focusing on AM epigenetic and metabolic 
changes, will be able to address whether human alveolar macrophages acquire a 




increased levels of IFN-γ detected in the BAL supernatant of Spn-colonised volunteers 
that had cleared nasal pneumococcal colonisation is a confounder that should be taken 
under consideration when evaluating potential AM reprogramming post exposure to 
pneumococcus. It is possible that that S. pneumoniae can persist within the human lung 
even after colonisation has been cleared, creating potentially a reservoir of bacteria that 
could cause ongoing immune stimulation.  
Our findings on CD4+ Th1 skewed responses and exogenous IFN-γ effect on AM 
antimicrobial function support the idea that Th1 type responses and interferons are 
crucial in controlling bacteria at the early stages of infection. Increased rates of 
pneumococcal colonisation in children and clinical cases of pneumonia in adults have 
been associated with a reduction in systemic circulating Th-1 (IFN-γ secreting) CD4+ T-
cells (Zhang et al. 2007, Kemp et al. 2002). Polymorphisms in the adaptor MAL, which 
regulates IFN-γ signalling (Ni Cheallaigh et al. 2016), have been associated with altered 
susceptibility to a number of infectious diseases including severe pneumococcal disease 
(Khor et al. 2007). Moreover, we observed a rapid priming of AMs when co-cultured with 
autologous lung derived CD4+ T cells in vitro. A very recent study in mice described a 
similar mechanistic link between adaptive and innate immune system, suggesting that 
effector CD8+ T cells, in the context of respiratory adenoviral infection, are able to prime 
AMs and render innate memory via IFN-γ (Yao et al. 2018).  
Our study highlighted that IFN-γ has a dose-dependent effect on human AM 
function, which offers an explanation to the contradictory reports around this topic. For 
instance, in a murine model high production of IFN-γ during influenza infection impaired 
phagocytosis and killing of S. pneumoniae by alveolar macrophages (Mina, Brown and 
Klugman 2015, Sun and Metzger 2008). In contrast, many other evidences suggest that 
induction of IFN-γ secretion, related to non-acute viral infection, is beneficial for innate 
immune cells, promoting a range of antimicrobial functions, plus macrophages 
polarization and activation (Matsuzawa, Fujiwara and Washi 2014, MacMicking 2012, 
Yao et al. 2018). The dose-dependent effect of IFN-γ on AM OPA could also explain why 
HIV-infected adults are still at an increased risk of developing pneumococcal pneumonia, 
despite the preserved Th1 responses against S. pneumoniae (Peno et al. 2018).  
Whereas the cytokine milieu in Spn colonised individuals, along with the CD4+ Th1 




shown to co-express M1/M2 markers and therefore they do not fit neatly in the current 
macrophage classification (Mitsi et al. 2018, Hussell and Bell 2014).  A recent study 
highlighted that human AMs possess considerable phenotypic diversity (Morrell et al. 
2018). By assessing AM gene expression levels, we found that AM population derived 
from Spn colonised individuals was characterized by increased antigen-presentation and 
decreased monocytes surface markers signature. Our flow-based data corroborated this 
result by showing greater AM levels and increased AM to monocyte ratio in the Spn 
colonised individuals. The positive correlation of AM OPA with genes such as  NT5E (or 
CD73) (Eichin et al. 2015) and TBX21 (a master regulator of Th1 responses) indicate at 
some degree that monocyte-to-macrophage differentiation and AM polarisation to a 
more active functional state occur in the human lung, after interacting with the 
pneumococcus. Studies on human monocytes/macrophages have reported detectable 
expression of CD73 in only M(LPS-TNF) polarised cells and increased of T-bet mRNA 
displayed by M1 polarized macrophages (Martinez et al. 2006, Bachmann et al. 2012). 
Also, our finding on increased expression of TLR8 in the Spn colonised group might be 
the readout of IFN-γ signalling, as TLR8 is responsive to interferons. Increase in TLR8 
levels might lead to enhanced viral sensing and thus have a beneficial effect upon viral 
infection, such as influenza. Furthermore, it has been reported that activation of TLR8 
signalling (TLR8-MyD88-IRAK4 signalling pathway) can reverse the suppression function 
of CD4+ Treg cells (Peng et al. 2005). 
In conclusion, this study emphasises the effect that nasopharyngeal pneumococcal 
colonisation has upon pulmonary immune system, describing the potential pathways for 
the development of a robust immune response. It is well accepted that colonisation is a 
prerequisite for disease. However, disease is more likely caused immediately after 
acquisition of colonisation (Ghaffar, Friedland and McCracken 1999, Robinson 2004). 
During longer colonisation episodes, AMs display the increased functionality we 
described, which in turn could lead to reduced risk of bacterial respiratory infections. It 
is also important to note that our findings derive from young healthy adults, which are 
not at high risk of pneumococcal disease. The elderly are at an increased risk of infection 
and these are colonised less frequently. The lack of repeated colonisation and associated 
AM (and other immunological) boosting could contribute to their increased susceptibility 




The seeding of human lung with activated AM that exert prolonged and enhanced 
opsonophagocytic properties has potential implications for vaccine development. 
Pneumococcal vaccines that focus solely on inducing a robust Th17 response may not be 
the best strategy for vaccine targeting serotype-independent protection against 
pneumonia. On the other hand, such a non-specific boosting of innate lung immunity, 
may be an alternative attractive strategy to successful pneumonia prevention, especially 
for the new-borns, whose immune system is still developing, or for the elderly, whose 
acquired immunity is beginning to wear off.  In particular the elderly, who have been 
described as the age group with the lowest pneumococcal colonisation rates and high 
incidence of community-acquired pneumonia cases, would benefit from the boosting 
effect that mucosal stimulation with whole cell pneumococcus confers to the pulmonary 
immune cell populations. These results, in combination with our previous finding on 
increased presence of pneumococcal-specific IL-17A secreting T cell in human lung post 
nasal colonisation (Wright et al. 2013), suggest that a nasally administered live-
attenuated pneumococcal vaccine could augment the pulmonary immune responses and 
confer serotype-independent protection against development of pneumococcal 
pneumonia.  
This study provides insights into the immune responses elicited at the pulmonary 
mucosa post a colonisation episode of the nasopharynx. We demonstrated that prior 
nasopharyngeal pneumococcal colonisation results in bacterial aspiration to the alveolar 
space. Moreover, the duration of this enhanced activity persisted for over three months 
post the clearance of colonisation. Aspirated pneumococci may act as the stimulus that 
leads to enhanced AM responsiveness against bacterial pathogens mediated by Th1 
cytokines. 
In addition, it would be of interest to investigate whether nasal colonisation leads 
to recruitment of monocytes to the alveolar spaces, which was not possible in the 
present study due to the single time point sampling. The one-time point sampling also 
disabled comparisons of immune responses pre- and post- colonisation on an individual 
level. Therefore, future studies including baseline sampling of the lung mucosa will 
attribute clarity to the direct effect of pneumococcal colonisation on the pulmonary 















Despite its pathogenicity, S. pneumoniae can colonise the human nasopharynx 
asymptomatically, a state known as colonisation or carriage (Bogaert et al. 2004). 
Pneumococcal carriage is critical in transmission and disease but paradoxically it is also 
essential for the development of adaptive immunity. Through this asymptomatic state, 
a carriage episode acts as an immunising event, inducing both humoral and cellular 
responses systemically (Ferreira et al. 2013, Pennington et al. 2016). Regarding the 
mucosal sites, we previously demonstrated that experimental human pneumococcal 
colonisation leads to induction of IgG to pneumococcal antigens, such as capsular 
polysaccharide and pneumococcal proteins (Mitsi et al. 2017, Ferreira et al. 2013) in the 
nasal lumen.  In the lung, we have shown that pneumococcal colonisation increases the 
frequency of pneumococcal specific IL-17A secreting CD4+ T cells (Wright et al. 2013).  
In murine models, the CD4+ Th17 subset has been associated with control of 
pneumococcal colonisation and protection against pneumonia (Lu et al. 2008, Wilson et 
al. 2015).  Moreover, a recent murine study also emphasised the importance of CD4+ T 
cells in lung mucosa, when resolution of previous pneumococcal infections seeded the 
lungs with CD4+ resident memory T cells.  These tissue resident memory (TRM) CD4+ T 
cells found in mice lungs responded to heterotypic pneumococcus stimulation by 
producing multiple effector cytokines, particularly IL-17A (Smith et al. 2018). The adult 




CD69, and at least some of these cells respond to influenza, which suggests that they 
resulted from prior respiratory infection(Purwar et al. 2011, Sathaliyawala et al. 2013). 
Upon stimulation, lung CD4+ TRM cells express a variety of cytokines, perhaps reflecting 
diverse specificities and functions (Purwar et al. 2011, Sathaliyawala et al. 2013). 
Whether and how the bacterial causes of pneumonia elicit or are influenced by lung CD4+ 
TRM cells is, to our knowledge, largely unexplored. 
In this study, we aimed to further investigate the effect of a recent pneumococcal 
episode in the adaptive lung immune responses. The immunising effects of colonisation 
observed by us and others both systemically and in the nasal mucosa, combined with our 
findings on cognate lung Th17 cells, postulate that other arms of adaptive immunity 
could be affected in a similar manner. Therefore, we hypothesised that a successful 
pneumococcal colonisation could induce both cellular and antibody responses. Herein, 
we performed research bronchoscopies in the EHPC model to expand our observations 
on Th17 cells to other lymphocyte subsets, including the non-conventional TCR-γδ T cells, 
as well as resident T cells of the lung mucosa. In parallel with cellular responses, mucosal 
antibodies against pneumococcus is an important defence mechanism, accelerating 
bacterial clearance through agglutination (Mitsi et al. 2017) and facilitating bacterial 
uptake by phagocytes, through opsonisation.  We assessed the antibody responses to 
the challenge strain in the lung mucosa post pneumococcal colonisation by measuring 
IgG to 6B capsular polysaccharide (6B-CPS) in the BAL fluid.   
 
5.2 Material and Methods 
Lung adaptive cellular responses to pneumococcus were measured in volunteers 
who underwent research bronchoscopy between Day21 to Day50 post inoculation. This 
time frame was deliberately selected to match with the previous EHPC study that had 
identified the presence of cognate IL-17A producing CD4+ T cells in the human lung post 
experimental pneumococcal challenge. On the other hand, pneumococcal-specific 
antibody levels were quantified in BAL fluid from samples acquired at any day between 
1 to 6 months post challenge.  
Lymphocytes derived from the BAL samples were separated from alveolar 




according to our published protocol (Wright et al. 2013). Full details of the methods used 
to produce the data presented within this chapter are given in Chapter 2.  
 
5.2.1 BAL Lymphocytes isolation 
Lymphocytes from BAL samples were separated from alveolar macrophages after 
adherence of the latter on a 24-well plate. Full details can be found in section 2.5.9. 
 
5.2.2 Stimulation and Flow cytometry 
Isolated BAL lymphocytes were stimulated with heat-inactivated pneumococcus 
(Spn6B) or left unstimulated, following immunophenotyping and intracellular staining 
for INF-γ, TNF-α and IL-17A production. Full details of this method can be found in section 
2.6.4.4.  
 
5.2.3 IgG ELISA to Spn6B capsular polysaccharide 
Levels of IgG to Spn6B- CPS were measured in the BAL fluid using our published 
ELISA protocol (Mitsi et al. 2017). Full details of the method can be found in section 
2.6.7.  
 
5.2.4 Statistical analysis 
Statistical analyses were performed using GraphPad Prism (Version 6, GraphPad 
Software, La Jolla, CA) and R software (version 3.5.1). Two-tailed statistical tests were 
used throughout the study. If two parametric groups were compared, a two-tailed t test 
was used for unpaired and paired groups. If two non-parametric groups were compared, 
a Mann-Whitney or Wilcoxon test was used for unpaired and paired groups respectively. 
To quantify association between groups, Pearson or Spearman correlation test was used 
for parametric or non-parametric groups, respectively. Differences were considered 





5.3.1 Nasal pneumococcal colonisation reduces the frequency of TCR-γδ T 
cells in the human lung  
We assessed carriage-mediated alterations of the frequency of T cell subsets in 
BAL and compared cellular responses to pneumococcus between Spn colonised and non-
colonised groups. Therefore, lymphocytes were immunophenotyped and stained 
intracellularly for IL17A, IFN-γ and TNF-α production after an 18-hour stimulation. The 
gating strategy used to identify CD4+, CD8+ and TCR-γδ cells is presented on Figure 5.1A, 
whereas identification of tissue resident memory CD4+ and CD8+ T cells is illustrated on 
Figure 5.1B. As over 1/3 of CD4+ CD69+ cells, commonly defined as TRM (Turner et al. 
2014), did not express the additional resident memory markers CD103 and CD49a, we 
defined TRM only as CD69+. In contrast, nearly all CD8+CD69+ cells also expressed CD103 
and CD49a (Figure 5.1B). 
The Spn colonised group had similar levels of total CD4+ or CD8+ among total T cells 
with those measured in the non-colonised (Figure 5.2). On the other hand, Spn colonised 
group had a 50% reduction in  TCR-γδ+ Τ cell frequency in the BAL compared to non-
colonised group (median=2.39, IQR: 1.62-3.58 in carriage+ vs median= 4.67, IQR: 3.42-
6.73 in the carriage- group) (Figure 5.2). A similar pattern was observed in the frequency 
of the different TRM T cell subsets. Proportions of both CD4+ and CD8+ TRM T cells 
remained stable post colonisation, whereas frequency of TCR-γδ+ TRM T cells had a 
moderate 12% reduction in the Spn colonised group (p=0.011) (Figure 5.3).   
We also assessed whether there were differences in the frequency of regulatory 
CD4+ T cells between the two experimental groups. T regs were identified as 
CD3+CD4+CD25+Foxp3+ (Figure 5.1A) in BAL samples. Percentages of T regs amongst CD4+ 





Figure 5.1A. Representative gating strategy to identify T cells and cytokine production by 
flow cytometry using intracellular staining. The following gating strategy was used: (A) FSC-
A/SSC-A to (B) FSC-A/ FSC-H (in order to exclude doublets) to (C) CD3/Viability to (D) 
CD4/TCR-γδ+ to (E) SSC-A/CD8. (F) The markers CD25/FOXP3 (CD25hi and FOXP3+) were used 
to assess the frequency of regulatory T cells. To assess cellular production of (G) IFN-γ, (H) 
TNF-α and (I) IL-17A cells were stained intracellularly after overnight stimulation with Spn6B 






Figure 5.1B. Representative plots of tissue resident memory T cells identified by flow 
cytometry. The markers CD69, CD103 and CD49a were used to assess the frequency of tissue 
resident memory cells in human BAL. (A) CD4+ T-cells gated into CD69 negative and positive 
cells. CD103 and CD49 marker expression are shown for (B) CD4+ CD69+ T cells and (C) CD4+ 
CD69- T cells. (D) CD8+ T cells gated into CD69 negative and positive cells. CD103 and CD49 
marker expression are shown for (E) CD8+ CD69+ T cells and (F) CD8+ CD69- T cells. 
 
 
Figure 5.2. Frequency of T cells subsets in the human lung post EHPC. Subset frequencies 
among viable T cells were measured after an overnight incubation of isolated BAL cells. Error 
bars depict medians and IQR of T cell subsets percentage among total T cells in carriage- 
(n=21) and carriage+ volunteers (n=24). Comparisons were made using Mann-Witney tests. 
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Figure 5.3. Frequency of TRM T cells in the human lung post EHPC.  % frequencies of A) CD4+ 
CD69+ of total CD4+ T cells, B) CD8+ CD69+ of total CD8+ T cells and C) TCR-γδ+CD69+ of total 
TCR-γδ T cells were measured after an overnight incubation of isolated BAL cells. Error bars 
depict medians and IQR of TRM T cell in carriage- (n=21) and carriage+ volunteers (n=24). 
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Figure 5.4. Frequency of CD4+ regulatory T cells in the human lung post EHPC.  Frequency 
of unstimulated CD4+ Tregs (CD3+ CD4+ CD25+ FOXP3+) was measured by flow cytometry in 
human BAL samples of carriage- (n=19) and carriage+ volunteers (n=22). Error bars depict 
geometric means with 95% CI are shown. Comparisons between the two groups were made 




5.3.2 Significant increase of pneumococcal-specific IL-17A secreting CD4+ T 
cells in the human lung post Spn colonisation 
Here, we used a larger cohort to validate our previous finding on increased lung 
CD4+ Th17 cells in colonised (Wright et al. 2013). In line with the previous observation, 
pneumococcal colonised individuals had increased frequency (median 7.5-fold increase, 
p=0.016) of cognate IL-17A producing CD4+ T cells in the BAL (Figure 5.5A).  In contrast, 
stimulation of lung lymphocytes with the HI-Spn6B elicited production of IFN-γ by CD4+ 
T cells in both group at a similar level (median 2.5x increase, p=0.026 in carriage- vs 1.8x, 
p=0.0005 in carriage+ when compared to non-stimulated condition). There was thus not 
significant induction of Spn specific IFN-γ responses post colonisation (Figure 5.5B). 
Similarly, stimulation with HI-Spn6B elicited high TNF-α responses by CD4+ T cells 
irrespectively carriage status, and thus specificity to Spn cannot be attributed to such 
immune response (Figure 5.5C).  
 
5.3.3 Non-significant increase of pneumococcal specific CD4+ TRM T cells in 
the human lung post Spn colonisation 
We next sought to address whether nasal Spn colonisation contributes to lung 
immunity by increasing the frequency of cognate CD4+ TRM T cells. Frequency  of 
pneumococcal specific CD4+ TRM T cells did not differ significantly between Spn 
colonised and non-colonised individuals for either Th17 or Th1 (IFN-γ and TNF-α) 
responses (Figure 5.6A-C). However, the frequency of spontaneous (non-stimulated) IL-
17 producing CD4+ TRM T cells was proportionally more in the Spn colonised group 
(median= 0.33 with IQR: 0.19-0.50 in the carriage+ vs median= 0.19 with IQR:0.06-0.31 
in the carriage- group). Post stimulation, IL-17A producing CD4+ TRM cells was increased 
by 1.7-fold in both experimental groups. Similarly, IFN-γ and TNF-α producing CD4+ TRM 
increased in frequency in both groups, when stimulated with HI-Spn6B. Spn colonised 
exhibited a 2.1-fold increase in frequency of IFN-γ producing CD4+ T cells and a 2.5-fold 
increase in the TNF-α producing ones. In the non-colonised group, a 1.8-fold increase 
was observed in the frequency of IFN-γ producing CD4+ T cells and a 2.4-fold increase in 
the CD4+ T cells that were producing TNF-α upon overnight stimulation with HI-Spn6B. 
Comparisons of fold changes (Spn-stimulated/ non-stimulated condition) between the 






Figure 5.5. Increased frequency of pneumococcal specific CD4+ Th17 T cells in the Spn 
colonised group. % Frequency of cytokine producing CD4+ T cells non-stimulated or 
stimulated with challenge HI-Spn6B in carriage- (black dots, n= 21) and carriage+ (red dots, 
n= 24). A) Frequency of IL-17A, B) IFN-γ and C) TNF-α producing BAL isolated CD4+ T cells per 
condition. Spn-specific CD4+ T cell responses were calculated by subtracting baseline from 
Spn stimulated values. Medians with IQR are depicted. p values shown on the graph. Mann 







Figure 5.6. Non-significant increase of pneumococcal specific CD4+ TRM T cells in the Spn 
colonised group. % Frequency of cytokine producing CD4+ TRM T cells non-stimulated or 
stimulated with challenge HI-Spn6B in carriage- (black dots, n= 21) and carriage+ (red dots, 
n= 24). A) Frequency of IL-17A, B) IFN-γ and C) TNF-α producing BAL isolated CD4+ TRM T 
cells per condition. Spn-specific CD4+ TRM T cell responses were calculated by subtracting 
baseline from Spn stimulated values. Medians with IQR are depicted. p values shown on the 




5.3.4 No responses to pneumococcus by CD8+ and CD8+ TRM T cells 
Next, we studied BAL-derived CD8+ T cells responses upon Spn stimulation. As 
known, CD8+ T cells (often called cytotoxic T lymphocytes, or CTLs) are very important 
for immune defense against intracellular pathogens, including viruses and bacteria. 
When they recognise their antigen, they become activated and can secrete TNF-
α and IFN-γ. In vitro stimulation of lung CD8+ T cells did not elicit any response in either 
group. In fact, the frequency of such cytokines producing CD8+ T cells amongst total lung 
CD8+ population was extremely low. As expected, there was no difference in frequency 
of IL17A, IFN-γ or TNF-α producing CD8+ T cells between the two experimental groups 
(Figure 5.7A). In line with the total CD8+ T cells behaviour, CD8+ TRM T cells did not 







Figure 5.7. Neither CD8+ nor resident CD8+ T cells respond to pneumococcus. % Frequency 
of pneumococcal specific IL-17A, IFN-γ and TNF-α producing BAL isolated A) CD8+ and B) 
CD8+CD69+ T cells in carriage- (n= 21) and carriage+ (n= 24) upon stimulation with HI-Spn6B. 
Spn-specific responses were calculated by subtracting baseline from Spn stimulated values. 




5.3.5 IFN-γ and TNF-α but not IL17 responses by TCR-γδ+ T cells to S. 
pneumoniae in vitro irrespectively carriage status 
 In addition, we studied the direct production of cytokines in lung isolated TCR-
γδ+ T cells ex vivo, as well as post in vitro stimulation with pneumococcus in both 
experimental groups. TCR-γδ+ cells, a subset of specialized innate-like T cells that can 
exert effector functions immediately upon activation, play an important role in 
pulmonary infection (Ivanov et al. 2014, Steele, Oppenheim and Hayday 2000).  
 In the unstimulated condition, Spn colonised group exhibited a greater 
proportion of both IL-17A (median 2.3-fold increase) (p=0.038) and TNF-α producing 
TCR-γδ+ (median 1.9-fold increase) when compared with the non-colonised group (Figure 
5.8A and 5.8C).  In both cases, less than 2.5% (median % frequency) of the total TCR-γδ+ 




Stimulation with HI-Spn6B did not confer any increase in the frequency of IL-17A 
producing TCR-γδ+ in either group (Figure 5.8A). However, it elicited robust IFN-γ and 
TNF-α responses in both groups. In respect with IFN-γ responses, stimulation with 
pneumococcus increased 6.4x the levels of IFN-γ producing TCR-γδ in the Spn colonised 
group and 4.5x in the non-colonised group. Frequency of TNF-α producing cells were 
proportionally increased in a similar manner in both groups (4.3x and 3.6x median 
increase in carriage- and carriage+, respectively) (Figure 5.8B and 5.8C).  
Despite the differential IL-17A and TNF-α responses by spontaneous responding 
TCR-γδ, observed in the unstimulated lymphocytes fraction between the two groups, 
there was no statistically significant differences in pneumococcal specific responses 
upon stimulation (Figure 5.8A and 5.8C). 
Tissue resident memory TCR-γδ+ Τ cells were also defined by CD69 marker, as 
nearly no such cells were expressing the additional CD49a and CD103 markers. The 
cytokine expression pattern of lung TCRγδ+ TRM post stimulation resembled the one 
obverted in total TCR-γδ+ Τ cells; no IL-17A responses but robust IFN-γ and TNF-α. The 
identical cytokine responses to spn6B and the fact that TCR-γδ+ was found to constitute 
only the 0.1-8% of the total T cell population in lung, prohibited any further description 
of TCR-γδ+ ΤRM in the lung. We thus focused our interest on describing the total lung 
TCR-γδ+ population in association with nasal pneumococcal colonisation and its 











Figure 5.8. Non-significant increase in the frequency of pneumococcal specific TCR-γδ+ T 
cells in the Spn colonised group. % Frequency of cytokine producing TCR-γδ cells non-
stimulated or stimulated with challenge HI-Spn6B in carriage- (black dots, n= 21) and 
carriage+ (red dots, n= 24). A) Frequency of IL-17A, B) IFN-γ and C) TNF-α producing BAL 
isolated TCR-γδ cells per condition. Spn-specific cell responses were calculated by subtracting 
baseline from Spn stimulated values. Medians with IQR are depicted. p values shown on the 





5.3.6 High frequency of pneumococcal responding IFN-γ and TNF-α 
producing TCR-γδ+ T cells in BAL 
Opposed to IL-17A responses, which were confined only to CD4+ T cells, IFN-γ and 
TNF-α responses were observed in both CD4+ and TCD-γδ+ Τ cells subsets post 
stimulation with Spn6B independent of colonisation status. Given that a) the frequencies 
of such cytokine producing cells differ between the T cell subsets and b) the proportion 
of CD4+ cells is a log higher from TCR-γδ frequency in the healthy human lung, a direct 
comparison between cells subsets would be more conclusive.  
In terms of IFN-γ responses, spontaneous producing cells were found more 
frequently detected in CD4+ population. After in vitro stimulation with Spn6B, IFN-γ 
producing TCR-γδ+ were 8-fold higher (p <0.0001), whereas IFN-γ producing CD4+ and 
CD4+ TRM T cells were only 2- and 2.5-fold greater, respectively, compared to the 
unstimulated condition (Figure 5.9A).  
A similar pattern was observed in TNF-α responses across the different cell 
populations. TNF-α producing cells were proportionally more amongst CD4+ T cell 
population measured ex vivo, whereas after the in vitro Spn6B stimulation there was no 
statistical difference between frequencies of TNF-α producing CD4+, CD4+ TRM and TCR-








Figure 5.9. Robust IFN-γ and ΤΝF-a responses by TCR-γδ+ Τ cells post stimulation with Spn6B 
in vitro. Frequencies of A) INF-γ and B) producing T cells subsets (CD4+, CD4+CD69+ and TCR-
γδ+) expressed as % of total viable T cells in the BAL measured in two condition: unstimulated 
and post stimulation with HI-Spn6B. Medians with IQR are depicted. p values shown on the 





5.3.7 Increased levels of IgG to capsular polysaccharide 6B in the human 
lung post pneumococcal colonisation 
We also sought to investigate whether humoral responses to pneumococcus in the 
lung mucosa are affected by nasopharyngeal pneumococcal colonisation, as previously 
had been shown in nasal wash samples and blood (ref). Therefore, we measured levels 
of total IgG against the capsular polysaccharide of the challenge strain (CPS-6B) in BAL 
samples collected from EHPC participants 1 to 6 months post inoculation. Spn-colonised 
individuals had 2.6x higher IgG to spn6B-CPS compared to the non-colonised (median= 
2.1, IQR: 1.13- 4.64 in Spn colonised vs median= 0.81, IQR: 0.62-1.10 in non-colonised 
group) (Figure 5.10A) and were sustained at relatively high levels throughout the period 
of six months (Figure 5.10B). Although, they had started waning off, no significantly 
decrease was observed at either 4 (Figure 5.11A) or 6 months post (Figure 5.11B) the 
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Figure 5.10. Increased IgG to capsular polysaccharide of the challenge strain in Spn 
colonised group. Α) Levels of IgG to capsular polysaccharide of Spn6B measured in the BAL 
fluid of carriage- (n= 34) and carriage+ (n= 46). Each dot represents an individual. Error bars 
depict medians with IQR. p value is shown on the graph. Mann Whitney test was used.  Β) 
Linear model (lines) and observed titers (dots) of IgG to CPS-6B on the day on the 
bronscoscopy, expressed as day post inoculation for both carriage- and carriage+ group. 
Association between the two ranked variables per group was tested using Spearman 
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Figure 5.11. Levels of IgG to CPS-Spn6B in BAL per defined time period in the Spn-colonised 
group. Chronological representation of BAL IgG titers in Spn-colonised (n=46) collected from 
one to six months post intranasal pneumococcal inoculation divided into A) three or B) two 
consecutive time periods. Medians with IQR are depicted. p values shown on the graph. 
Mann Whitney and Wilcoxon tests were used.   
 
To examine correlative supporting evidence that BAL CPS-Spn6B IgG might be 
derived from serum leakage, levels of IgG to CPS-Spn6B in BAL of Spn colonised 
individuals, who had bronchoscopy up to 2 months post the challenge, were correlated 
with the equivalent IgG levels in serum. Capsular-specific IgG titres measured in serum 
and BAL fluid per participant were positively correlated (r=0.46, p=0.03) (Figure 5.12).  
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Figure 5.12. Correlation between IgG to CPS-Spn6B in BAL and serum. Levels of IgG to CPS-
Spn6B in BAL samples collected from D29 to D60 were correlated with those measured in 
sera at D29 per individual (n=23, volunteers with paired values). Spearman correlation test 




5.4 Discussion  
Here we investigated the antibody and adaptive cellular responses of lung 
immunity to pneumococcus. We observed that carriage was not associated with altered 
frequency of neither CD4+ nor CD8+ T cell populations, but was associated with a 50% 
reduction in proportion of TCR-γδ+ T cells in BAL. In regards with tissue resident memory 
T cells, the frequency of both CD4+ and CD8+ TRM remained unaltered post colonisation, 
whereas TCR-γδ+ TRM had a moderate 12% reduction. In consistence with our previous 
findings (Wright et al. 2013), pneumococcal colonisation resulted in IL-17A responses, 
seeding the human lung with pneumococcal-specific IL-17A secreting CD4+ memory T 
cells. However, there was no increase in the frequency of pneumococcal-specific CD4+ 
TRM, as identified upon in vitro stimulation with the challenge strain. Although, we 
observed greater proportion of both IL-17A producing CD4+ TRM and TCR-γδ T cells in 
the direct BAL sample of Spn colonised volunteers, stimulation with pneumococcus did 
not significantly increase their frequency when compared to the non-colonised group. In 
contrast to IL-17A, frequency of IFN-γ and TNF-α producing cells (both CD4+ T cells and 
TCR-γδ) were robustly elevated in response to pneumococcus irrespective of carriage 
status. In addition to cellular responses, pneumococcal colonisation was associated with 
increased titres of IgG to capsular polysaccharide of Spn6B, which remained high for at 
least four months post the intranasal challenge.   
Human pneumococcal-specific IL-17A responses have been demonstrated 
previously in peripheral blood (Lu et al. 2008, Lundgren et al. 2012, Mureithi et al. 2009) 
but in our studies (past and present) we focused on the mucosal compartment where 
pneumonia occurs – the lung. Using a similar experimental approach, such as challenge 
with 6B serotype and the backbone of the previous used flow cytometry panel, we 
replicated the main findings described by our group 5 years ago; pneumococcal 
colonisation seeds the human lung with cognate CD4+ Th17 T cells. IL-17A responses 
were a) confined to CD4+ T cell population, b) specific to pneumococcus and c) minimum 
or non-detectable in the non-colonised group. In fact, pneumococcal-responding IL-17A 
CD4+ memory T-cells were present at decreased frequency in the healthy adult lung in 
the absence of colonisation. Many functions have been attributed to IL-17A secreted 
from Th-17 cells (Kolls and Khader, 2010). It can enhance neutrophil recruitment and 




(iBALT) formation (Rangel-Moreno et al. 2011). Given these antimicrobial-related 
functions attributed to IL-17A, such a cell deposit in lung post colonisation could 
potentially reduce susceptibility to pneumococcal pneumonia.  In addition, it has been 
described that human Th17 cells persist for longer and are more resistant to apoptosis 
compared to Th1 cells (Kryczek et al. 2011). This ability highlights the importance of our 
reproducible finding and makes pneumococcal-specific CD4+ Th17 T cells increase of 
frequency an attractive goal for vaccinations relying on cellular immunity.  
Surprisingly, pneumococcal colonisation was not associated with an increase of 
cognate CD4+ TRM T cells. A moderate 1.7-fold increase in levels of IL-17A producing 
CD4+ TRM cells was observed in both experimental groups upon stimulation, which could 
be the result of heterotypic response by CD4+ TRM generated in the lung due to life-time 
exposure to other pneumococcal serotypes. The increased frequency, although of low 
numbers, of IL-17A producing CD4+ TRM T cells in the unstimulated lymphocyte fraction 
of Spn colonised group, is an observation that seeks further explanation. Theoretically, 
in vivo exposure of cognate CD4+ TRM to aspirated pneumococci could result to their 
activation. However, the lack of other supportive data weakens this hypothesis. 
Although, our findings did not showcase the importance of pneumococcal specific CD4+ 
TRM in lung immunity, they should be interpreted with caution. Unlike CD8+ TRM, which 
express other tissue resident markers, such as CD49a and CD103, only 1/3 of the total 
CD4 population express either CD49a or CD103. Therefore, in case of CD4+ T cell 
population is difficult to define what is a real CD4+ TRM cell.  
Conversely to CD4+, total CD8+ T cells did not respond to pneumococcus after in 
vitro stimulation. Although CD8+ T cell functions have been mainly described in the 
context of viral infections, there is an unconventional CD8+ subpopulation- the mucosal 
associated invariant T (MAIT) cells. We recently studied MAIT cells in both blood and 
nasal biopsies collected from challenged volunteers and we found that they may play a 
role in protection against acquisition of pneumococcal colonisation, through increased 
production of TNF-α and IFN-γ (Jochems et al, 2019). Unlike the CyTOF panel, the flow 
cytometry panel used in immunophenotyping lymphocytes in BAL had not included 
markers that would enable us to study CD8+ MAIT cells in the lung (CD161++TCRvα7.2+).  
The last lymphoid population that we studied in the human lung in association with 




distinctive T-cell receptor (TCR) on their surface. They are considered unconventional T 
cells and a bridge between innate and acquired immunity (Nishimura et al. 2004). γδ cells 
is the least frequent cell population amongst T cells in the BAL, constituting only 1-10% 
of the total T cells in the healthy adult human lung (Wu et al. 2009, Mwale et al. 2017). 
Using the EHPC model, we found that pneumococcal colonisation decreased 
substantially their frequency 3 to 7 weeks post the challenge, with Spn colonised 
individuals to have 50% less TCR-γδ compared to non-colonised. We can speculate that 
this carriage-mediated reduction may be associated with either TCR-γδ+ exhaustion or 
return to local lymph nodes. A previous study had demonstrated that human TCR-γδ+ are 
capable of phagocytosis via Ab opsonisation and CD16 (FcγRIII) and present Ag on MHC 
class II (Wu et al. 2009). However, the lung is equipped with an enormous number of 
professional and highly differentiated phagocytes- the alveolar macrophages. As TCR-γδ 
are highly outnumbered by AM in alveoli, it seems more pragmatic that their presence 
in the lung is necessitated due to cytokines production, antigen-presentation and to 
bridge innate and adaptive immunity  (Hayday and Tigelaar 2003).  Their encounter with 
pneumococcal cells or particles in the airspaces of Spn colonised volunteers could 
provide an explanation for the increased frequency of spontaneously producing IL-17A 
and TNF-α TCR-γδ compared to the non-colonised group. Activated TCR-γδ produce a 
range of cytokines, including IFN-γ and TNF-α. They also up-regulate CCR7 and home to 
local lymph nodes where they interact with αβ T cells and other APCs (Devilder et al. 
2006, Wu et al. 2009). It has been shown that the activation profile and behaviour of γδ 
T cells bears resemblances to that of the innate myeloid lineage dendritic cells  (Moser 
and Eberl 2007). It is also important to emphasize that γδ Τ cells had the greatest IFN-γ 
response to pneumococcus post in vitro stimulation with the challenge strain. The 
frequency of IFN-γ producing T cells increased 10x post stimulation, reaching levels 
similar to IFN-g producing CD4+ T cells amongst total T cells. This finding suggests that, 
although rarely found in alveoli, TCR γδ can be an important source of IFN-γ in the lung 
mucosa.  
The fact that there was no alteration in the frequency of regulatory CD4+ T cells - 
known for their regulatory function to preventing inflammation-related local tissue 
damage (Zhang et al. 2011)- post colonisation indicates that nasopharyngeal colonisation 
is primarily associated with cell stimulation and immunological “boosting” rather acute 




Antecedent pneumococcal colonisation also affected the antibody responses in 
the lung. Serum immunoglobulins are critical in defence against invasive disease and 
lung-lining fluid Ig are critical in primary mucosal defence, particularly to 
opsonophagocytosis of capsulate pneumococci by alveolar macrophages (Gordon et al. 
2000). In this study we found that Spn colonised volunteers had 2.6-fold increased IgG 
against CPS of the challenged strain. Our focus was on IgG because IgA is likely to be 
insufficient in bacterial opsonisation due to the activity of pneumococcal IgA1 protease 
to cleave IgA1- the dominant IgA (Janoff et al. 2014). The positive correlation found 
between serum and BAL pneumococcal specific IgG levels suggests that transudation of 
antibody from serum into the alveoli may occur and can contribute to the increased 
pneumococcal-specific IgG in BAL, in support to local antibody synthesis. Pneumococcal 
fragments (PAMPs) presented by antigen-presenting cells could potentially trigger the 
maturation of local memory B cells in the lung (Condon et al. 2011). Future studies need 
to assess whether presence of colonisation elevates antibody levels to conserved 
pneumococcal proteins amongst the different serotypes in the lung, as we previously 
reported in nasal mucosal antibodies of Spn colonised individuals (Ferreira et al. 2013). 
Most importantly, the high-throughput CyTOF platform must be applied on BAL samples 
to allow us to immunophenotype tissue resident memory B cells to pneumococcus 
amongst the other rare lung cellular populations.   
Collectively, these findings have important implications for vaccine design against 
pneumococcal pneumonia. Ideally, an effective, non-serotype independent vaccine 
against pneumonia should induce both cellular and humoral responses. Our data suggest 
that nasal pneumococcal colonisation triggers both arms of adaptive immunity, without 
leading to acute inflammation or homeostasis disruption. Enhanced, long-lasting 
immune memory to pneumococcus might render the host less susceptible to 














Nasopharyngeal pneumococcal colonisation is a natural source of immunisation 
for the human host (Ferreira et al. 2013, Pennington et al. 2016, Wright et al. 2013).  The 
study of host-pathogen interactions, using a controlled human pneumococcal infection 
model, can provide insights on immunologic mechanisms that control colonisation and 
accelerate the development of better or novel vaccines against S. pneumoniae. The safe 
and reproducible experimental human pneumococcal challenge model allows us to 
describe the dynamics between carriage state and host immune responses in blood, nose 
and lung, during a known initiation and duration colonisation episode. Amongst these 
three compartments, lung immune responses induced by nasal colonisation are 
incompletely described. 
This thesis provides new evidence on the relationship between nasopharyngeal 
pneumococcal colonisation and lung immune responses, focusing on innate immunity 
and alveolar macrophage behaviour in healthy young adults. The overarching research 
aims of the present study were:  
• To investigate alveolar macrophage polarisation, shift and other 
phenotypic changes post pneumococcal colonisation 
• To test the hypothesis of pneumococcal aspiration in the lungs during 
nasopharyngeal colonisation 
• To investigate the effect of colonisation on lung innate immune 
responses  





6.2 Discussion of key findings 
6.2.1 Human alveolar macrophages phenotypic and gene expression analysis 
Assessment of human alveolar macrophage phenotype in adults living in two 
different geographical locations using flow cytometry, underlined the complexity of this 
lung resident cell population, revealing a unique phenotype with combined M1/M2 
features. We hypothesise that this hybrid phenotype may confer to alveolar 
macrophages an ability to quickly switch between M1 or M2 associated function allowing 
for appropriate responses to stimuli and tissue environment. However, it raises the 
question of whether changes associated with alveolar macrophage polarisation can be 
detected with the exclusive use of surface markers that have derived from murine 
models and in vitro polarisation of human macrophages using a combination of 
cytokines. Our transcriptome data showed that AMs from pneumococcal colonised 
individuals have increased antigen-presentation and their opsonophagocytic capacity 
was positively correlated with genes that either have been linked with Th1 responses or 
drive monocyte differentiation towards an “M1-like phenotype”. The controversy of our 
findings emphasises the necessity for the development of a standardised way of 
assessing alveolar macrophage polarisation in humans. The lack of consensus on how to 
define macrophage activation/polarisation both in in vitro and in vivo experiments have 
been recently highlighted by researchers (Murray et al. 2014). The source of 
macrophages, the activators, enforcement of feedback and feedforward signalling loops 
including autocrine production of cytokines and epigenetic and/or developmental 
effects built into the life history of a macrophage (Ivashkiv 2013, Lawrence and Natoli 
2011, Porta et al. 2009) are parameters that can alter macrophage activation state and 
add into their complexity.  Therefore, assessment of AM activation and polarisation 
mode should rely on combined transcriptome, immunophenotyping and functional data. 
Additionally, epigenetic and metabolic data may provide a means to dissect intrinsic 






6.2.2 Micro-aspiration as a proposed mechanism that introduces 
pneumococci in the human lung during colonisation  
The relationship between aspiration of pneumococci from the nasopharynx to 
the lung has been only studied in presence of respiratory infection. The current paradigm 
is that high pneumococcal densities, especially in periods of viral co-infection, lead to 
increased risk of pneumonia development (Howard et al. 2019). Here we demonstrated 
for the first time that pneumococcal aspiration occurs during a nasal colonisation 
episode without leading to disease in the healthy human lung. Contrary to the paradigm, 
it acts as a natural source of lung immunisation against S. pneumoniae, with higher 
pneumococcal densities positively associated with greater alveolar macrophage 
antimicrobial properties. Our evidences on pneumococcal presence in the lung of 
colonised individuals, in the form of live pneumococci or intact pneumococcal cells 
within alveolar macrophages and/or as detected pneumococcal DNA in the 
bronchoalveolar samples, support the hypothesis that trafficking of bacteria from the 
nasopharynx to the lung airway is the mechanism that links these two compartments in 
the context of pneumococcal colonisation. Low levels of micro-aspiration have been 
reported to occur in patients with obstructive sleep apnea (Beal et al. 2004), as well as 
in healthy adults during sleep (Gleeson, Eggli and Maxwell 1997). Additionally, a study 
that combined oral/nasopharyngeal and lung sampling showed that bacteria are present 
in the lungs of healthy people at low levels compared to the upper respiratory tract. 
These bacterial populations were indistinguishable in community composition from 
upper airway microbiota, suggesting that respiratory tract harbours a homogenous 
microbiota that decreases in biomass from upper to lower tract (Charlson et al. 2011).  
 
6.2.3 Nasal pneumococcal colonisation is an immunising event for the lung, 
affected both innate and adaptive immune responses 
The immunising effects of nasal pneumococcal colonisation on human lung 
immune responses are presented in this thesis in a comprehensive way. We found that 
colonisation enhances lung immunity triggering both non-specific and pneumococcal 
specific responses. Most importantly this immunological “boosting” was not 
accompanied by acute inflammation, homeostatic disruption or neutrophils infiltration.  




elevated on the day of lung sampling, we cannot rule out that a transient increase of 
their respective levels could had been occurred during high-density nasopharyngeal 
colonisation.  
 
6.2.3.1 Augmented alveolar macrophage responsiveness to pneumococcus and 
unrelated bacterial pathogens 
Data presented here are the first to describe in vivo priming of alveolar 
macrophages after colonisation has been successfully established in the nose and 
provide insights on the mechanism whereby their functional enhancement is achieved. 
Assessment of alveolar macrophage function post experimental human pneumococcal 
colonisation demonstrated that they are more able to phagocytose or kill extracellularly 
both S. pneumoniae and other respiratory bacterial pathogens. This enhanced 
opsonophagocytic capacity persisted for approximately three months after the bacterial 
challenge. Similar enhanced function, with same duration, and also phenotypic 
alterations have been previously described in peripheral blood monocytes in the context 
of vaccination with attenuated bacterial strains (Kleinnijenhuis et al. 2012, Pennington 
et al. 2019). In particularly, BCG vaccination induces monocytes genetic reprogramming, 
through the NOD2 receptor, and confers protection against reinfection and heterologous 
infection (Kleinnijenhuis et al. 2012, Saeed et al. 2014). This relatively long-term, 
increased responsiveness exhibited by cell populations of innate immunity have been 
termed as “trained immunity” or innate immune memory (Netea et al. 2016). Only 
recently, this type of memory was reported in tissue resident macrophages- the alveolar 
macrophages- in a murine model of respiratory adenoviral infection (Yao et al. 2018). In 
this study, AM priming required the help of effector CD8 T cells in an IFN-γ- and contact-
dependent manner. In our case, AM priming was induced by CD4+ T cells, most likely via 
an IFN-γ driven axis. The type of infection could explain why AM priming was mediated 
by different T cell type in each model. During viral infection, CD8 T cells are the major 
population induced by the virus and it was seen to entry the mouse airway (Yao et al. 
2018). In our controlled human pneumococcal infection model, CD4+, but not CD8, 
responded to in vitro stimulation with pneumococcus. Yao et al, also demonstrated that 
these memory AMs, with sustained changes in surface markers, gene expression, 




of in situ proliferation independently of circulating monocytes or bone marrow 
progenitors. In our study, we found that AMs have altered gene expression and 
heightened responsiveness to respiratory bacterial pathogens post in vivo exposure to 
pneumococcus. However, lack of epigenetic and metabolic data disables us on 
concluding whether pneumococcal colonisation mediates innate immune memory in the 
human lung. Future studies are warranted to explore the potential of pneumococcal 
colonisation to generate memory macrophages and a long-term protective effect.  
 Additionally, in our study the decreased monocyte-surface signature found in 
AMs, in combination with the increased ratio AM to monocytes observed in the lung 
samples of those who had been colonised, implies to some degree that monocyte-to-
macrophage differentiation may be promoted by colonisation. This observation merits 
further investigation, as this process has mainly been investigated in the mouse system, 
whereas no data of this and its long-lasting consequences exist in humans (Morales-
Nebreda et al. 2015).  
Despite hypotheses, such as reprogramming of resident AMs or generation and 
settlement of a monocyte-derived AM macrophage population in the lung that confers 
increased lung protection against subsequent infection, as recently shown in a mouse 
model of influenza infection(Aegerter et al. 2020), we have to consider other plausible 
alternatives. For instance, the elevated levels of IFN-γ detected in the BAL supernatant 
up to 50 days post the initial challenge may promote an going immune cell stimulation, 
sustain AM activated and hence more sufficient against the elimination of bacterial 
infection.  
6.2.3.2 Prompt non-specific Th1 responses and long-term pneumococcal-specific 
Th17 responses  
The role of T helper responses to pneumococcal immunity has been extensively 
studied in mouse models but little is known about these responses in humans. The 
immunophenotypic analysis of CD4+ T cells directly after lung sampling allowed us to 
assess their activation state in the lung mucosa. We found that Th1 (mainly IFN-γ) 
responses were elicited against the inhaled pneumococci, which were either alive or 
fragmented when entered the alveolar spaces. Our finding is in line with previous in vitro 
work on human cells, demonstrating that live pneumococci trigger a Th1-biased 




revealed the presence of cognate, IL-17A secreting memory CD4+ T cells in the human 
lung post colonisation. These pneumococcal-specific Th17 CD4+ T cells seem to be the 
acquired memory result of the lung cellular interactions with S. pneumoniae.  
Pneumococcal fragments released after bacterial lysis are presented by APCs, such as 
dendritic cells, and may trigger Th17 responses, seeding the human lung mucosa with 
cognate Th17 CD4+ T cells. Schlitzer et colleagues showed that in both humans and mice 
a subset of IRF4 expressing CD11b+ dendritic cells, secrete IL-23 and control Th17 cell 
responses in the lung mucosa (Schlitzer et al. 2013).  
Whereas previously we have shown that treatment with exogenous IL-17A 
augmented AM opsonophagocytic capacity to pneumococcus (Wright et al. 2013), in the 
current study AM pneumococcal uptake was not correlated with the levels of IL-17A 
producing CD4+ T cells post stimulation with heat-killed pneumococci. The different 
source and/or higher concentrations of IL-17A may offer a plausible explanation of such 
a discrepancy. Moreover, the importance of Th1 response and AM-CD4+Th1 synergy 
against pneumococcal infection had been overlooked in the previous study, as immunity 
to pneumococcus post EHPC was only investigated under the prism of pneumococcal-
specific T cell memory.  
 
6.2.3.3 Alveolar macrophage and T cells synergy in the host defence to S. 
pneumoniae 
The alveolar macrophage capacity to kill pneumococci in vitro was enhanced 
during co-culture with autologous CD4+ T cells irrespective of nasal carriage status. AM 
treatment with exogenous IFN-γ conferred a similar phenotype at low doses, including a 
dose that mimicked the relative levels of IFN-γ in the BAL of colonised volunteers, 
whereas neutralisation of IFN-γ receptor abrogated this effect. We hypothesise that 
during pneumococcal aspiration bacteria are internalised by alveolar macrophages and 
subsequently skew the responses to Th1. Production of IFN-γ by activated CD4+ Th1 cells 
in turn enhances AM capacity to take up pneumococci, leading to further IFN-γ secretion 
and a positive feedback loop between AM and Th1 cells. γδ-Τ cells, despite their low 
numbers in the lung mucosa, produce large amounts of IFN-γ upon stimulation and 
therefore might act as an additional source of this cytokine. Data derived from In vitro 




induced post pneumoccal internalisation and is dependent on the presence of 
monocyte-derived IL-12p40 (Olliver et al. 2011). In the same study, it was also shown 
that the IFN-γ response to live pneumococci was 100-fold higher than to heat-killed 
pneumococci, while the IL-17 response was not inhibited by heat killing (Olliver et al. 
2011). We speculate that IL-17A production is restrained as long as AM can promptly 
remove pneumococci from the alveolar spaces. This is supported by our data, as IL-17A 
was not elevated, neither neutrophil infiltration occurs in the lung mucosa post 
colonisation. It is also possible that the amount of pneumococci present in the alveolar 
spaces was not enough to induce detectable IL-17A in the BAL sample. 
In the scenario that AM are unable to control infection, neutrophils are recruited 
to the lung via IL-17A production (Lu et al. 2008). Recruited neutrophils reinforce the 
lung immune responses but also cause tissue damage (Pechous 2017). In the setting of 
intracellular pathogens, IL-17 can induce the production of IL-12 in dendritic cells and 
drive Th1 immunity and intracellular bacterial control (Kolls and Khader 2010). Recently, 
Ercoli and collegues demonstrated replication of S. pneumoniae inside splenic 
macrophages in mice, questioning the previous dogma of pneumococcus as a strictly 
extacellular pathogen (Ercoli et al. 2018). Our preliminary data on pneumococcal 
presence inside AM isolated from prior colonised volunteers, days after natural or 
antibiotic-mediated pneumococcal clearance in the nasopharyngeal, suggest a 
fundamental shift on the way that we understand the pathogenesis of community 
acquired pneumonia. Therefore, it is yet to be investigated whether and under what 
circumstances alveolar macrophages can act as a pneumococcal reservoir.  
 
6.3 Implications  
6.3.1 Implications for pneumococcal vaccine development 
Current licenced pneumococcal vaccines have been successful in reducing the 
incidence of invasive pneumococcal disease by mainly conferring B cell-mediated 
protection. However, this type of immune response is less effective against mucosal 
infections. Additionally, vaccine escape serotypes, serotype replacement, 
compartmentalisation of the human immune responses are reasons that advocate the 





Quick clearance of bacteria from the lung by alveolar macrophages is the key 
aspect for the prevention of disease development at the very early stages of infection. 
Also, it prevents neutrophil recruitment that can trigger excessive lung inflammation. 
Our data highlight the importance of alveolar macrophages and Th1 responses in 
achieving this ideal immunological state in lung mucosa and suggest that the research 
interest for pneumonia prevention has to be shifted towards innate immunity and 
Th1/Th17 responses, rather than focuses on new vaccine strategies that exclusively elicit 
Th17 responses. Colonisation of nasopharynx with pneumococcus confers such ideal 
immunological “boosting” to the lung mucosa and lack of it could explain the paradox of 
low colonisation and high disease in the elderly.  Adaptive Immunological memory has 
reached plateau in this age group (Patin et al. 2018), and thus current licensed 
pneumococcal vaccine may have minor benefits in this age group. Additionally, there are 
theoretical concerns that PPV may cause immunological harm resulting from exhaustion 
of present memory B-cells (Clutterbuck et al. 2012). Therefore, an inhaled live-
attenuated pneumococcal vaccine that enhances innate and adaptive immunity could 
confer increased and broader protection to the elderly.  
In other risk groups (smokers, COPD, HIV-infected individuals, infancy) increased 
susceptibly to pneumonia is mainly associated with impaired AM function or perturbed 
communication between AMs and lung epithelium cells or abnormal/underdeveloped 
CD4+ Th1 responses, which support the importance of the AM-Th1 cells cross talk 
described here.  These groups most likely require targeted therapeutic strategies that 
would aim to correct the defective immunological factor and restore the cellular 
communication.  
 
6.3.2 Implications for pneumococcal biology and pneumonia treatment  
 Alveolar macrophages are central players of the lung defence against 
extracellular pathogens, but they can provide a niche for intracellular pathogens, such as 
Mycobacterium tuberculosis. Presence of intact pneumococcal cells within human 
alveolar macrophages, derived from volunteers that cleared colonisation days before 
bronchoscopy or after treatment with amoxicillin, is an unexpected but important 
finding, which suggests a potential role of AMs as pneumococcal reservoir. Influenced by 




macrophages, our results of prolonged pneumococcal survival in the human lung imply 
an intracellular phase of pneumococcus within alveolar macrophages. If this is the case, 
macrolides, classically known as protein synthesis inhibitors, might be more effective 
than amoxicillin for pneumonia treatment, due to their ability to penetrate macrophages 
and act intracellularly. Although known for their immunoregulatory effects on excessive 
inflammation, a mice colonisation model study showed that macrolides promote 
macrophage recruitment, through CCL2, and subsequently clearance of pneumococci 
from the nasopharynx (Iwanaga et al. 2015).  
 
6.4 Future work  
 The findings presented within this thesis open up new avenues of research. 
Further characterisation of lung cellular populations using high throughput techniques, 
such as single cell RNA sequencing (sc-RNAseq) and CyTOF, will i) yield important insights 
into the mechanisms responsible for generation of protective lung immune responses, 
ii) enable the identification and study of rare lung cell population and iii) allow us to study 
alveolar macrophage population at the single cell level. The latter is of major importance, 
as can shed light on the developmental origin of AMs during the adult life and identify 
molecular signatures that either enhance AM responsiveness to pathogens or promote 
pneumococcal survival within them. Avenues that seek further exploration as the 
following:  
6.4.1 Assess the potential of colonisation to generate innate immune 
memory in the lungs 
 Analysis and comparison of alveolar macrophage transcriptome pre and post 
pneumococcal colonisation will further inform us on the direct effect of nasopharyngeal 
colonisation upon AM in the level of individual, reducing the variation introduced to the 
model due to differential immunological profile and respiratory tract microbiome.  
Applying this approach to the single cell level will allow us to define AM subpopulations 
with changed functionality, their underlying transcriptomic networks and subsequently 
their functional differences. Additionally, assessment of changes in the availability of 
DNA for transcription (epigenetic changes) and alterations on metabolic pathways will 
provide evidences on whether pneumococcal colonisation seeds the lung with memory 




6.4.2 Pneumococcal survival assessment in the healthy and susceptible lung 
  
In vitro investigation of pneumococcal survival within AM from both healthy 
adults and risk populations (etc COPDs, HIV-infected, elderly), as well as people with 
ongoing influenza infection will inform us on how apiece lung conditions facilitate the 
development of pneumococcal pneumonia. High-resolution phenotypic (CyTOF) and 
transcriptomic analysis of AM from these different groups will yield important insights 
on the mechanisms that drive such a phenomenon. Additionally, combination of EHPC 
with optical molecular imaging techniques of the distal lung will enable us to visualise 
inhaled pneumococci in vivo and define potential lung deposits.  
6.4.3 Controlled human pneumococcal infection combined with 
pneumococcal protein lung delivery.  
 Data presented here bring to the table the topic of immune 
compartmentalisation and highlight the importance of lung immunisation. Mucosally 
delivered pneumococcal vaccines may be a more suitable vaccine strategy for 
pneumonia prevention, as they could activate local cell population and confer increased 
lung immunity. Recent advances on vaccine-antigens delivery systems have made a step 
forward to the administration of such vaccines to the human lung (Goncalves et al. 2019). 
The EHPC model could serve as a platform for testing lung delivered pneumococcal 
protein-based vaccines by assessing their ability to immunise the human lung and 
comparing it with the systemic and mucosal immunising effects of pneumococcal 
colonisation. A randomised control clinical trial that would include the following 
experimental arms: a) intranasal inoculation of live wild type S. pneumoniae, b) 
inoculation with saline (control group), c) lung administration of pneumococcal protein-
based vaccine (protein loaded to nanoparticle or nanogels) and d) combined intranasal 
inoculation of live pneumococcus and lung delivery of the pneumococcal protein-vaccine 
would be required to test the superiority of each single-immunisation approach versus 










In conclusion, we have demonstrated that nasopharyngeal pneumococcal 
colonisation acts an immunising event for the lung mucosa. We found evidences of the 
natural process that links the two mucosal sites during colonisation and provided insights 
into the mechanism that promotes increased lung immune responses (Figure 6.1). The 
benefits of nasopharyngeal colonisation were beyond those specific to pneumococcus, 
as it influences immune responses to non-related bacterial pathogens.  Additionally, the 
presented work provides a significance advance in understanding the development of 
pneumococcal pneumonia.  
Figure 6.1. Schematic overview of the events that result in augmented lung immunity 
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IL2 0.17 0.17 0.936 0.936 
IL17 0.3 0.3 0.142 0.634 
TNFα 0.42 0.42 0.741 0.931 
FGF Basic 0.65 0.65 0.183 0.634 
GM-CSF 0.49 0.96 0.034 0.484 
EGF 1.01 1.01 0.619 0.912 
IL 10 0.92 1.11 0.443 0.831 
IL 1β 1.09 1.09 0.290 0.725 
IL 4 1.25 1.24 0.617 0.912 
Eotaxin 1.19 1.33 0.914 0.936 
RANTES 1.79 1.79 0.903 0.936 
IL 5 2.3 2.78 0.361 0.831 
IFN-γ 1.89 3.82 0.048 0.484 
IFNα 2.96 3.61 0.044 0.484 
MIG 2.07 7.37 0.111 0.634 
IL 13 4.87 6.03 0.100 0.634 
IL 12 8.13 7.07 0.884 0.936 
MIP 1α 9.35 9.57 0.429 0.831 
MIP 1β 11 11.42 0.503 0.887 
IL 15 16.56 11.29 0.232 0.634 
IL 6 13.49 16.22 0.203 0.634 
IL 2R 17.62 22.65 0.406 0.831 
IL 7 17.58 25.34 0.177 0.634 
IP 10 23.07 29.58 0.212 0.634 
G-CSF 33.03 43.81 0.733 0.931 
MCP 1 51.34 48.13 0.895 0.936 
VEGF 56.4 61.4 0.638 0.912 
HGF 79.2 73.13 0.800 0.936 
IL 8 61.92 90.55 0.538 0.897 
IL 1RA 959.97 775.27 0.745 0.931 
 
Table I.  Levels of 30 cytokines and chemokines measured the in the BAL fluid of carriage 
negative (n=20) and carriage positive (n=22) volunteers, who underwent research 
bronchoscopy up to 50 days post the pneumococcal inoculation. Levels are expressed as 
pg/ml and are ordered from low to high values. Median per group, p-values by Mann-
Whitney test and p-values corrected by multiple-comparison testing (Benjamini-Hochberg) 






chemokine cluster (I) 
(M27.0) 
("CXCL2", "CXCL11", "CXCL10", "IL8", "CCL13", "CCL18", 
"PPBP", "CCL20") 




("HLA-DQA1", "CLEC7A", "LY96", "HLA-DPB1", "CD247", 
"FYN", "TLR1", "LILRB1", "IRAK3", "TLR7", "PTPN22", 
"CD19") 
TLR and inflammatory 
signalling (M16) 
("LY96", "TLR8", "CSF3R", "TLR1", "LILRB1", "IRAK3", 
"TLR7", "LILRA6", "CXCR2") 
immune activation - 
generic cluster (M37.0) 
("LY96", "CEACAM6", "PAX5", "IL1R2", "TLR1", "PTGS2", 
"TLR7", "ENTPD1", "CD19", "CTSS", "CXCR2", "ITGAM", 
"CXCL1", "IL18RAP", "PTK2") 
cell cycle and 
transcription (M4.0) 
("CD36", "PRKCD", "TGFBI", "CD163", "IL1RN", "PLAUR", 
"FCGRT", "ITGAX", "CSF1R", "CD14", "PTAFR") 
enriched in monocytes 
(II) (M11.0) 
("FCGRT", "S100A8", "ITGAX", "CSF1R", "CD14", "PTAFR") 
Monocyte surface 
signature (S4) 
("FCGR2A", "TLR4", "TNFRSF1B", "LILRB2", "LTBR", "CD36", 
"TNFSF12", "CD163", "MARCO", "PYCARD", "CD4", 
"FCGRT", "PTAFR") 
 
Table II: List of differentially expressed genes presented in the pathways identified by gene 




























Gene log2FoldChange p-value 
adjusted  
p-value 
C1QA -1.73 0.001 0.425 
CD14 -1.86 0.004 0.500 
CSF1R -1.84 0.008 0.500 
IRF4 1.77 0.008 0.500 
C1QB -1.66 0.009 0.500 
CXCL11 1.96 0.011 0.500 
GPI -1.27 0.011 0.500 
NT5E 1.38 0.018 0.500 
CCND3 -1.45 0.018 0.500 
CLEC7A 2.37 0.021 0.500 
CEACAM6 1.29 0.022 0.500 
LY96 2.19 0.022 0.500 
TAPBP -1.34 0.024 0.500 
TNFSF4 1.32 0.026 0.500 
HLA-
DRB3 
-3.36 0.028 0.500 
ITGAX -1.83 0.029 0.500 
IL13 1.18 0.030 0.500 
FCGRT -1.32 0.032 0.500 
CMKLR1 -1.55 0.033 0.500 
TNFSF13B 1.78 0.034 0.500 
CD164 2.01 0.035 0.500 
S100A8 -1.46 0.035 0.500 
CXCL2 2.08 0.036 0.500 
PYCARD -1.02 0.036 0.500 
TBX21 1.42 0.037 0.500 
TAGAP 1.08 0.037 0.500 
KLRC4 1.24 0.038 0.500 
CCRL1 1.27 0.039 0.500 
GAPDH -1.42 0.041 0.508 
IL10RA -1.14 0.045 0.543 
TLR8 1.56 0.047 0.545 
KIR3DL2 1.25 0.048 0.545 
ITGB2 -1.41 0.049 0.545 
    
Table III. List of differentially expressed genes (DEG with p < 0.05) in sorted AMs on the day 
of the bronchoscopy (36 to 115 days post intranasal inoculation), compared Spn colonised 
(n=5) to non-colonised (n=5) individuals. Log2fold change (carriage positive over carriage 
negative), p-values by Mann-Whitney test and corrected p-values by using Benjamini-





Gene p value Rho 
KLRD1 0.007 0.818 
SLAMF1 0.008 0.806 
IL13RA1  0.011 0.760 
CCL15 0.016 0.758 
KIR3DL1 0.018 0.745 
KLRAP1 0.018 0.745 
IL16 0.021 0.733 
PRDM1 0.024 0.721 
CCR10 0.028 0.709 
LAG3 0.028 0.709 
TRAF4 0.028 0.709 
IRF8 0.030 0.681 
EDNRB 0.035 0.669 
KLRK1 0.035 0.669 
IL6R 0.035 0.685 
NT5E 0.035 0.685 
ZAP70 0.035 0.685 
DPP4 0.039 0.657 
CD7 0.039 0.673 
CEACAM6 0.039 0.673 
FCER1A 0.039 0.673 
LILRA4 0.039 0.673 
IL12A 0.042 0.650 
BCL2 0.044 0.661 
MASP2 0.044 0.661 
TBX21 0.044 0.661 
TNFRSF9 0.044 0.661 
HLA.DOB 0.049 0.648 
IRF5 0.049 0.648 
LILRA3 0.049 0.648 
LILRA5 0.049 0.648 
SELL 0.049 0.648 
TLR8 0.049 0.648 
TNFRSF14 0.049 0.648 
 
Table IV. List of genes for which expression significantly positively correlates with AM 
opsonophagocytic activity.  
